{"title": "Análise proteômica aplicada na caracterização subcelular do córtex orbitofrontal de pacientes com esquizofrenia", "authors": ["Nuñez Velásquez, Erika Lourdes.", "orient.", "Nogueira, Fabio Cesar Sousa orient.", "Domont, Gilberto Barbosa orient.", "Universidade Federal do Rio de Janeiro. Instituto de Química"], "abstract": "A esquizofrenia é um distúrbio neuropsiquiátrico crônico caracterizado pelo comprometimento das funções mentais que afeta cerca de 1% da população mundial. A caracterização proteômica de frações subcelulares do córtex orbitofrontal podem fornecer informações valiosas sobre os mecanismos moleculares envolvidos na fisiopatologia desta doença. O proteoma quantitativo de sinaptossomas (SIN), mitocôndrias (MIT), fração nuclear (NUC) e citoplasma (CIT) foi obtido para 12 pacientes com esquizofrenia e para um pool com 8 controles saudáveis livres de doenças mentais usando técnicas quantitativas diferentes como iTRAQ, label-free e targeted (PRM e SRM). Na fração SIN foram identificadas um total de 2018 grupos de proteínas usando uma abordagem label-free e marcação com iTRAQ. Análises estatísticas revelaram a variação significativa na abundância de 12 e 55 proteínas quantificadas por iTRAQ e label-free, respectivamente. As principais proteínas desreguladas estavam relacionadas ao desequilíbrio da via de sinalização do cálcio, estresse do retículo endoplasmático e morte celular programada, refletidas na desregulação de proteínas como o Reticulon-1 e o Citocromo c. Além disso, encontramos um aumento significativo de proteínas associadas à regulação do comportamento humano como a LSAMP e Proteína quinase II dependente de cálcio e calmodulina. Por outro lado, a análises de espectrometria de massas identificou 939 grupos de proteínas na fração MIT, 2021 em NUC e 2433 em CIT. Um total de 358 grupos de proteínas foi encontrado desregulado entre as frações MIT, NUC e CIT.Por meio da análise proteômica quantitativa, detectamos como principais vias biológicas afetadas as relacionadas ao desequilíbrio de cálcio, apoptose, metabolismo de glutamato, ruptura da sinalização celular da ativação de CREB, orientação de axônios e proteínas envolvidas na ativação da sinalização de NFkB juntamente com o aumento da proteína complemento C3. Com base em nossa análise de dados, sugerimos a ativação do NF-kB como uma possível via que liga a desregulação do glutamato, do cálcio, a apoptose e a ativação do sistema imune em pacientes com esquizofrenia.", "bibliography_pages": [55, 83], "keywords": ["Esquizofrenia Fisiopatologia.", "Proteômica quantitativa", "Córtex orbitofrontal. Caracterização."], "urls": ["http://objdig.ufrj.br/13/teses/931778.pdf"], "pdf_url": "http://objdig.ufrj.br/13/teses/931778.pdf", "id": "931778", "sentences": ["RESUMO", "VELÁSQUEZ NUÑEZ , Erika Lourdes . Análise proteômica aplicada na caracterização subcelular do córtex orbitofrontal de pacientes com esquizofrenia. Tese (Doutorado em Bioquímica) – Instituto de Química, Universidade Federal do Rio de Janeiro, Rio de Janeiro, 2019", "A esquizofrenia é um distúrbio neuropsiquiátrico crônico caracterizado pelo comprometimento das funções mentais que afeta cerca de 1% da população mundial. A caracterização proteômica de frações subcelulares do córtex orbitofrontal podem fornecer informações valiosas sobre os mecanismos moleculares envolvidos na fisiopatologia desta doença. O proteoma quantitativo de sinaptossomas (SIN), mitocôndrias (MIT), fração nuclear (N UC) e citoplasma (CIT) foi obtido para 12 pacientes com esquizofrenia e para um pool com 8 controles saudáveis livres de doenças mentais usando técnicas quantitativas diferentes como iTRAQ, label -free e targeted (PRM e SRM). Na fração SIN foram identificad as um total de 2018 grupos de proteínas usando uma abordagem label -free e marcação com iTRAQ. Análises estatísticas revelaram a variação significativa na abundância de 12 e 55 proteínas quantificadas por iTRAQ e label -free, respectivamente. As principais p roteínas desreguladas estavam relacionadas ao desequilíbrio da via de sinalização do cálcio, estresse do retículo endoplasmático e morte celular programada, refletidas na desregulação de proteínas como o Reticulon -1 e o Citocromo c. Além disso, encontramos um aumento significativo de proteínas associadas à regulação do comportamento humano como a LSAMP e Proteína quinase II dependente de cálcio e calmodulina. Por outro lado, a análises de espectrometria de massas identificou 939 grupos de proteínas na fraçã o MIT, 2021 em NUC e 2433 em CIT. Um total de 358 grupos de proteínas foi encontrado desregulado entre as frações MIT, NUC e CIT. Por meio da análise proteômica quantitativa, detectamos como principais vias biológicas afetadas as relacionadas ao desequilíb rio de cálcio, apoptose, metabolismo de glutamato, ruptura da sinalização celular da ativação de CREB, orientação de axônios e proteínas envolvidas na ativação da sinalização de NF - kB juntamente com o aumento da proteína complemento C3. Com base em nossa a nálise de dados, sugerimos a ativação do NF -kB como uma possível via que liga a desregulação do glutamato, do cálcio, a apoptose e a ativação do sistema imune em pacientes com VII esquizofrenia.", "Palavras -chave: Esquizofrenia, frações celulares, córtex orbitof rontal, proteômica quantitativa.", "VIII ABSTRACT VELÁSQUEZ NUÑEZ , Erika Lourdes . Proteomic analysis applied in the subcellular characterization of the orbitofrontal cortex of patients with schizophrenia. Análise proteômica aplicada na caracterização subcelular do córtex orbi tofrontal de pacientes com esquizofrenia. Tese (Doutorado em Bioquímica) – Instituto de Química, Universidade Federal do Rio de Janeiro, Rio de Janeiro, 2019 Schizophrenia is a chronic neuropsychiatric disorder characterized by the impairment of mental functions which affects about one percent of the world population. The proteomic characterization of subcellular fractions from the orbitofrontal cortex is usefu l for providing valuable information about the molecular mechanisms involved in the physiopathology of these disease. The quantitative proteome of synaptosome (SYN) (MIT), crude nuclear (NUC) and cytoplasm fractions (CIT) were obtained from 12 patients wit h schizophrenia and a pool of 8 healthy controls free of mental illness using different quantitative techniques such as iTRAQ, label -free and targeted (PRM and SRM). In SYN fraction was identified a total of 2018 protein groups using a Label -free and iTRAQ labelling approach. Statistical analyses reveal the significant variation in the abundance of 12 and 55 proteins by iTRAQ and label -free, respectively. The main dysregulated proteins were related to calcium signaling pathway imbalance, endoplasmic reticul um stress and programmed cell death, reflected through the dysregulation of proteins such as Reticulon -1 and Cytochrome c. Also, we found a significant increase of proteins associated to the regulation of human behaviour as limbic system -associated membran e protein and α -calcium/calmodulin -dependent protein kinase II. On the other hand, mass spectrometry analyses identified 939 protein groups in MIT fraction, 2021 in NUC and 2433 in CYT. A total of 358 protein groups were found dysregulated among MIT, NUC a nd CYT fractions. Through the quantitative proteomic analysis, we detect as the main biological pathways those related to calcium imbalance, apoptosis, glutamate metabolism, cell signaling disruption of CREB activation, axon guidance and proteins involved in the activation of NF -kB signaling along with the increase of complement proteins C3. Based on our data analysis, we suggest the activation of NF -kB as a possible pathway that links the deregulation of glutamate, calcium, apoptosis and the activation of the immune system in schizophrenia patients", "IX Keywords: Schizophrenia, cellular fractions, orbitofrontal cortex, quantitative proteomics.", "X SUMÁRIO 1 CAPÍTULO I -INTRODUÇÃO: CARACTERÍSTICAS GERAIS DA ESQUIZOFRENIA 17 1.1 ESQUIZOFRENIA: CARACTERÍSTICAS CLÍNICAS, DIAGNÓSTICO E TRATAMENTO 17 1.3 ESQU IZOFRENIA: NEURODESENVOLVIMENTO E ALTERAÇÕES NEUROANATÔMICAS 23", "2.1 ANÁLISES PROTEÔMICA E SUAS DIFERENTES ABORDAGENS 2.3.1 Quantificação por marcação com isóbaros (iTRAQ) 29 2.3.3 Quantificação alvo direcionada: Monitoramento de Reação Selecionada (SRM) e Monitoramento Paralelo de Reações (PRM) 32", "XI", "APÊNDICE A - APLICAÇÃO DO ITRAQ SHOTGUN PROTEOMICS PARA A MEDIÇÃO DE PROTEÍNAS CEREBRAIS EM ESTUDOS DE DISTÚRBIOS PSIQUIÁTRICOS . Capítulo de livro publicado na Proteomic Methods in Neuropsychiatric Research 84 APÊNDICE B - ANÁLISES PROTEÔMICA DO SINAPTOSSOMA XII DO CÓRTEX ORBITOFRONTAL DE PACIENTES COM ESQUIZOFRENIA USANDO LABEL -FREE E iTRAQ . Artigo publicado na edição especial da revista Journal of Proteome Research 95 APÊNDICE C - ANÁLISES PROTEÔMICA DA FRAÇÃO MITOCONDRIAL, NÚCLEO E CITOPLASMA DO CÓRTEX ORBITOFRONTAL DE PACIENTES COM ESQUIZOFRENIA. Artigo submetido na edição especial da revista Journal of Proteome Research 129", "XIII LISTA DE SIGLAS", "ACC Córtex cingulado anterior BD-HPP O projeto proteoma humano orientado à biologia / doença, do inglês, The biology/disease -driven human proteome Project C-HPP Proteoma Humano – Projeto Proteoma Humano Centrado no Cromossomo, do inglês, Chromosome -Centric Human Proteome Project CIT citopl asma CREB Proteína de ligação ao elemento de resposta cAMP, do inglês cAMP response element binding protein CYT citoplasma, do inglês, cytoplasm DC Corrente direta DLFL Lobo frontal dorsolateral DSM -V Manual Diagnóstico e Estatístico de Transtorn os Mentais, do inglês, Diagnostic and Statistical Manual of Mental Disorders eIF4G2 Tradução eucariótica factor de iniciação 4 G gamma 2, do inglês, Eukaryotic translation initiation factor 4 gamma 2 ERK1 Quinase regulada por sinal extracelular 1, do inglê s, Extracellular signal –regulated kinase 1 ESI Ionização por eletrospray, do inglês, Electospray Ionization GABA Ácido gama -aminobutírico GNA13 Subunidade G da Proteína Alfa 13, do inglês, G Protein Subunit Alpha 13 GRIN2A Subunidade 2A do receptor iono trópico do glutamato tipo NMDA, do inglês, Glutamate ionotropic receptor NMDA type subunit 2A GWAS Estudos de associação genômica ampla, do inglês, genome -wide association study HCD Dissociação de colisão por alta energia, do inglês, High Energy Collisio n Dissociation HUPO Organização do projeto proteoma humano, do inglês, The Human Proteome Organization iTRAQ Marcadores isobáricos de quantificação absoluta e relativa, do inglês , Isobaric Tags for Relative and Absolute Quantification LC-MS Cromatografia líquida com espectrômetro de massa XIV LSAMP Proteína de membrana associada ao sistema límbico, do inglês, Limbic system -associated membrane protein m/z Massa –carga MALDI Ionização e dessorção a laser assistido por matriz, do inglês, Matrix - Assisted Laser D esorption/Ionization MIT mitocôndrias mPC Córtex pré -frontal medial MS Espectrometria de massas MS/MS Espectrometria de massas sequencial ou em tandem nano -LC Nano -cromatografia NF-κB Factor nuclear kappa B NMDA N-metil D -Aspartato NUC fração nuclear PET Tomografia por emissão de pósitrons PRM Monitoramento Paralelo de Reações PSMs Do inglês, Peptide -spectrum match PTMs Modificações pós -traducionais Q Quadrupolos RF Radiofrequência SIN sinaptossoma SPECT Tomografia por emissão de fóton único SRM Monitoramento de Reação Selecionada SRR Serine racemase SYN Sinaptossoma, do inglês, synaptosome", "XV LISTA DE FIGURAS", "do um a nalisador triplo quadrupolo. 29", "reagente de iTRAQ utiliza isótopos 13C, 15N e18O para manter as mesmas massas. c) Em uma varredura inicial as massas para cada grupo repórter são iguais. Uma vez fragmentados, cada repórter é liberado e sua intensidade é proporcional à abundância relativa desse peptídeo em cada amostra. (Figura adaptada de ROSS et. al, 2004) 30", "(Figura adaptada de BURNUM -JOHNSON et. al, 2016) 33", "XVI LISTA DE TABELAS", "segundo o DSM -V. 17", "(Adaptado de STEPNICKI, KONDEJ e KACZOR, 2018) 19", "1 CAPÍTULO I - INTRODUÇÃO: CARACTERÍSTICAS GERAIS DA ESQUIZOFRENIA", "1.1 ESQUIZOFRENIA: CARACTERÍSTICAS CLÍNICAS, DIAGNÓSTICO E", "TRATAMENTO A esquizofrenia é um transtorno neuropsiquiátrico crônico caracterizado pelo comprometimento das funções psíquicas superiores. A doença se manifesta principalmente através dos sintomas positivos caracterizados por delírios, alucinações, distúrbios motores; e negativos como avolição, alogia, apatia substancial, deterioração funcional nas relações interpessoais e cuidado pessoal e déficit cognitivo (GAUR et al., Segundo a Organização Mundial da Saúde (2018) a esqu izofrenia afeta mais de 23 milhões de pessoas em todo o mundo, sendo mais comum em homens do que em mulheres. A idade média de aparição da enfermidade varia entre os 18 anos nos homens e 25 anos nas mulheres, no caso do sexo feminino existe um risco maior de manifestar a doença nos meados dos 40 anos (SIE, 2011) .", "O diagnóstico e a categorização da esquizofrenia são baseados nas apreciações subjetivas obtidas nas entrevistas com os pacientes, classificando -se em diferentes subtipos clínicos através da ponderação dos diversos sintomas. De acordo com a última atualização do Manual Diagnóstico e Estatístico de Transtornos Mentais (EROGLU et al., 1994) a esquizofrenia é classificada em cinco subtipos conforme a Tabela 1.", "Código DMS -V Subtipo de esquizofrenia Principais sintomas paranóico • Delírios Alucinações auditivas frequentesNão apresenta fala desorganizada, comportamento catatônico ou desorganizado, afeto plano ou inadequado 295.10 Tipo Fala desorganizada Comportamento desorganizado desorganizado • Afeto plano ou inadequado catatônico • Imobilidade motora, evidenciada pela catalepsia ou estupor • Atividade motora excessiva (sem propósito e nãoinfluenciado por estímulos externos) • Negativismo extremo ou mutismo • Peculiaridades do movimento voluntário • Posturas inadequadas ou bizarras, maneiri smos proeminentes ou careta proeminente • Ecolalia ou ecopraxia indiferenciado • Não são atendidos exclusivamente os critérios de classificação para os de tipo paranoide, desorganizado ou tipo catatônico 295.60 Tipo residual • Ausência de delírios proeminentes. Pode apresentar de forma atenuada crenças, experiências perceptuais incomuns, alucinações, fala desorganizada, comportamento desorganizado ou catatônico.", "• Presença continua de sintomas negativos", "Os antipsicóticos, também conhecidas como neurolépticos, são os medicamentos indicados para o tratamento da esquizofrenia e de outros transtornos com episódios psicóticos (Tabela 2). A eficácia do tratamento antipsicótico apresenta limitações significativas. Apenas 50% dos pacientes tratados respondem positivamente ao tratamento, observando -se principalmente a melhoria dos sintomas positivos concomitantemente com os diversos efeitos colaterais da medicação (LALLY; MACCABE, 2015a) . Os sintomas negativos e cognitivos permanecem atualmente sem uma opção terapêutica totalmente eficaz (MÖLLER, 2016) . Por último, é necessário destacar que 30% dos pacientes com esquizofrenia não respondem a nenhum tratamento farmacológico disponível (NUCIFORA et al., 2018) .", "(STĘPNICKI; KONDEJ; KACZOR, 201 8) Classificação do antipsicótico Mecanismo de ação Efeitos colaterais Antipsicóticos de primeira geração ou típicos.", "Exemplos:", "clorpromazina, haloperidol, loxapina • Antagonista dos receptores D2 • Efeitos extrapiramidais • Elevação da prolactina • Perturbações do sono, demência, perda dememória e depressão • Afecção no sistema cardiovascular, sistema urinário e reprodutivo, sistema gastrointestinal, fígado, depressão do sistema respiratório e imunológico • Desordens metabólicas como hiperlipidemia, hipe rglicemia, aumento de peso Antipsicóticos de segunda geração ou atípicos.", "Exemplos:", "clozapina, olanzapine, risperidone • Antagonistas dos receptores receptores D4 e D2 (parciais) • Agonistas parciais dos receptores 5 - HT 1A • Obesidade • Diabetes • Sedação • Agranulocitose (clozapina) Antipsicóticos de terceira geração. • Agonistas parciais dos receptores D1, D2/D3, 5 -HT 1A • Insônia, ansiedade, dor de cabeça, constipação ou náusea • Acatisia Exemplos:", "aripiprazol, brexpiprazole, cariprazine • Antagonistas dos receptores HT 2B e 5-HT 7", "1.2 NEUROQUÍMICA DA ESQUIZOFRENIA", "1.2.1 Teoria dopaminérgica", "A hipótese dopaminérgica da esquizofrenia surgiu inicialmente de várias evidências indiretas, uma delas na década de 1970 com a eficácia clínica dos antipsicóticos antagonistas dos receptores D2 de dopamina no tratamento dos sintomas positivos da doença (SEEMAN et al., 1976) . Posteriormente, foi demostrado que a administração de anfetaminas e outros compostos que aumentam as concentrações extracelulares de d opamina podem induzir sintomas psicóticos semelhantes aos observados na esquizofrenia (BREIER et al., 1997) .", "A teoria clássica da psicose estabelece que na esquizofrenia existe uma hiperatividade da dopamina na via mesolímbica, abundante em receptores de tipo D2 o alvo dos neurolépticos, o que gera a manifestação dos sintomas positivos (BRISCH et al., 2014) . Paralelamente, foi observa da uma hipoatividade da dopamina na via mesocortical com hipostimulação do receptor da dopamina D1 do córtex pré -frontal, o que é manifestado nos sintomas negativos e cognitivos (CHOHAN et al., 2016) . Foi demonstrado que o bloque io prolongado dos receptores D2 leva à regulação negativados receptores D1 no córtex pré -frontal, resultando na deterioração significativa da memória de trabalho (CASTNER; WILLIAMS; GOLDMAN -RAKIC, 2000) .", "Recentemente, a meta -análise de estudos utilizando tomografia por emissão de pósitrons (PET) e tomografia por emissão de fótonúnico (SPECT) achou inconsistências na teoria mesolímbica, demonstrando que há um aumento significativo na síntese e liberação da dop amina no corpo estriado dorsal durante as psicoses (MCCUTCHEON et al., 2018) . Em tecido cerebral post-mortem de pacientes com esquizofrenia, especificamente no nucleus accumbens e no corpo estriado dorsal, foram encontradas concentrações de dopamina elevadas assim como aumento dos receptores dopaminérgicos (MCCOLLUM et al., 2015) . Finalmente, foi demonstrado que a dopamina do corpo estriado e a dopamina cortical têm uma relação bidirecional, sendo que o incremento da liberação da dopamina na área estriada dorsal pode diminuir a liberação de dopamina na região mesocortical produzindo alterações cognitivas (SIMPSON; KELLENDONK; KANDEL, 2010) .", "1.2.2 Teoria glutamatérgica", "O glutamato é o neurotransmissor excitatório mais comum no cérebro dos mamíferos, os neu rônios glutamatérgicos representam aproximadamente 60 -80% da atividade metabólica cerebral total (ROTHMAN et al., 2003) . Distúrbios na neurotransmissão glutamatérgica, especialmente no funcionamento do recepto r N-metil D-Aspartato (NMDA), pode influenciar a plasticidade sináptica e os microcircuitos corticais (HARRISON, P. J.; WEINBERGER, 2005) . Os antagonistas do receptor NMDA, co mo a fenciclidina e cetamina podem mimetizar a psicose com sintomas semelhantes à esquizofrenia (FARBER NB, 2003) . Num estudo in vivo utilizado SPECT, foi observado um déficit relativo na atividade do receptor de NMDA no hipocampo de pacientes com esquiz ofrenia que ainda não tinham recebido tratamento antipsicótico (PILOWSKY et al., 2006) . Por outro lado, os níveis de glutamato e glutamina encontra - se aumentados em indivíduos com risco familiar de esquizofrenia (TANDON et al., 2013) . No primeiro episódio psicótico de pacientes não medicados, o nível de glutamato foi achado aumentado no núcleo caudado (FUENTE -SANDOVAL et al., 2011) . Da mesma forma, pacientes com esquizofrenia resistentes ao tratamento farmacológico, possuem uma maior quantidade de glutamato no córtex cingulado anterior em comparação com o grupo de pacientes com esquizofrenia que responde ao tratamento e ao grupo controle (DEMJAHA et al., 2014) .", "O papel potencial do glutamato na fisiopatologia da esquizofrenia tem sido reforçado pelas descobertas genéticas recentes, onde se verificou polimorfismos de nucleotídeo único no gene GRIN2A (subunidade 2A do receptor ionotrópico do glutamato tipo NMDA), que codifica para uma subunidade do receptor NMDA, assim como no gene SRR (Serine racemase), que desempenha um papel fundamental nas vias que conduzem à ativação do receptor NMDA (RIPKE et al., 2014) . Do mesmo modo, estudos no tecido cerebral post-mortem de cérebro de pacientes com esquizofrenia, detectaram alterações na densidade dos receptores do tipo NMDA no córtex pré -frontal e no giro frontal superior (CATTS et al., 2015) . Alguns propõe que a anormalidade da densidade deste receptor se deve primariamente a uma localização aberrante e não a um déficit generalizado (J.C. HAMMOND, D. SHAN, 2 014).", "O mecanismo completo pelo qual os antagonistas do receptor de NMDA geram alterações no metabolismo do glutamato e neurotóxicidade em modelos animais ainda não foi completamente elucidado. Evidências indicam que a hipofunção dos receptores NMDA dos interneurônios GABAérgicos, implicaria a desinibição dos neurônios piramidais com o aumento da neurotransmissão glutamatérgica (HOMAYOUN; MOGHADDAM, 2008) . Porém, também foi proposta a hipóteses de que a hipofunção glutamatérgica dos interneurônios pode ser devida a diminuição da neurotransmissão dos interneurônios parvalbumina -positivos (ROTARU; LEWIS; GONZALEZ -BURGOS, 2013) . Outrossim, como parte central deste mecanismo, foram consideradas as alterações nos níveis de espécies reativas de oxigênio induzidas pelos antagonistas do receptor de NMDA, já que a redução dos níveis de superóxido evitou as alterações induzidas pela cetamina na atividade dos interneurônios bloqueand o o efeito comportamental em modelos animais (BEHRENS et al., 2007) .", "1.2.3 Teoria serotoninérgica e GABAérgica", "A hipótese serotoninérgica da esquizofrenia é derivada das observações sobre o mecanismo de ação da droga alucinógena dietilamida do ácido lisérgico e sua ligação à serotonina (AGHAJANIAN; MAREK, 2000) . Além disso, a maioria dos chamado s antipsicóticos atípicos, agem como agonistas parciais ou antagonistas sobre os receptores de serotonina do tipo 5 -HT 1A e 5-HT 2A respectivamente (QUEDNOW; GEYER; HALBERSTADT, 2010) . Foi sugerido que o incremento na atividade do sistema serotoninérgico no núcleo dorsal da rafe pode perturbar a atividade dos neurônios corticais na esquizofrenia, sendo que se esta hiperatividade for de forma extensa e prolongada, pode impactar o funcionamento do córtex cingulado anterior (ACC) e o lobo frontal dorsolateral (DLFL), gerando os sintomas deste distúr bio psiquiátrico (EGGERS, 2013) . Imagens adquiridas por PET demonstraram a desregularão na densidade do receptor da serotonina, comprovando que a alteração no sistema serotoninérgico está presente durante as fases iniciais da doença e antes da exposição aos neurolépticos Por outro lado, também tem sido postulada a hipótese GABAérgica. O ácido gama -aminobutírico (GABA) é o principal neurotransmissor inibitório no sistema nervoso e o desequilíbrio na sua sinalização causa o desbalanço entre os sinais excitatórios e inibitórios no córtex cerebral, fator chave na fisiopatologia da esquizofrenia (GUIDOTTI et al., 2005) . Estudos post-mortem apoiam a hipótese de uma transmissão GABAérgica alterada na esquizofrenia, devido à redução na e xpressão do glutamato descarboxilase -67, dos interneurônios parvalbumina positivos e do transportador GAT -1 no córtex pré -frontal dorsolateral, ACC e córtex visual primário (JONGE, DE et al., 2017) . Pesquisas recentes sugerem que a modulação seletiva do sistema GABAérgico é uma intervenção promissora para o tratament o dos defeitos cognitivos associados à esquizofrenia (XU; WONG, 2018) .", "1.3 ESQUIZOFRENIA: NEURODESENVOLVIMENTO E ALTERAÇÕES", "NEUROANATÔMICAS Por muitos anos, a esquizofrenia tem sido classificada como uma doença do neurodesenvolvimento. Desde o ano 1982, o pesquisador Feinberg (FEINBERG, 1982) observou uma redução importante na densidade sináptica cortical nos pacientes com esquizofrenia, o q ual considerou um defeito na maturação análoga à poda sináptica e eliminação programada de elementos neurais nas etapas inicias do desenvolvimento. Os primeiros sintomas da doença geralmente aparecem na adolescência e são eventos estressantes, indicando qu e fatores ambientais podem contribuir de forma significativa na aparição dos primeiros sintomas da esquizofrenia (SIRIS, 1988) .", "Os primeiros achados em relação às mudanças estruturais no cérebro de pacientes com esquizofrenia datam da década de 70, detectando -se do volume ventricular em pacientes com esquizofrenia (JOHNSTONE; FRITH; KREEL, 1976) . Atualmente, a meta -análise de diversos estudos morfométricos de diferentes áreas do cérebro de pacientes com esquizofrenia determinou que existem alterações significativas. Foi reportada a diminuição na matéria branca, especificamente nas regiões do corpo caloso, ACC, cápsula interna, na área temporal esquerda e no córtex pré -frontal medial (mPC), por o utro lado, na matéria cinzenta, houve uma diminuição nas áreas da insula bilateral /giro temporal superior, ACC dorsal e rostral, tálamo e no mPC (BORA et al., 2011) . Diversos estudos longitudinais e transversais apontaram a redução generalizada e progressiva do volume de massa cinzenta principalmente no lobo frontal de pacientes com esq uizofrenia (ZHANG, X. et al., 2018) . É necessário enfatizar que a primeira fase do desenvolvimento do córtex pré -frontal se dá na gestação, f inalizando o amadurecimento na adolescência com a eliminação de sinapses, constituindo dois períodos críticos de vulnerabilidade (PETANJEK et al., 2011) . Durante a adolescência, período no qual geralmente se manifestam os primeiros sintomas psicóticos, as situações sociais adversas elevam o estresse e aumentam a estimulação dopaminérgica da via mesocortical levando a uma poda sináptica exager ada (SELTEN et al., 2013) . Num modelo p rimata, comprovou -se que a hiperestimulação dopaminérgica diminui a densidade dos neurônios piramidais do córtex pré -frontal provocando disfunção cognitiva (SELEMON et al., 2007) .", "1.4 GENÔMIC A E PROTEÔMICA NA ESQUIZOFRENIA", "A taxa de herdabilidade da esquizofrenia está estimada em 64 -81%, no entanto, a importância da influência dos fatores ambientais é importante nesta doença (DONGEN, VAN; BOOMSMA, 2013) . Existe uma herança genética como parte importante da etiologia da esquizofrenia (RIPKE et al., 2014) . Atualmente são conhecidos pelo menos 108 loci por estudos de associação genômica ampla (GWAS) relacionados a genes envolvidos na neurotransmissão glutamatérgica, plasticidade sináptica, receptor de dopamina D2, subunidades de canais de cálcio voltagem -dependentes e também o complexo de histocompatibilidade princi pal, um candidato consistente encontrado em outros estudos de GWAS (RIPKE et al., 2014) (GIEGLING et al., 2017) Emb ora as análises de GWAS gerem dados importantes, esses não respondem completamente às perguntas elementares sobre a fisiopatologia da doença, nem tampouco contribuem na identificação de biomarcadores com valor preditivo para o risco da doença ou resposta terapêutica. Na última década, os esforços foram centrados nos estudos de transcriptômica baseados em microarranjos usando tecido cerebral post-mortem de pacientes com esquizofrenia e indivíduos -controle. Os dados mostraram que existem várias vias moleculares afetadas na esquizofrenia, incluindo inflamação, metabolismo energético, função sináptica e via da mielinização. Um fator limitante de tais pesqui sas é a ocorrência de mudanças sutis na expressão dos genes que, nem sempre, podem ser extrapoladas à expressão de proteínas (PENNINGTON; COTTER; DUNN, 2005) .", "Na última década, estudos de proteômica tentaram contribuir na elucidação da fisiopatologia da esquizofrenia a analisando diferentes áreas de tecidos cerebrais post- mortem de pacientes esquizofrênicos em comparação com controles livres de doenças mentais. Atualmente, a cara cterização proteômica de áreas cerebrais, como o córtex pré - frontal, revelou alteração de proteínas envolvidas no metabolismo energético e dos oligodendrócitos (MARTINS -DE-SOUZA ; GATTAZ; SCHMITT; REWERTS; MARANGONI et al., 2009) nas vias de sinalização comprometidas com a formação de axônios e plasticidade sináptica, como GNA13 -ERK1 -eIF4G2 (HIRAYAMA -KUROGI et al., 2017) desequilíbrio na homeostase do cálcio e no sistema imunológico (MARTINS - DE-SOUZA; GA TTAZ; SCHMITT; REWERTS; MACCARRONE et al., 2009) e aumento significativo da expressão de proteínas sinápticas como a proteína de união à sintaxina e a proteína de membrana associada ao sistema límbico (LSAMP) (BEHAN et al., 2009) . A análise proteômica do lobo temporal (MARTINS -DE-SOUZA; GATTAZ; SCHMITT; NOVELLO et al., 2009) tálamo mediodorsal (MARTINS -DE-SOUZA et al., 2010) e corpo caloso (SAIA -CEREDA, Verônica M. et al., 2015) também report aram a desregulação das proteínas envolvidas no metabolismo energético, oligodendrócito, homeostase do cálcio e regulação do citoesqueleto. No caso do córtex cingulado anterior, apresenta variação na abundância de proteínas vinculadas ao processo de endoci tose mediada por clatrina e dos receptores NMDA (FÖCKING et al., 2015) . Até o momento, foram realizados poucos estudos utilizando uma abordagem proteômica subcelular, entre os quais podemos mencionar a caraterização do proteoma nuclear de tecido cerebral do corpo cal oso e lobo temporal anterior (SAIA -CEREDA, Verônica M. et al., 2017) , no qual se reportaram as proteínas do spliceosome e à sinalizaçã o cálcio/calmodulina como os principais processos biológicos afetados.", "2 CAPÍTULO II - INTRODUÇÃO: ANÁLISE PROTEÔMICA", "2.1 ANÁLISES PROTEÔMICA E SUAS DIFERENTES ABORDAGENS", "O proteoma pode ser definido como o complemento proteico do genoma e consiste no conjunto de proteínas expressas por um sistema biológico num momento determinado (WILKINS et al., 1996) . A proteômica, é um conjunto de técnicas cujo fim é o estudo do proteoma ; (HUBE R, 2003) . A análise proteômica fornece informação sobre o conjunto de proteínas expressas por um organismo em condições determinadas (EIDHAMMER et O estudo do proteoma pode ser ab ordado através de três estratégias diferentes, a primeira delas, através da análise direta de proteínas intactas, chamada top-down (CATHERMAN; SKINNER; KELLEHER, 2015) e a segunda, denominada bottom -up, onde as proteínas são hidrolisadas por uma enzima de clivagem específica, geralmente a tripsina, a partir de amostras em solução ou previamente separadas numa corrida eletroforética (WOLTERS; WASHBURN; YATES, 2001) . Esta última estratégia é a mais comum, fornecendo a detecção indir eta das proteínas através de análises, identificação e quantificação de seus respectivos peptídeos (ZHAN et al., 2013) . E finalmente, a terceira estratégia chamada de middle -down, é aplicada na analises peptídeos longos naturais ou gerados através da digestão da amostra com enzimas com sítios de c livagem menos frequentes que a tripsina como GluC ou AspN. Uma aplicação clássica desta abordagem é no estudo das caudas das histonas, com a finalidade de obter mais informações sobre modificações pós -traducionais (PTMs) coexistentes (SIDOLI;", "2.2 ESPECTROMETRIA DE MASSA", "Atualmente, a espectrometria de massas (MS) é a ferramenta analítica que permite a identificação do analito em função de sua relação massa –carga (m/z). Na proteômica, o MS é constituído por três elementos essências: (1) fonte de ionização branda, geralment e acoplada a um sistema de nano -cromatografia (nano -LC), (2) analisador de massas, que seleciona e fragmenta os analíticos para serem analisados em função da sua razão m/z (3) detector que permite captar e registrar a informação dos espectros obtidos (JAYARAM, 2013) . Em seguida, descrever -se-á cada um dos elementos separadamente", "2.2.1 Fonte de ionização", "A aplicação da MS na análise de amostras biológicas como as proteínas foi possível graças ao desenvolvi mento de técnicas eficazes de ionização branda, como a ionização por electrospray (ESI) e a dessorção/ionização por laser assistida por matriz (MALDI), onde as moléculas ionizadas alcançam a fase gasosa sem sofrer uma fragmentação excessiva.", "Na ionização por ESI, as amostras em solução são dispersas em forma de aerossol, gerando gotículas carregadas (LOO; UDSETH; SMITH, 1989) . Uma vez aplicado o potencial elétrico no capilar onde se encontra retida a amostra, sobre o líquido agem duas forças a saber, a tensão superficial e as forças de Coulomb, o que conduz à forma ção do “Cone de Taylor”. O analito carregado emerge do cone através de um processo de “brotamento” no qual a força eletrostática aplicada supera à tensão superficial (BANERJEE; MAZUMDAR, 2012) . Uma vez expelidas do cone, tem -se proposto que as gotículas carregadas sofrem um processo de evaporação e fissão por meio de explosões de Coulomb até a formação eventual de gotículas conten do um único íon (GASKELL, 1997) ou através da evaporação progressiva do solvente das gotículas até a ejeção dos íons solvatados (WILM, 2011) .", "Por outro lado, na técnica de ionização por MALDI, a amostra é co -cristalizada em conjunto com uma matriz geralmente composta por ácidos orgânicos fracos de baixo peso molecular, cuja função principal é assi stir à ionização do analito através da doação de prótons (LEWIS; WEI; SIUZDAK, 2006) . O cristal formado é bombardeado comum laser UV que permite a volatilização d a amostra junto com a matriz; dois modelos principais foram postulados para este tipo de ionização (1) o modelo de ionização fotoquímica, onde os íons são produzidos a partir de um processo de protonação ou desprotonação envolvendo uma molécula de analito colidindo com íons da matriz na fase gasosa (2) O modelo de ionização por cluster de íons, onde o analito carregado é dessorvido por forte foto absorção pelas moléculas da matriz (CHANG et al., 2007) .", "2.2.2 Analisadores de massa", "Neste momento encontram -se no mercado diversos tipos de analisadores de massa como os instrumentos de temp o de vôo, o triplo quadrupolo, a armadilha de íons linear, o analisador por ressonância ciclotrônica de íons e o Orbitrap, que utilizam diferentes técnicas de fragmentação para as análises das amostras. Nesta secção serão apenas descritos os métodos de fra gmentação e instrumentos utilizados nesta pesquisa de tese, o analisador Orbitrap nos instrumentos LTQ Orbitrap Velos (espectrômetro de massa híbrido) e no Q Exactive Plus e o TSQ Quantiva, um triplo quadrupolo.", "O Orbitrap consiste em uma armadilha com um eletrodo externo em forma de barril e um eletrodo central fusiforme ao longo do eixo (Figura 1A). Os íons são injetados tangencialmente no campo elétrico entre os eletrodos, movimentando -se em trajetórias estáveis de rotação e oscilação ao longo do eixo; a frequência dessa oscilação harmônica é independente da velocidade do íon e é inversamente proporcional à raiz quadrada da relação m/z (MAKAROV, 2000) . A aquisição de imagens, que procedem do sinal da tensão induzida pelas oscilações dos íons e registrada em forma de transientes e transformada rapidamente mediante as transformações de Fourier para obter o espectro de massa (HU et al., 2005) . Geralmente o Orbitrap, utiliza uma técnica de fragmentação exclusiva chamada de dissociação de colisão por alta energia ( High Energy Collision Dissociation – HCD). A fragmentação por HCD é realizada com gás nitrogênio numa câmara de colisão ou octopolo; o peptídeo é transportado e acelerado por um gradiente de pressão que provoca sua aceleração e colisão com o nitrogênio, gerando fragmentos que posteriormente são anali sados no Orbitrap (THERMO FISHER SCIENTIFIC, 2009). No caso do triplo quadrupolo, como o nome indica, é uma seria linear de três quadrupolos Q1, Q2 e Q3 onde cada um consiste em quatro hastes de metal dispostas de forma paralela (GROSS; GROSS, 2011) (Figura 1B). Q1 e Q3 agem com filtros de massas, que no caso do TSQ Quantiva ( ThermoScientific ), utiliza uma relação variável de tensão de radiofrequência (RF) assimétrica que aumenta a sensibilidade e a transmissão iônica e de tensão de corrente direta (DC) gerando um camp o elétrico que dá oscilações estáveis aos íons com um m/z específico. O Q2 atua como cela de colisão cheia de argônio de alta pressão onde uma determinada RF cria um campo elétrico que fornece oscilações estáveis aos íons numa janela de valores m/z; no eix o axial uma DC acelera o trânsito de íons dentro da célula (THERMO FISHER SCIENTIFIC, 2017).", "quadrupolo.", "Disponível em: A) http://analyteguru.com/resources/intact -monoclonal -antibody -characterization - using -a-bench -top-orbitrap -mass -spectromet er/. B) www.researchgate.net/figure/Figura -1-Esquema - de-um-analisador -triplo -quadrupolo_fig1_297659998Acesso: 15 fevereiro 2019.", "2.3 PROTEÔMICA QUANTITATIVA", "Para uma maior compreensão dos sistemas biológicos, a proteômica desenvolveu várias estratégi as para efetuar com precisão a análise quantitativa tanto absoluta como relativa da expressão de proteínas num proteoma determinado. Assim, através da proteômica podemos efetuar uma quantificação exata de uma proteína, por exemplo, em termos de ng ou nmol es. Contudo, uma das estratégias mais amplamente implementadas, são aquelas que visam à quantificação relativa das proteínas, isto é, a relação de duas o mais condições (por exemplo, paciente versus controle) calculada em termos de razão para determinar qu antas vezes aumenta ou diminui uma condição experimental com relação à outra (LI, H. et al., 2017) . A seguir, serão apresentadas as técnicas de quantificação relativa mais empregada nos estudos proteômica e na presente teses de pesquisa.", "2.3.1 Quantificação por marcação com isóbaros (iTRAQ) A marcação química por iTRAQ é um método de quantificação relativa que permite quantificar ao mesmo tempo várias condições experimentais, através da introdução de uma modificação química nas amostras. O reagente iTRAQ, constituído por diferentes combinaçõe s de isótopos 13C, 15N e 18O é formado por um grupo repórter (N-metilpiperazina) unido a um grupo de equilíbrio de massa (carbonil) e um grupo amino -reativo (éster NHS) o qual se une aos grupos Ɛ -amino de lisina e à porção N - terminal dos peptídeos (ROSS et al., 2004) (Figura 2A). As diversas combinações de", "isótopos, permite estabelecer várias etiquetas isóbaras com grupos repórter de massas diferentes sem mudar a massa total do r eagente (Figura 2B).", "Por essa razão, as amostras de várias condições podem ser analisadas simultaneamente no espectrômetro de massas, já que, após sofrer o processo de fragmentação MS2, a estrutura do reagente de iTRAQ é clivada, e o grupo repórter é liberado permitindo calcular a concentração relativa dos peptídeos a partir das intensidades obtidas dos íons repórteres correspondentes (Figura 2C) (ROSS et al., 2004) .", "iTRAQ utiliza isótopos 13C, 15N e18O para manter as mesmas massas. c) Em uma varredura inicial as massas para cada grupo repórter são iguais. Uma vez fragmentados, cada repórter é liberado e sua intensidade é proporcional à abundância relativa desse peptídeo em cada amostra. (Figura adaptada de ROSS et. al, 2004) Uma das principais vantagens da marcação com o iTRAQ é a diminuição do tempo de análises no espectrômetro de massas e a melhora na reprodutibilidade entre as diferentes réplicas experimentais. Por outro lado, entre as desvantagens encontra -se o elevado custo dos reagentes e a restrição no número de canais disponíveis para efetuar a marcação limitando a comparação ao núm ero de amostras. Primeiramente, foi desenvolvido o reagente de iTRAQ 4 -plex de quatro canais (ROSS et al., 2004) e posteriormente o iTRAQ 8 -plex (CHOE et al., 2007) . Atualmente, e ncontram -se disponíveis no mercado outras estratégias de marcação com isóbaros como TMT2 -plex, 6-plex, 10 -plex e 11 -plex, mas estudos sinalizam que o reagente iTRAQ - 4plex se destaca por ser mais eficiente em termos de identificação e quantificação de pept ídeos e proteínas (PICHLER et al., 2010) .", "2.3.2 Quantificação livre de marcação", "Em contraste com os métodos quantitativos por marcação química, nos métodos livres de marcação, cada amostra é preparada separadamente e submetida à análise individual por LC -MS. Geralmente são utilizadas duas estratégias para este tipo de quantificação relativa, a primeira delas, baseada no valor da área do pico obtida no LC - MS. Cada íon de uma determinada m/z possui uma intensidade que é detectada e registrada num momento determinado da análise. Nos primeiros testes para avaliar esta metodologia, foram utilizadas diversas concentrações de mioglobina. Verificou -se que na medida em que aumentava a concentração do analito, a intensidade do sinal e a áreas cromatográficas dos picos procedentes dos peptídeos de mioglobina, aume ntavam guardando uma correlação linear com a concentração de proteína (CHELIUS; BONDARENKO, 2002) . Esta abordagem apresenta diversas limitações, uma destas é a variabilidade da intensidade dos picos entr e cada corrida de LC -MS, além disso, o tempo de retenção também pode variar após múltiplas injeções de amostra numa mesma coluna, gerando imprecisões na quantificação (LAI; WANG; WITZMANN, 2013) .", "Outra estratégia de quantificação relativa consiste na contagem espectral. A quantificação da proteína é obtida comparando o número de PSMs da mesma proteína em cada um dos conjuntos de corridas. Segundo este método, qu anto mais abundante o peptídeo, maior é a probabilidade de ser selecionado para análise MS / MS, resultando no aumento da cobertura da sequência proteica, no número de peptídeos únicos identificados e no número de espectros MS / MS totais identificados par a cada proteína (WONG; CAGNEY, 2009) . A contagem espectral ofereceu uma ampla faixa dinâmica de quantificação e com boa reprodutibilidade, no entanto, várias considerações devem ser levadas em conta, como por exemplo, a influência de parâmetros experimentais como a exclusão d inâmica de íons precursores, velocidade de varredura do instrumento MS, distribuição do comprimento dos peptídeos gerados que determina quantos peptídeos diferentes podem ser detectados dentro da uma faixa de massa, a variabilidade na quantificação de prot eínas curta se o efeito de saturação em altas concentrações de proteína (BANTSCHEFF et al., 2012) .", "2.3.3 Quantificação alvo direcionada: Monitoramento de Reação Selecionada", "(SRM) e Monitoramento Paralelo de Reações (PRM) A quantificação alvo direcionada é uma estratégia que permite a análise de um conjunto específico de proteínas ou uma proteína de interesse. No caso do SRM, este é realizado em espectrômetros de massa triplo quadrupolo onde o primeiro analisador de massa está configurado para filtrar um íon peptídeo precursor de interesse numa jane la de isolamento estreita. O peptídeo isolado é fragmentado no Q2, e cada transição ou par precursor/íon produto é analisada separadamente no Q3 (BORRÀS; SABIDÓ, 2017) (Figura 3A). A probabilidade de dois fragmentos peptídicos terem a mesma massa, deriva r de dois peptídeos isobáricos diferentes, com exatamente o mesmo tempo de retenção é muito baixa, portanto, o método do uso de transições torna esta estratégia de quantificação altamente específico e sensível (LANGE et al., 2008) .", "Uma das principais diferenças entre o PRM e o SRM é a análise simultânea de todos os fragmentos gerados do peptídeo de interesse. Neste método, o primeiro analisador de massa (um quadrupolo) é definido para filtrar numa janela de m/z estreita e isolar o íon de in teresse. O peptídeo selecionado é fragmentado e os íons resultantes são analisados simultaneamente no analisador de massa de alta resolução (Figura 3B) (PETERSON et al., 2012) . Estudos utilizando SRM e PRM de mostraram que ambos métodos têm sensibilidade, linearidade e faixa dinâmica comparáveis, com alta precisão e reprodutibilidade e na quantificação de proteínas, contudo, o PRM tem certas vantagens sobre o SRM, devido a que é mais simples construir o método de aquisição de dados, fornece alta especificidade porque os dados MS/MS são adquiridos em alta resolução sendo capaz de incluir nas análises todos os íons potenciais derivados do peptídeo alvo e confirmar sua identidade (RAUNIYAR, 2015) .", "2.4 ANÁLISE DE DADOS", "A informação dos espectros obtidos está contida num arquivo RAW o qual é utilizado para as análises de dados. Atualmente, as buscas dos espectros são automatizadas, implementando para interpretação de dados estratégias de alinhamento entre o espectro teórico, gerado in silico utilizam do banco de dados, e o espectro experimental, atribuindo -se um score para essa associação. Esta estratégia de alinhamento é chamada de Peptide Spectrum Match (PSM) e existem diversos algoritmos disponíveis como o SEQUEST (ENG et al., 1994) , Mascot (PERKINS et al., 1999) , ProLuCID (XU et al, 2006) , Comet (ENG; JAHAN; HOOPMANN, 2013) entre outros, que usam a PSM como estratégia de busca.", "Contudo, diferença entre os dados experimentais e os peptídeos preditos in silico , como a presença de modificações pós -traducionais, modificações na sequência peptídica, problemas na digestão e fragmentação dos peptídeos, não geram nenhuma identificação (ZHAN et al., 2013) . Geralmente, os algoritmos de buscas consideram parâmetros como modificações inerentes à preparação da amostra, tolerância de massa, enzima utilizada, presença de PTMs ou o uso de técnicas de quantificação por marcação como o iTRAQ, para identificação cor reta dos espectros. Do mesmo modo, quando se investiga por proteômica um organismo com genoma não -sequenciado, a análise por PSM é menos eficaz, sendo necessário recorrer a outro tipo de estratégia como o uso de sequenciamento de novo dos espectros MS/MS e busca por similaridade de sequência de proteínas nas bases de dados para validar as identificações pouco confiáveis geradas por PSM (SHEVCHENKO et al., 2009) ; (LEPREVOST et al., 2014) . Figura 3. a) Representação do esquema geral do SRM. b) Representação do PRM. (Figura adaptada de BURNUM -JOHNSON et. al, 2016)", "3 CAPÍTULO III -JUSTIFICATIVA E OBJETIVOS", "3.1 JUSTIFICATIVA", "A esquizofrenia é uma doença incurável com episódios recorrentes de internação dos pacientes em centros de saúde especializados, tornando -a a doença psiquiátrica de maior custo com uma despesa anual estimada de U$ 2,3 bilhões (ASCHER -SVANUM et. al, 2010). A terapia farmacológica disponível está dirigida na melhora dos sint omas positivos, sendo ineficazes no tratamento dos sintomas negativos e cognitivos, indicadores importantes da função social (STEEDS, CARHART -HARRIS e STONE, 2015). Além disso, há uma perda de 50 -75% da eficácia dos tratamentos convencionais e cerca de 30% dos pacientes não respondem aos antipsicóticos (LALLY E MACCABE, 2015). Outro problema associado a esta doença são as altas taxas de ideação suicida; 40% dos pacientes com esquizofrenia tenta suicídio pelo menos uma vez e 15% morrem por esta causa (HOR e TAYLOR, 2010).", "Apesar dos esforços da comunidade científica, a fisiopatologia da esquizofrenia ainda não é totalmente compreendida. Foram desenvolvidos diferentes modelos biológicos, porém esses modelos são limitados na avaliação de sintomas negativos e ideação suicida (FILIOU et al., 2011) Por essa razão, o estudo do tecido cerebral post - mortem ainda pode fornecer informações valiosas sobre a fisiopatologia deste transtorno. O primeiro objetivo deste estudo é realizar a caracterização proteômica das fraçõe s de sinaptossoma, mitocôndria, núcleo e citoplasma de uma das áreas cerebrais menos compreendidas, como é o córtex orbitofrontal, cuja função está envolvida na regulação da resposta emocional adequada, participando na aprendizagem, na previsão e tomada de decisões em relação aos comportamentos emocionais e relacionados à recompensa (KRINGELBACH , 2005). Por outro lado, é conhecido que a função proteica está relacionada à localização subcelular e essas mudanças na localização das proteínas regulam a atividad e de diversos processos biológicos ( ITZHAK et al., 2016). Neste contexto, a identificação e quantificação das proteínas das frações subcelulares utilizando as técnicas de iTRAQ, label -free, PRM e SRM, abre a possibilidade de observar alterações dinâmicas do proteoma subcelular, com uma abordagem diferente ao reportado na literatura para este tipo de amostras, que possa sugerir novos mecanismos celulares na fisiopatologia desta doença. Final mente, este projeto contribui na construção de um mapa abrangente do proteoma humano dentro do projeto do Proteoma Humano – Projeto Proteoma Humano Centrado no Cromossomo, (C -HPP) criado pela Organização do projeto proteoma humano (HUPO) sendo o Brasil res ponsável pelo cromossomo 15. Estudos de GWAS relacionam o cromossomo 15 (regiões 15q11.2 e 15q13.3) com a esquizofrenia (GIEGLING et al., 2017). O objetivo do C -HPP é inicialmente mapear e anotar pelo menos uma proteína codificada pelos genes de cada cromo ssomo humano incluindo as “missing proteins”, que são aquelas que possuem alguma evidência por transcriptômica, anticorpos e/ou por homologia, mas não possuem evidência por espectrometria de massas, e correlacioná -las às doenças ( projeto proteoma humano orientado à biologia / doença , BD -HPP) para compreender os processos moleculares na presença ou ausência de determinada patologia (AEBERSOLD et al., 2013).", "3.2 OBJETIVOS 3.2.1 Objetivo Geral 1. Caracterizar e comparar o proteoma subcelular do córtex orbito frontal de pacientes com esquizofrenia e grupo controle.", "3.2.2 Objetivos Específicos", "1.- Quantificar por marcação com iTRAQ as proteínas das frações de núcleo, citoplasma, mitocôndria e sinaptossoma de pacientes com esquizofrenia e controles. 2.- Quantifi car por label -free as proteínas da fração de sinaptossoma de pacientes com esquizofrenia e controles.", "3- Validar por SRM e PRM os peptídeos das proteínas de interesse nas diferentes frações. 4- Detectar as possíveis “ missing proteins ” com ênfase no cromoss omo 15.", "4 CAP ÍTULO IV -METODOLOGÍA", "4.1 AMOSTRAS", "As amostras de tecido cerebral post -mortem (córtex orbitofrontal ) foram coletadas de 12 pacientes com esquizofrenia classificadas de acordo com os critérios DSM -IV como esquizofrenia residual e 8 controles livres de doenças mentais. Todos os pacientes e controles eram alemães brancos sem história de abuso de álcool ou drogas. As amostras de pacientes foram coletadas no Hospital Mental do Estado de Wiesloch e amostras controle no Instituto de Neuropatologia da Universidade de Heidelberg, em Heidelberg, Alemanha. Todos os cérebros analisados foram submetidos à caracteriza ção neuropatológica para descartar quaisquer outros distúrbios cerebrais associados. O estágio de Braak (Doença de Parkinson e Alzheimer) para todos os cérebros foi inferior a II. Os pacientes com esquizofrenia têm registro de tratamento antipsicótico, de modo que os equivalentes de clorpromazina (CPE) foram calculados. Todas as avaliações e procedimentos foram aprovados pelo comitê de ética da Faculdade de Medicina da Universidade de Heidelberg, Heidelberg, Alemanha.", "4.2 PREPARAÇÃO DAS FRAÇÕES SUBCELULARES", "4.2.1 Isolamento de núcleo, citoplasma e mitocôndria", "Para o enriquecimento da fração do nucleo, homogeneizaram -se cinquenta miligramas de tecido do córtex orbitofrontal ( OFC ) em 10 volumes de tampão A (sacarose 0,32 M, HEPES 4 mM e comprimido s inibidores de cocktail de protease ( Roche )) e inibidores da fosfatase I e II ( Sigma ) pH 7,4 ). O homogeneizado foi centrifugado a 1.000g por 10 min, 4 oC, obtendo -se a fração P1 dos núcleos celulares brutos. No caso do enriquecimento das frações de mitocôndria e do citoplasma, trinta miligramas de tecido cerebral do OFC foram incubados durante 15 min em gelo com 180 µl de tampão 250 - STM (250 mM de sacarose, 50 mM Tris -HCl pH 7,4, 5 mM MgCl2, inibidor d e mini - protease e inibidor de fosfatase ( Roche )). A homogeneização do tecido foi feita duas vezes com um pilão durante 1 -2 minutos incubando durante 10 min no tampão 250 -STM . A amostra foi centr ifugada a 800g por 15 min a 4 ° C, obtendo -se o sobrenadante Cy t 1 (citoplasma + mitocôndria). O sedimento foi ressuspenso em 640 ul de tampão 250 -STM, centrifugando a 800g, 15 min, 4 °C até o sobrenadante ficar límpido. Todos os sobrenadantes foram combinados e centrifugados a 6.000 g, 15 min, 4 °C. O último sobrenad ante foi coletado como fração CYT e guardado a -80 ° C até o seu uso, e o pellet (PM) foi usado para enriquecimento das mitocôndrias.", "O PM foi ressuspenso em 250 de tamp ão 250-STM e centrifugado a 6.000 g, 15 min, 4 °C. O sedimento foi ressuspenso em 250 µl de tampão HEPES ( HEPES 10 mM pH 7,9 / Mini -inibidor de protease e inibidor de fosfatase ( Roche )) e incubado a 4 ° C durante 30 min utos (Eppendorf ThermoMixer® ). As mitocôndrias foram carregadas em um gradiente de sacarose contendo 1,75ml de sacarose a o 50%, 1,75 ml de sacarose a o 36% e 0,75 ml de 20% de sacarose centrifuga ndo a 25.000 rpm, 4 ° C, 60 min. A fração MIT foi transferida para um novo tubo, preenchendo com tampão HEPES até 2 ml e centrifugado a 17.200g, 20 min, 4 ° C. Este procedim ento foi repetido quatro vezes. Finalmente , o sedimento foi guardado a -80 ° C até o uso.", "4.2.2 Isolamento de sinaptossoma", "O tecido (50 mg) foi homogeneizado em 10 volumes de tampão A (0,32 M de sacarose, 4 mM HEPES , cocktail inhibitor de protease pH 7.4 ( Roche ) e cocktail inibidor de fosfatase I e II ( Sigma )). A amostra foi centrifugada a 1000g durante 10 min, 4°C (S1, P1: núcleos, detritos celulares). O sobrenadante S1 se transferiu para um tubo diferente. O pellet P1 foi ressuspenso em 10 volumes de tampão A , centrifugado a 1.000 g durante g por 55 min, 4°C gerando S3 e P3: fração de membrana com sinapto ssomas intactos. O pellet P3 foi ressuspenso e m sacarose 0,32 M e colocado num gradiente de densidade de sacarose descontínua (1ml 0,32 / 1ml 0,8 / 1ml 1.2) ultracentrifuga ndo a 25.000 rpm durante 2 h, 4 °C. A fração de sinaptos soma foi extraída da interfase 1,2 / 0,8 e diluída em água 1: 1 para ser ultracentrifugada a 40.000 rpm durante 60 min, 4°C (S4, P4). O pellet P4 foi armazenado a -20C até o uso .", "4.3 WESTERN BLOT", "Uma vez feito o enriquecimento das frações celulares, as proteínas foram extraídas conforme descrito no estudo de Saia -Cereda e colaboradores (2016). Os lisados de proteínas tiveram suas concentrações de proteína determinadas utilizando um ensaio de Bradford ( BioRad ). Os extratos de proteína (20 μg) de cada amostra foram submetidos à eletroforese em 12% de SDS -PAGE ( BioRad ). As proteínas foram então transferidas a membranas de fluoreto de polivinil -difenilo de Immobilon -FL (PVDF) ( Millipore ) a 100 V durante 1 h. As membranas de PVDF contendo as proteínas transferidas foram tratadas com 5% de leite sem gordura em solução salina tamponada com Tris (pH 7, 4) /0,1% de Tween -20 (TBS -T) durante 4 h e enxaguadas em TBS -T três vezes. As membranas foram incubadas com colapsina, 2 para proteínas citosolicas, ATP5A1 para proteínas mitocondriais, PSD95 para proteínas do sinaptossoma, e HDAC 1 para proteínas nucleares, em uma diluição de 1: 1000 em TBS -T durante a noite a 4° C (anticorpos Abcam ). Após a incubação durante a noite, as membranas foram lavadas duas vezes com TBS-T durante 15 min por lavagem. Em seguida, as membranas foram incubada s com anticorpo anti -c-MYC -peroxidase ( GE Healthcare ) durante 40 min à temperatura ambiente, lavado com água e TBS -T e incubado com solução Enhanced Chemiluminescence (ECL) (GE Healthcare) durante 1 min. As membranas foram digitalizadas usando um sistema GelRMXR + (Silk Scientific Incorporated) e as densidades ópticas das bandas imunorreativas foram medidas utilizando o software Quantity One (Bio -Rad).", "4.4 DIGESTÃO TRÍPTICA EM SOLUÇÃO", "As amostras foram dissolvidas em uma solução de ureia 7 M/ tiourea 2 M e quantificadas por fluorimetria ( Qubit, Invitrogen ) de acordo com as instruções do fabricante. Dez microgramas de proteína das frações de mitocôndria e sinaptossoma, 20 µg de núcleo e 50 ug de citosol foram reduzidos com tris (2 -carboxyethyl) phosphine (TCEP) 5mM durante 1 hora a 30oC e alquilados com iodoacetamida 10 mM (30 minutos à temperatura ambiente). Para a digestão com tripsina, as amostras foram diluídas em TEAB 100 mM pH 8 (1:10) e submetidas à digestão durante um período de 18 horas a 35oC. Para parar a reação foi adicionado ácido trifluoracético (TFA) em uma concentração final de 0,1%.", "4.5 DESSALINIZAÇÃO E CONCENTRAÇÃO DAS AMOSTRAS", "Os peptídeos trípticos de cada amostra foram dessalinizados separadamente em mini-colunas preparadas com resina Poros® R2 ( Applied Biosystems ). Inicialmente, cada coluna foi lavad a com acetonitrila (ACN) 100%, e equilibrada com uma solução de TFA 0,1%. Para as lavagens da coluna foi utilizada igualmente uma solução de TFA 0,1%. Os peptídeos foram eluídos em dois passos sucessivos com e ACN 50% / TFA 0,1 % e ACN 70%/ TFA 0,1% . Finalme nte, os peptídeos foram secos no SpeedVac (Thermo Fischer Scientific ), ressuspensos em 30 µl de 20mM TEAB pH 8 e quantificados pelo método fluorimétrico Qubit (Invitrogen ). No caso da quantificação relativa por Label -free, as amostras de sinaptossoma foram ressuspens as em ácido fórmico 0.1% para análises LC/MS -MS.", "4.6 MARCAÇÃO COM iTRAQ", "Seguindo as instruções do fabricante, foram marcados 5 µg de peptídeos das frações de mitocôndria e sinaptossoma, 15µg de peptídeos do núcleo e 20 µg de peptídeos do citoplasma . Para a marcação com o reagente iTRAQ de quatro canais (114, 115, 116 e 117) ca da set foi organizado com três amostras de pacientes (114, 115,116) e um pool (n=8) de controle s (117).", "4.7 TROCA IÔNICA", "As amostras dos peptídeos marcados foram concentradas no SpeedVac (Thermo Fischer Scientific ) até um volume de 20 µl. Para efetuar a limpeza do reagente de iTRAQ remanescente foram acrescentados 80 µl de uma solução de KH2PO4 5 mM / ACN 25% pH 3, para efetuar uma cromatografia de troca iônica em spin column SCX (Harvard ). Foi utilizado um único passo de sal de 400 mM de KCl nas amostras de mitocôndria , sinaptossoma e núcleo 85, 150, 250 e 400 mM de KCl nas amostras de citosol. Imediatamente, as amostras foram dessalinizadas seguindo o protocolo descrito previamente e secas no SpeedVac (Thermo Fischer Scientific ). Finalmente, os peptídeos marcados foram ressuspensos em ácido fórmico 0,1%.", "4.8 ANÁLISES POR ESPECTROMETRIA DE MASSAS", "A mistura de peptídeos foi analisada em triplicatas técnicas empregando nano -LC (Proxeon EASY -nLC II ) on-line em coluna ReprosilPur C18 (esferas de 3 µm de diâmetro) de 15 cm . Para este fim, utilizou -se o solvente A ( 95% H 2O/5% ACN/0,1% de ácido fórmico ) e o solvente B ( 95% ACN/5% H 2O/0,1% de ácido fórmico ) num gra diente de três horas (de 5% até 40% de B/ 167 minutos; de 40% até 95% de B/ 5 minutos; 95% de B/ 8 minutos). No caso das análises das amostras com marcação de iTRAQ, a aquisição dos espectros foi efetuada no espectrômetro de massas LTQ Orbitrap Velos no modo Data Dependent Acquisition (DDA) com lista de exclusão dinâmica de 90s. Os parâmetr os de operação do espectrômetro de massas foram: voltagem de 2.5 kV no spray , fluxo zero de sheath e auxiliary gás e temperatura de 235 ° C no capilar aquecido. A varredura inicial do MS ( full scan ) foi adquirida em 60.000 de resolução no analisador Orbitra p. Foram selecionados os dez íons mais intensos para fragmentação HCD mediante aquisição no Orbitrap (7.500 de resolução) , usando energia de colisão normalizada de 40.", "Nas análises de quantificação por label-free na fração de sinaptossoma foi utilizado o instrumento QExactive Plus no modo FullScan -DAA usado uma lista de exclusão dinâmica de 45 s e voltagem de 2.30 kV no spray . O espectro MS1 foi adquirid o numa resolução de 70.000 e tempo de injeção máximo de 50 ms. Foram selecionados para fragmentação HCD os vinte íons mais intensos, utilizando uma resolução de 17.500, tempo máximo de injeção de 100 ms e uma energia normalizada de colisão de 30.", "4.9 ANÁLISES DOS DADOS", "Para as análises dos espectros foi feita a busca por PSM através do prog rama Proteome Discoverer 2.1 contra a base de dados humana (target -reverse) do neXProt, considerando um FDR < 1% . Foram comtempladas como modificações variáveis a oxidação das metioninas , a acetilação N -terminal das proteínas e a incorporação do reagente iTRAQ nos resíduos K, Y e N -terminal e como modificações fixas a carboxamidometilacão das cisteínas.", "4.10 ANÁLISE ESTATÍSTICA", "A avaliação estatística dos dados foi realizada no programa Inferno RDN (Polpitiya et al., 2008), sendo os peptídeos únicos normalizados usando Tendência Central e o desvio absoluto da mediana ajustada. Os peptídeos foram extrapolados para a proteína corre spondente através do RRollup usando o teste Grubbs, com um mínimo de três peptídeos e p -valor <0,05. Para determinar a significância estatística das proteínas desreguladas, calcularam -se o escore z e o p -valor associado utilizando um intervalo de confiança de 95%.", "4.11 ANÁLISE FUNCIONAL", "As análises comparativas foram realizadas com o programa Venny 2.1 . Para as análises do componente celular, processos biológicos e função molecular de proteínas quantificadas, foram usados os programas DAVID 6.8 e Reactome Pathways . Para a análise da localização subcelular foi utilizada a base de dados Uniprot Nas proteínas cuja variação na abundância foi estatisticamente significativa, os programas Reactome Pathways, STRING 10 (considerando interações de alta confiança) e KEGG foram utilizados para análises de interação proteína -proteína e avaliações de enriquecimento funcional.", "4.12 ANÁLISE PRM", "Analisaram -se 2 μg de peptídeos das amostras de pacientes e pool de paci entes controle com a versão pesada do peptídeo VAGALQAQVK (K: 13C (6) 15N (2)) ( JPT Peptide Technologies ). A separação dos peptídeos foi realizada utilizando um EASY - nLC 1000 ( Thermo Scientific ), pre-coluna de 2 cm (100 μm ID, 5 μm esferas -Reprosil Pur C18 , Dr. Maish ) e coluna analítica de (30 cm x 75 μm ID, esferas de 3 μm - Reprosil Pur C18, Dr. Maish ). A eluição dos peptídeos foi realizada aplicando um fluxo de 300 nL/min e gradiente separação de 5 a 40% do solvente B (95% de acetonitrilo, 0,1% de ácido fórmico) ao longo de 100 minutos seguido por 10 min de 40 -95% d o solvente B e 10 min de lavagem a 95% d o solvente B. A analises por PRM foi realizado num Q Exactive Plus (Thermo Scientific ) usando uma lista de inclusão para os íons alvo com janela 2-Th, resolução de 35.000 , AGC de 5x105, tempo máximo de injeção de 150 ms e energia de colisão normalizada de 27. Os dados PRM foram analisados no software", "4.13 ANÁLISE SRM", "A análise SRM foi realizada num EASYII -nano -LC (ThermoScientific ) utilizando uma coluna C18 PicoChip 75µm x 105mm ( New Objective ) e pre-coluna C18 Acclaim PepMap 75µm x 2cm ( ThermoScientific ). Como solvente s foram utilizadas uma solução A de 95% de H 2O/5% de ACN/0,1% de ácido fórmico e solvente B 95% ACN/5% de H2O/0,1% de ácido f órmico num fluxo de 320 nL/min durante 60 min. Os dados foram adquiridos em modo positivo usando o modo SRM do espectrômetro de massa s TSQ Quantiva (Thermo Scientific) . O primeiro e terceiro quadrupolos foram configurados numa resolução de 0,7 (FWHM) usando um tempo de ciclo de 2 s. A fragmentação dos íons precursores foi realizada com gás de árgon usando energia de colisão normalizada entre 10 -30. Com relação aos parâmetros da fonte de íons, a voltagem do spray e a temperatura do tubo de transferência de íons foram 2,6kV e 280ºC respectivamente. A análise dos dados foi realizada no software Skyline v. 4.2 utilizando uma biblioteca pública NIST de espectros de fragmentação disponível no Peptide Atlas ( Ion Trap: Human . Formato SpectraST com peptídeos curtos (<7AA) excluídos. Nome do ficheiro: NIST_human_IT_2012 -05-30_7AA. splib.zip). Para normalização de dados, usamos como padrão global a sequência do peptídeo pesado: AVLDLFEETSNIGSK. Para as análises quantitativas, fo ram consideradas ao menos três transições por peptídeos, dois peptídeos por família de proteínas e dotp > 0,7. Para proteínas com mais de um peptídeo monitorado, a soma das áreas normalizadas de todos os peptídeos foi usada para as análises estatísticas. O software Statistix 8.0 foi utilizado para calcular as variações significativas na abundância d as proteínas, aplicando -se um teste ANOVA, seguido d as comparações pareadas d o Test de Tukey HSD, considerando um p -valor <0,05.", "5 CAPÍTULO V -RESULTADOS E DISCU SSÃO", "5.1 FRAÇÃO DE SINAPTOSSOMA", "Nas análises do proteoma total da fração do sinaptossoma (ver apêndice B) , foram identificadas 2018 grupo de proteínas combinando os resultados das técnicas de quantificação relativa iTRAQ e label -free. A análise quantitativa pelo método de iTRAQ identificou 1176 proteínas para um total de 513 grupos de proteínas, 127 deles com uma quantificação robusta de ao menos 3 peptídeos únicos por proteínas. Por outro lado, a quantificação livre de marcação identi ficou 4904 proteínas em 1917 grupos de proteínas, sendo 341 proteínas robustamente quantificadas. Os p rocessos biológicos mais importantes do proteoma total reportados pelo programa DAVID estão relacionados à transdução de sinal e adesão célula -célula ; já segundo o programa Reactome , a orientação dos axônio s e o tráfego de membranas são os processos biológicos mais destacados. A análise qualitativa da quantificação livre de marcação demonstrou que 161 proteínas foram detectadas apenas no controle , sendo apenas 10 delas identificadas com dois ou mais peptídeos únicos. As proteínas detectadas no controle estão envolvidas nos processos biológicos de adesão das células neurais e ativação do receptor GABA A . Deficiências na função GA BA no córtex pré -frontal resultam em disfunção da neurotransmissão e cogni ção em pacientes com esquizofrenia (YOON et al., 2010) . Por outro lado, 741 proteínas foram identificadas no grupo de pacientes; apenas 6 destas identificadas com dois ou mais peptídeos únicos . As funções biológicas das proteínas identificadas nos pacientes estão associadas a os processos de tráfego de membrana e transmissão sináptica química . Neste grupo, destacam -se a proteína de adesão Cadherin - 1, a Proteína de interação com o fator de morte celular programada 6 (PDCD6IP ) e a proteína de choque térmico HSP70. A caderina -13 medeia a adesão célula -célula e está envolvida na sinaptogênese e plasticidade sináptica (REDIES; HERTEL; HÜBNER, 2012) . O gene da Caderina -13, Cdh13 , está associad o ao risco genético da esquizofrenia (OTSUKA et al., 2015) . Recentemente, foi demonstrada a relação entre a Cadherin -13 e o sistema GABA. A Caderina -13 está localizada nas sinapses GABA érgicas, e os camundongos Cdh13 -/- mostram um aumento na atividade sináptica inibitória sem alterações na atividade sináptica excitat ória, resultando num desequilíbrio no balance do circuito excitatório -inibitório (RIVERO et al., 2015) .", "Em relação às análises quantitativas, os critérios de seleção das proteínas desreguladas incluem, além do p-valor, o mesmo comportamento quantitativo em ao menos a metade dos pacientes estudados para esta fração subcelular (n≥3). A análise estatística dos dados determinou 12 proteínas significativamente desreguladas na quantificação por iTRAQ e 55 proteína s com variações estatisticamente significativas em sua abundância pela quantificação livre de marcação . Segundo as análises funcionais as proteínas desreguladas participam na atividade sináptica e nas vias de sinalização do metabolismo do cálcio . A análise por PRM confirmou a quantificação de proteínas -chave como SERCA, MARCKS, CAM1, CYCS, RTN1 -C, LSAMP e PDCD6IP , obtendo resultados semelhantes à quantificação por iTRAQ e livre de marcação.", "A análise da interação proteína -proteína das proteínas desr eguladas mostrou que o principal ponto de interação converge n a Calmodulina (CaM ), um importante sensor intracelular d o cálcio que participa em diversas vias de sinalização como apoptoses e plasticidade sináptica (XIA; STORM, 2005) . A CaM regula a liberação da s vesícula s sináptica s (PANG et al., 2010) . Além disso, foi reportada a diminuição de CaM na terceira camada da área de Brodman n 9 nos pacientes com esquizofrenia, indicando perda dos neurônios piramidais do córtex pré-frontal (BROADBELT; JONES, 2008) . Ao mesmo tempo, CaM interage com proteínas relevantes nos p rocessos de plasticidade sináptica, como MARCKS e αCaMKII . CaM se liga a MARCKS, removendo -a das membranas (KIM, J. et al., 1994) . Curiosamente, nossos dados revelam o aumento de MARCKS concomitantemente com a diminuição de CaM , forte indicio da possível localização de MARCKS na membrana dos neurônios . Foi demonstrado que a regulação positiva d e MARCKS prejudica significativ amente a aprendizagem espacial (MCNAMARA et al., 2005) . Além do mais, f oi reportado o aumento de MARCKS na fração d e membrana do tecido cerebral post-mortem do hipocamp o de pacientes com comportamento suicida (PANDEY et al., 2003) e no córtex pré-fronta l dorsolatera l de pacientes com esquizofrenia e transtorno bipolar (KONOPASKE et al., 2015) . Atualmente, pesquis as indicam que ratos com administração crônica de haloperidol ou clozapina não apresentaram alterações significativas na expressão relativa do mRNA e da expressão de proteína de MARCKS (KONOPASKE et al., 2015 ; ANITA L. PINNER, VAHRAM HAROUTUNIAN, 2014) . Por outro lado, outro parceiro molecular de CaM, a proteína αCaMKII , é importante para a potenciação de longo prazo através de sua interação com CaM e o receptor NMDA (GRIFFITH, 2004) . Estudos relata m que a superexpressão de αCaMKII em camundongos mutantes induz um aumento signific ativo na ansiedade e alterações no comportamento social (HASEGAWA et al., 2009) .", "Paralelamente à análise de associação de rede s de interação proteína -proteína , o programa KEGG confirmou a participação das proteínas desreguladas na via de sinalização do cálcio , destacando -se a ativação dos receptores acoplados à proteína G e a ativação d a PLCβ. A ativação d a PLCβ gera a hidrolises do 4,5 -bifosfato de fosfatidilinositol , produzindo inositol 1,4,5 -trifosfato (IP3) (SZEBENYI et al., 2014) . O IP3 medeia o aumento do Ca2+ citosólico através da liberação das reservas intracelulares por meio da ativação do receptor de IP3 do retículo endoplasmático (RE) (DECUYPERE et al., 2011) . Em resposta à liberação de cálcio do R E, a regulação positiva de SERCA e Ca2+ ATPase da membrana plasmática foi observada nes ta via de sinalização . Um excesso do cálcio intracelular está associado ao estresse do R E e à ativação da morte celular (GHIBELLI; CERELLA; DIEDERICH, 2010) . Nesse sentido, foi reportado em nossos dados o incremento da proteína Reticulon -1 (RTN1 -C). A RTN1 -C está localizad a na membrana do R E, e sua superexpressão está associada à morte celular induzida por estresse do R E, com alterações ultraestruturais nas mito côndrias (SANO, DI et al., 2007) . Além disso , como foi menci onado anteriormente, a prote ína PDCD6IP , identificada apenas nos pacientes com esquizofrenia , quando ocorre o desequilíbrio na homeostase d o cálcio e o estresse do R E, PDCD6IP participa como mediador crucial da apoptose ativando a Caspase -9 (STRAPPAZZON et al., 2010) .", "O fluxo de Ca2+ afeta a permeabilidade do poro de transição mitocondrial, propiciando a apoptose com a liberação do citocromo C (CYCS ) e outros fatores pró - apoptóticos (MARCHI; PATERGNAN I; PINTON, 2014) . De fato, o segundo ponto principal na análise de associação de redes de interação proteína -proteína, inclui proteínas como SLC25A6 e VDAC2 envolvidas na apoptose através do controle da permeabilidade mitocondrial (TSUJIMOTO; NAKAGAWA; SHIMIZU, 2006) . O aumento na abundância de SLC25A6 ativa as caspases 9 e 3 (ZAMORA et al., 2004) e o VDAC2 facilita a estabilização d e Bax na membrana externa mit ocondrial (MA, S. B. et al., 2014) . Outro indicador imp ortante e clássico da apoptose , o CYCS, faz parte des ta rede de interação. O aumento do CYCS aprimora a ativação da s caspase s (CHANDRA; LIU; TANG, 2002a) . Igualmente , a Proteína Serina/ Treonina fosfatase PGAM5, um novo parceiro do Fator indutor d a apoptose na indução d a morte celular (LENHAUSEN et al., 2016) , encontra -se incrementad a nos pacientes com esquizofrenia. Por outro lado , foram identificadas proteínas anti -apoptóticas como BAG3, HSP70 e 14-3-3η importantes na inibição dos processos de apoptose mediados por Bax e Fas (LEE, J. -H. et al., 1999 ; ROSATI et al., 2011) , na sobrevivência celular sob condições de estresse do R E (GUPTA et al., 2010) e na neuroproteção ao estresse celular induzido por NMDA (CHEN, J. et al., 2007) , respectivamente.", "A apoptose tem sido proposta como um processo na fisiopatologia da esquizofrenia. Há evidências que sugerem uma forma de morte celular programada na perda progressiva do volume de massa cinzenta durante o curso da doença nas áreas frontal, parietal e temporal (GLANTZ et al., 2006) . Um estudo longitudinal determinou os efeitos a longo prazo do tratamento antipsicótico no volume ce rebra l, propondo que tratamento antipsicótico agravar a reduç ão progressiva no volume do tecido cerebral de pacientes com esquizofrenia (HO et al., 2011) . De fato, foi relatado o aumento na atividade da caspase -3 como efeito retardado ao tratamento com antipsicóti cos típico s e atípico s sem evidências d e fragmentação no DNA, indicando que o s psicofármacos não induz em apoptose por si só, mas podem contribuir na perda progressiva da matéria cinzenta nos estágios iniciais da esquizofrenia (GLANTZ et al., 2006) . Outrossim , a cultura de fibroblastos provenientes de pacientes que cursam o primeiro episódio psicótico da esquizofrenia, apresentam maior suscetibilidade à apoptose, exibindo uma correlação entre o volume cerebral e as alterações nos níveis de glutamato cerebral e N - acetilaspartato no cingulado anterior e no tálamo esquerdo (BATALLA et al., 2015) . Além do mais , os níveis séricos de marcadores apoptóticos foram significativamente maiores em pacientes com síndrome deficitária da esqui zofrenia do que em pacientes com síndrome não -deficitária da esquizofrenia e em controles saudáveis (ALBAYRAK et al., 2016) , sugerindo a importância d a apoptoses nos sintomas negativos desta doença . Finalmente , é necessá rio destacar variações na abundância de proteínas relacionadas aos processos de adesão celular e à organização do citoesqueleto . Uma dessas proteínas é LSAMP, aumentada em todos os pacientes analisados por iTRAQ. LSAMP é predominantemente express a na superfície dos dendritos e soma s proximais e atua na adesão celular neural e na formação e crescimento de neurites (INNOS et al., 2013) . O gene LSAMP está associado ao comportamento humano e foi demonstrado que o incremento no nível de transcrição na área amigdalóide, cinza periaq uedu ctal, Rafe, hipocampo e córtex frontal estão relacionados à reação aguda ao medo, condicionamento do medo e ansiedade (PHILIPS et al., 2015) . As variantes alélicas localizadas na região intrônica do gene LSAMP estão correlacionadas com a etiologia do comportamento suicida (MUST et al., 200 8) e existe uma associação alélica e de haplótipos significativa entre o gene LSAMP e esquizofrenia (KOIDO et al., 2014) . Num estudo proteômico de microdomínios de membrana de tecido cerebral post-morte m do córtex pré -frontal dorsolateral de pacientes com esquizofrenia, a expressão de LSAMP se encontrou aumentada (BEHAN et al., 2009) , indicando que essa proteína pode desempenhar um papel importante na fisiopatologia da doença . Atualmente, sugere -se que LSAMP te m um possível papel na regulação do comportamento emocional nos transtornos psiquiátricos (INNOS et al., 2013) .", "5.2 FRAÇÃO MITOCONDRIAL", "Nas análises por espectrometria de massa, foram identifica dos 655 grupos de proteínas na fração mitocondrial ( MIT) (Ver apêndice C). As proteínas identificadas em MIT estão envolvidas no transporte de elétrons, no ciclo do ácido cítrico e na síntese de ATP. A marcação por iTRAQ quantificou de maneira robusta um total 329 grupos de proteínas com ao menos três peptídeos únicos . O critério de seleção das proteínas desreguladas foi o mesmo aplicado na fração de sinaptossoma.", "Treze proteínas foram encontradas desreguladas na fração MIT . As proteínas CLTC e PPIase foram reportadas como diminuídas e suas funções biológicas estão relacionadas à endocitose e enovelamento de proteínas. Além disso, foram encontradas onze proteínas aumentadas , envolvidas principalmente em processos biológicos como o ciclo do ácido cítrico , transporte de elétrons, organização da membrana e formação de cristas mitocondria is. Neste último grupo, destaca -se a proteína do Canal Aniônico Voltagem Dependente (VDAC1), anteriormente relatada como desregulada em pacientes com esquizofrenia (ENGLISH, Jane A. et al., 2011) . A superexpressão d e VDAC1 media a apoptose mitocondrial ; sua oligomerização é importante na formação de poros que facilitam a mobilização das proteínas pró -apoptóticas do espaço intermembranar da mitocôndria ao citosol (WEISTHAL et al., 2014) desencadeando a liberação do citocromo c e ativação das caspases (LEE, M. et al., 2004 ; CHO et al., 2007 ; QU et al., 2009) . Outro forte indicio da ativação da apoptose é o aumento de proteínas como o Complexo III e NipSnap1. Sob condição de estresse oxi dativo, o Complexo III propicia a ativação da via intrínseca da apoptose (DIBROVA et al., 2013) , por outro lado, NipSnap1 , envolvid a na homeostase do Ca2+ (SCHOEBER et al., 2008) , fomenta as vias de sinalização celular da mitofagia (PRINCELY ABUDU et al., 2019) . Estes resultados concordam com os relatados anteriormente na fração do sinaptossoma (VELÁSQUEZ et al., 2017) onde também se observa a desregulação da via do metabolismo do cálcio concomitantemente com a ativação do processo apoptótico .", "Quando um sinal apoptótico é ativado, o equilíbrio entre estímulos pró e an ti- apoptóticos determina a morte celular. Uma das alterações mais notáveis nos processos apoptóticos é a modificação estrutural das mitocôndrias , sugerind o-se que o remodelamento das cristas mitocondriais pode afetar a liberação de proteínas como o citocromo c (FREZZA et al., 2006) . Em resposta aos sinais apoptóticos, encontramos nos pacientes com e squizofrenia um aumento das proteínas como o Inibidor da ATPase (IF1) , Mic19 e Mic25. O incremento na abundância de IF1 tem capacidade de limitar a morte celular, evitando a depleção de ATP da matriz mitocondrial induzida pelo bombeamento reverso da F1Fo -ATP sintase durante condições na que o potencial de membrana mitocondrial se encontra reduzid o (CAMPANELLA et al., 2009) . O IF1 também controla a estrutura da crista mitocondrial (FACCENDA et al., 2017) e juntamente com Mic19 e seu par álogo Mic25, contribuem para a manutenção da arquitetura e a organização da membrana e crista s mitocondria is (ELLISMAN et al., 2010 ; AN et al., 2012 ; FRIEDMA N et al., 2015) .", "5.3 FRAÇÃO NUCLEAR", "Nas análises por espectrometria de massa foram identificados 1500 grupos de proteínas na fração NUC (Ver apêndice C) , cuja função biológica se encontra principalmente associada à splicing de mRNA . Após a normalização e tratamento dos dados, quantificou -se um total 888 grupo s de proteínas . O critério de seleção das proteínas desreguladas foi o mesmo aplicado na fração de sinaptossoma , detecta ndo-se 87 proteínas com variação estatisticamente significativa em sua abundância relativa . As proteínas APP, S100A1, PRKCB apresentaram diminuição na abundância, e estão relacionadas à transdução de sinal do Ca2 +. e apoptose . Por outro lado, 8 4 proteínas incrementaram sua abundância, muitas delas estão envolvidas na apoptose e na transmissão d as sinapses químicas .", "5.3.1 Proteínas localizadas no núcleo celular", "A função biológica relacionada a um dos principais grupos de proteínas desreguladas, está envolvida na ativação da apoptose e aos fatores de transcrição FOXO . Pode -se destacar a família d as proteínas 14 -3-3, envolvida na regulação de vários eventos celulares como a autofagia (JIA et al., 2017) e apoptose , através da interação com proteínas como BAX, BAD , caspases (ROSENQUIST, 2003 ; SMIDOVA et al., 2018) e MAPK (XING et al., 2000 ; DONG et al., 2007) . As proteínas 14-3-3 regulam o fator de transcrição FOXO através d e sua fosforilação (OBSILOVA et al., 2005) , inibindo sua ligação ao DNA e sua translocação citoplasmática (OBSILOVA et al., 2005 ; SILHAN et al., 2009) . O FOXO citoplasmático não está disponível para regular a transcrição de vários genes, como os pertencentes à via de sinalização NF-kB (ZANELLA; SANTOS, DOS; LINK, 2013) . O déficit na função FOXO leva a um aumento na atividade in vivo de NF -kB (LIN; HRON; PENG, 2004 ; ZHOU et al., 2009) .", "Paralelamente, foi possível detectar o aumento de várias proteínas nucleares relacionadas à a tivação de NF -kB, como 1) RhoB (RODRIGUEZ et al., 2007) , que também pode elevar a caspase -3 nos neurônios corticohipococampais (BARBERAN et al., 2011) , 2) HMGB1, envolvid a na excitoneuro toxicidade mediada por NF -kB (SAKAMOTO et al., 2017) e liberado dos neurônios para os astrócitos ativando o fator nuclear -kB (KARATAS et al. , 2013 ; SHI et al., 2018) . É importante mencionar que o HMGB1 ativa a via de sinalização de NF-kB por mecanismo um dependente de ERK (PALUMBO et al., 2007) ; nesse sentido, detectamos por SRM o aumento da proteína ERK -2 na fração NUC, uma evidência indireta d a ativação de ERK (CHEN, B. et al., 2016) . Além disso, foi detectada a diminuição da Proteína kinase C beta nuclear envolvida na regulação de NF -kB (SAIJO et al., 2002 ; KIM, S. W. et al., 2014) . Um estudo de microarray realizado no giro temporal superior de pacientes com esquizofrenia sugeriu o detrimento da sinalização de NF -kB nessa área do cérebro (ROUS SOS et al., 2013) , porém um estudo recente de Volk e colegas (VOLK et al., 2019) , mape ou extensivamente a expressão de genes relaciona dos à sinalização canônica e não canônica de NF -kB no córtex pré -frontal de pacientes com esquizofrenia, concluindo que ambas vias estão aumentadas e não são afetadas pelo tratamento antipsicótico.", "Por outro lado, foram encontradas proteínas desreguladas que se destacam por participarem na transmissão d as sinapses químicas, representadas principalmente pelo aumento de proteínas como gama quinase tipo II dependente de cálcio / calmodulina (γCaMKII). Após o aumento citosólico de Ca2+, a γCaMKII transloca a CaM do citoplasma para o núcleo (LI, B.; TSIEN; MA, 2016) . Essa proteína foi relatada previa mente como des regulada (juntamente com CaM) na fração nuclear de corpo caloso e lobo temporal anterior de pacientes com esquizofrenia (SAIA -CEREDA, et al., 2017) , também foi demonstrado que γCaMKII tem uma regulação anormal no córtex pré -frontal (COYLE, 2009) . Os peptídeos únicos de γCaMKII foram mapeados e quantificados usando a técnica SRM nas frações NUC e CYT (onde anteriormente não era possível identificar) demonstrando que γCaMKII aparentemente e stá localizad a principalmente NUC , já que, encontrado um aumento significativo nessa fração e nenhuma alteração na abundancia da γCaMKII em CYT. No entanto, como pode estar aumentad a γCaMKII nuclear em nossos resultados se o CaM nuclear tem a tendência de permanecer diminuído? Anteriormente, estudos demonstraram que γCaMKII precisa ser fosforilad a na Thr287 para transportar a CaM ao núcleo de forma eficaz (MA, et al., 2014a ; COHEN et al., 2018) e, para esse processo, foi demo nstrado que a função da quinase βCaMKII é responsável pela fosforilação de pThr287 (MA, et al., 2014a ). De acordo com essas observações, encontramos a βCaMKII diminuída na fração CYT. Ma e coleg as (2014) demonstraram que sem a fosforilação de βCaMKII em T287, a translocação nuclear da γCaMKII não é afetada, porém o transporte nuclear de CaM e a ativação de CREB é prejudicada juntamente com a plasticidade sináptica (MA, et al., 2014a ; SAURA;", "5.3.1 Proteínas mitocôndrias e de membrana localizadas na fração nuclear A fração nuclear obtida durante o processamento da amostra, além de enriquecer as proteínas nucleares, traz contaminantes comuns como mitocôndrias (principalmente aquelas localizadas na região perinuclear) e membr ana plasmática e, possivelmente, contaminantes menores, como lisossomos, peroxissomos, membranas de Golgi e várias vesículas de membrana (GRAHAM, 2002) . A metodologia utilizada restringe a interpretação da função biológica de proteínas que podem compartilhar diferentes localizações subcelulares além do núcleo. Neste conjunto de dados, detectamos como os principais contaminantes da fração NUC, proteínas cuja localização subcelular foi relatada nas mitocôndrias e na membrana celular, no entanto, algumas dessas proteínas são interessantes de mencionar devido à sua importância biológica. Entre elas podemos destacar proteínas mitocôndrias que participam no metabolismo do glutamato como a glutamina sintetase (GS), aumentada na fração NUC e a glutamato desidrogenase (GLDH) encontrada como diminuiu na fração CYT e a proteína de membrana como o transportador de aminoácido excitatório 2 (EAAT2) responsável por cerca de 90% da depuração do gl utamato na fenda sináptica (PARKIN et al., 2018) .", "O segundo grupo de proteínas de membrana importantes de mencionar est á envolvido na via do sistema complemento. Encontrou -se aumentada a glicoproteína CD59, cuja principal função é a inibição da proteína do complemento C9 para impedir a formação do complexo de ataque da membrana (FARKAS et al., 2002) . Na doença de Alzheimer, observou -se que a ativação do CD59 não é eficiente para suprimir a ativação do complemento (YASOJIMA; MCGEER; MCGEER, 1999) . Recentemente, foi descrita a ativação da via do complemento através da sinalização de NF -kB. Os astrócitos são uma das principais fontes de NF -kB, que promovem a estimulação d os receptores neuronais do complemento C3 (chamados C3R), desequilíbrio de cálcio e a alteração morfológica nos dendritos (LIAN et al., 2016) . Com base nes tas informações e na evidência indireta da desre gulação de NF -kB, decidimos implementar uma abordagem direcionada pa ra quantificar o complemento C3 e membros da família NF -kB usando SRM . Observamos que o C3 está aumentado , apenas na fração NUC, em pacientes com esquizofrenia comparado ao controle o que provavelmente indica a localização d e C3 na membrana plasmática e a ativação d a via do complemento . Os membros da família NF -kB, como NF-kB1 e NF -kB2, também aumentaram na fração NUC , sugerindo um papel importante dessa via como um possível mecanismo para a ativação de C3. As p roteínas d o complemento são necessárias para a eliminação de sinapses inadequadas do sistema nervoso central (STEPHAN; BARRES; STEVENS, 2012) . Por outro lado, a expressão de C3 na superfície celular também permite o reconhecimento desse sinal pelos receptores CR3 da microglia, promovendo a remoção dos elementos sinápticos (PRESUMEY; BIALAS; CARROLL, 2017) . Esse processo também pode participar na eliminação ativa das sinapses em depressão de longa duração quando o mecanismo apoptótico da caspase - 3 é ativado sem causar morte celular nos dendritos (LI, et al., 2010 ; STEPHAN; BARRES; STEVENS, 2012) . Ao longo dos anos, o sistema complemento tem sido indicado como um elemento importante na patogênese da esquizofrenia. Recentemente, um dos estudos genéticos mais extensos vincula o complexo principal de histocompatibilidade humana como um dos genes mais importantes relacionados à esquizofrenia (RIPKE et al., 2014) . Em 2016, Sekar e colaboradores relataram a expressão elevada do transcrito C4A em pacientes com esquizofrenia, reforçando a teoria de que C4 lidera a ativação de C3 e a eliminação de sinapses nestes pacientes.", "5.4 FRAÇÃO CITOPLASMÁSTICA", "Na fração citoplasmática ( CYT ) foram identificados 1591 grupos de proteínas, cuja função biológica predominante está relacionada ao metabolismo das poliaminas e na ativação de NF -κB (Ver apêndice C) . Foram detectadas 87 proteínas desreguladas utilizando o mesmo critério de seleção que na fração de sinaptosoma . Esta fração se destaca porque a maioria das proteínas , que atendem aos nossos critérios de seleção, não está apenas diminuída , mas a s mesma s proteína s se encontra m aumentada s na fração NUC ou MIT. Entre a s funções biológicas associadas às proteínas desreguladas está o processo de orientação do axônio, que inclui a desregulação das proteínas do proteassoma e das proteínas ribossômicas .", "Uma das principais proteínas envolvidas na orientação do axônio, crescimento neuronal e plasticidade sináptica é a neuromodulina (GAP -43), diminuída nos pacientes com esquizofrenia . Na esquizofrenia, observou -se uma redução significativa do GAP -43 no giro dentado (CHAMBERS et al., 2005) . Além disso, o knockdown astrocítico do GAP43 induz a superexpressão do EAAT2, o que causa a captação excessiva de glutamato extracelular, ativando a neurotoxicidade induzida p elos astrócitos e a ativação da microglia (HUNG et al., 201 6).", "As proteínas ribossômicas são outro cluster importante que também participa do crescimento axonal com a tradução local do mRNA (JUNG; YOON; HOLT, 2012) . Encontramos diminuição principalmente das proteínas ribossômicas (RP), das subunidades ribossômicas 60S e 40S (RS), responsáveis por catalisar, durante o processo de síntese protéica , a formação de ligações peptídicas e pela ligação, decodificação e emparelhamento dos códons de mRNAs e tRNAs aminoacilados, respectivamente (JENNIFER A DOUDNA, 2002) . A nova síntese protéica é essencial para orientação dos axônios, remodelação estrutural e mudança fu ncional por trás da potencia ção e depressão de longa duração , para estabelecer novas conexões sinápticas e / ou fortalecer a comunicação sináptica preexistente; a base molecular para a formação e manutenção da memória (BUFFINGTON ; HUANG; COSTA -MATTIOLI, 2014) . Um estudo integrado de proteômica e análise transcriptômica usando neurosfera olfativa humana derivada de paciente com esquizofrenia, detectou uma redução significativa em 17 proteínas ribossômicas com uma menor taxa de s íntese global de proteínas em comparação com o controle, também foi observada uma desregulação nas vias de sinalização a montante que controlam a síntese de proteínas, como a sinalização eIF2 e mTOR (ENGLISH, J. A. et No entanto, neste estudo, nosso conjunto de dados revela algo mais sobre o cluster de proteínas ribossômicas , revelando uma possível função extraribosomica para estas proteínas na es quizofrenia ( Ver apêndice C) . Finalmente, as proteínas pertencentes ao sistema ubiquitina -proteassoma (UPS) foram encontradas desreguladas. O UPS é o principal sistema de degradação de proteínas, mas atua na reciclagem de receptores, tráfico de vesículas, degradação vacuolar (KLEIGER; MAYOR, 2014) e desenvolvimento de axônios (HSU et al., 2015) . A diminuição do sistema UPS nos neurônios do giro temporal superior e dos grânulos dentados de indivíd uos com esquizofrenia resulta no comprometimento da homeostase em AMPAR, na estrutura dos dendritos e no acúmulo de proteínas no retículo endoplasmátic o (ALTAR et al., 2005 ; RUBIO et al., 2013) . Uma UPS ineficiente pode tornar os neurônios mais vulneráveis a espécies reativas de oxigê nio, contribuindo para os comprometimentos mitocondriais relatados na esquizofrenia (RUBIO et al., 2013) .", "6 CAPÍTULO VI -CONCLUSÕES GERAIS", "1. O desbalanço das proteínas relacionadas ao metabolismo do cálcio e glutamato são importantes na fisiopatologia da esquizofrenia, especificament e no córtex orbitofrontal.", "2. A desregulação da proteína MARCKS pode contribuir na plasticidade sináptica anormal em pacientes com esquizofrenia.", "3. O incremento de LSAMP e αCaMKII pode estar relacionado ao comportamento social aberrante.", "4. A apoptose mediada pelo estresse do RE no córtex orbitofrontal, pode ser um mecanismo fisiopatológico importante na esquizofrenia.", "5. A ativação anormal de CREB pode estar relacionada ao déficit cognitivo em pacientes com esquizofrenia.", "6. NF-kB é proposta com o uma via de sinalização importante nos pacientes com esquizofrenia para ativação da inflamação e das proteínas do sistema do complemento.", "7 REFER ÊNCIAS", "AGHAJANIAN, G. K.; MAREK, G. J. Serotonin model of schizophrenia: emerging role of glutamate mechanisms . Brain Research Reviews , [s.l.], v. 31, no 2–3, p. 302 –312, 2000. ISSN: 01650173, DOI:", "AKARSU, S. et al. Mitochondrial complex I and III gene mRNA levels in schizophrenia, and their relationship with clinical features. Journal of molecular psychiatry , [s.l.], v. 2, no 1, p. 6, 2014. ISBN:", "ALBAYRAK, Y. et al. Increased serum levels of apoptosis in deficit syndrome schizophrenia patients: a preliminary study . Neuropsychiatric Disease and Treatment , [s.l.] , p. 1261, 2016. ISSN: 1178 -2021,", "ALTAR, C. A. et al. Deficient hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial genes in multiple schizophrenia cohorts . Biological Psychiatry , [s.l.], v. 58, no 2, p. 85 –", "AN, J. et al. CHCM1/CHCHD6, novel mitochondrial protein linked to regulation of mitofilin and mitochondrial cristae morphology . Journal of Biological Chemistry , [s.l.], v. 287, no 10, p. 7411 –7426,", "ANITA L. PINNER1,*, VAHRAM HAROUTUNIAN2, and J. H. M. -W. Alterations of the myristoylated, alanine -rich C kinase substrate (MARCKS) in prefrontal cortex in schizophrenia .", "ARION, D. et al. Transcriptome Alterations in Prefrontal Pyramidal Cells Distinguish Schizophrenia From Bipolar and Major Depressive Disorders . Biological Psychiatry , [s.l.], v. 82, no 8, p. 594 –600,", "BANERJEE, S.; MAZUMDAR, S. Electrospray Ionization Mass Spectrometry: A Technique to Access the Information beyond the Molecular Weight of the Analyte . International Journal of Analytical", "BANTSCHEFF, M. et al. Quantitative mass spectrometry in proteomics: Critical review update from 2007 to the present . Analytical and Bioanalytical Chemistry , [s.l.], v. 404, no 4, p. 939 –965, 2012. ISSN:", "BARBERAN, S.; , KARA MCNAIR, KHALIL IQBAL, NICOLA C. SMITH, G. C. P.; TREVOR W. STONE, STUART R. COBB, and B. J. M. Altered apoptotic respons es in neurons lacking RhoB CHAPTER 18 APPLICATION OF iTRAQ SHOTGUN PROTEOMICS FOR MEASUREMENT OF BRAIN PROTEINS IN STUDIES OF PSYCHIATRIC DISORDERS", "Erika Velásquez Núñez, Paul C. Guest , Daniel Martins -de-Souza, Gilberto Barbosa Domont, and Fábio César Sousa Nogueira", "18.1 Introduction", "Psychiatric disorders are a leading cause of medical disability throughout the world, affecting one out of every three people at some point in their lifet ime [1]. Despit e the fact that years of intensive research have led to a better understanding of the biological pathways that are perturbed in people with these disorders, none of this information has led to newer and better approaches for patient manageme nt, particularly in the area of improved diagnosis and treatment. Thus far, this has been hindered by a poor understanding of the molecular pathways affected in these diseases and may also be a direct cause of disease complexity and overlap of symptoms acr oss the supposedly different disorders [2, 3]. The current state -of-the-art diagnosis is based on evaluation of symptoms during clinical interviews, but this is only subjective and can vary depending on the experience, training, and methodology of the atte nding clinician and the validity of information given by the patient. Taken together, this can make effective disease management a difficult prospect.", "The availability of biomarker tests based on the pathologies underlying psychiatric disorders would help to overcome some of these difficulties. Using biomarker tests targeting the affected pathways would give empirical readings, which could be used in combination with the standard methods for improved accuracy and timeliness of diagnosis. In turn, this would allow the access of patients to earlier and more efficient treatment options. In the initial discovery stages, it is important that brain tissue is analyzed in order to identify potential biomarkers, considering that this is likely to be the direct cause of symptoms due to effects on neuronal pathways [4].", "E.V. Núñez • G.B. Domont • F.C.S. Nogueira (*) Laboratory of Protein Chemistry – Proteomics Unit, Chemistry Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil e-mail: fa biocsn@ufrj.br P.C. Guest • D. Martins -de-Souza Department of Biochemistry and Tissue Biology, Laboratory of Neuroproteomics, Institute of Biology, University of Campinas, CidadeUniversitáriaZeferinoVaz, Campinas, Brazil © Springer International Publishing AG 2017 P.C. Guest (ed.), Proteomic Methods in Neuropsychiatric Research, Advances in Experimental Medicine and Biology,", "Furthermore, proteomic -based biomarkers are likely to be the most useful for development of diagnostic and prognostic tests considering the dynamic nature of proteins in general in response to changing environmental stimuli [5].", "Mass spectrometry (MS) profiling is one of the key proteomic techniques in the study of disease biomarkers [6], and the incorporation of isobaric labeling methods in MS approaches, such as isobaric tags for relative and absolute quantitation (iTRAQ), has allowed measurement of multiple proteomes simultaneously [7]. Although the iTRAQ labels have an indistinguishable mass i n MS mode, reporter fragment ions of different masses are released in MS/MS mode in the collision chamber. This enables peptides from different samples to be differentiated and quantitated based on the intensity of their specific reporter ions [8]. The iTR AQ approach has now been used for analysis of up to four [7] or eight samples [9]. In comparison to label -free MS techniques, the multiplexing potential of the iTRAQ approach allows a simultaneous analysis of different biological samples, decreases the inh erent variations in chromatographic analysis between the samples, and requires fewer technical replicates to obtain a good accuracy in the measurement. In the iTRAQ 4 -plex approach, the reagent contains an N -methylpiperazine reporter, carbonyl balance, and NHS -ester reactive groups. Each reagent has the same mass (145 Da) achieved by a combination of 13C, 15N, and 18O in the reporter (114 – 117 Da) and balance groups (31 –28 Da). The labeled peptides have identical retention times during chromatographic separa tion, and the peptides appear as a single peak with the same m/z in MS spectra. However, fragmentation of the precursor ion produces MS/ MS spectra with reporter ion peaks at low mass region (114, 115, 116, and 117 Da) and peptide fragmentation ion peaks o f higher masses. The intensity of the reporter ion peaks directly reflects the abundance of the peptide in each sample (Fig. 18.1).", "Fig. 18.1 Schematic diagram of the iTRAQ4 -plex mass spectrometry approach", "Here, we describe a detailed sample preparation and iTRAQ 4-plex labeling protocol for relative quantification of postmortem brain samples from patients with psychiatric disorders such as schizophrenia compared to those from controls. In addition, we outline a strategy for peptide fractionation after the iTRAQ -labeling procedure.", "18.1 Materials (See Note 1) 18.1.1 Protein Extraction of Brain Tissues (See Note 2)", "Procedure 1 1. RapiGest® (Waters Corporation; Milford, MA, USA) 2. 1 M triethylammonium bicarbonate (TEAB; Sigma -Aldrich; Sao Paulo, Brazil)", "Procedure 2 1. Extraction solution: 7 M urea/2 M thiourea and 2% sodium deoxycholate (Sigma - Aldrich) 2. Cold acetone", "18.1.2 Enzymatic Digestion", "1. Qubit® 2.0 fluorometric assay kit for protein analysis (Invitrogen; Waltham, MA, USA) 2. Reducing solution: 100 mM dithiothreitol (DTT) or 50 mM tris(2 -carboxyethyl) phosphine (TCEP) ( see Notes 3 and 4 ) 3. Alkylating solution: 400 mM iodoacetamide (IAA) ( see Note 5) 4. Sequencing grade modified trypsin (Promega; Madison, WI, USA)", "5. Acetic acid", "6. 10% trifluoroacetic acid (TFA)", "18.1.3 iTRAQ Peptide Labeling", "2. 0.1% TFA, 50% acetonitrile (ACN) 3. 0.1% TFA, 70% CAN 3. iTRAQ reagent 4 -plex kit (Applied Biosystems Sciex; Foster City, CA, USA) 4. C18 macro -spin column (Harvard Apparatus; Holliston, MA, USA) (see Note 6) 5. Strong cation exchange (SCX) macro -spin column (Harvard Apparatus) (see Note 7) 6. Buffer A: 5 mM KH 2PO 4, 25% ACN (pH 3)", "7. Buffer B: 1 M KCl stock solution", "8. LC-20AT high-performance liquid chromatography (HPLC) instrument for hydrophilic interaction chromatography (HILIC) (Shimadzu Corporation; Kyoto, Japan) (see Note 8) 9. 3 μm x 5 cm x 2 mm TSKgel® amide -80 column (Sigma -Aldrich) for use with the LC-20AT instrument ( see Note 9) 10. Solvent A (HILIC -A): 90% ACN, 0.1% TFA", "11. Solvent B (HILIC -B): 0.1% TFA", "18.1.4 Labeled Peptide Analysis by Nano LC-MS/MS 1. Trap column: 2 cm length, 200 μm inner diameter 2. Analytical capillary column: 18 cm length, 100 μm inner diameter, 5 μm resin ReproSil -Pur C18 (Dr. Maisch GmbH; Ammerbuch, Germany) 3. Phase A: 0.1% formic acid, 5% ACN 4. Phase B: 0.1% formic acid, 95% CAN 5. Nano LC EASY II (Thermo Fisher Scientific; Waltham, MA, USA) 6. LTQ Orbitrap Velos mass spectrometer (Thermo Fisher Scientific)", "18.1.5 Data Analysis", "1. Data inspection: Xcalibur 2.1 software (Thermo Fisher Scientific) 2. Database searches: Proteome Discoverer 2.1 software (Thermo Fisher Scientific) with the SEQUEST algorithm 3. Databases: UniProt ( www.uniprot.org /), NCBI ( www.ncbi.nlm.nih.gov /), and neXtProt (www.nextprot.org /)", "18.3 Methods", "18.3.1 Protein Extraction in Brain Tissues 1. Pulverize and macerate the tissues in liquid nitrogen [ 10]. 2. Add 0.1% RapiGest in 50 mM TEAB ( see Note 10 ) or extraction solution. 3. Vortex the samples and centrifuge 30 min at 20,000 × g at 4 °C. 4. Transfer the supernatant to another tube and take one aliquot for protein quantification .", "5. When using the extraction solution, precipitate the proteins with 4 volumes of cold acetone overnight and centrifuge at 20,000 × g at 4 °C for 30 min. 6. Wash the pellet three times with cold acetone followed by centrifugation at 7. Remove the acetone excess and dry the pellet. 8. Solubilize the pellet in 7 M urea and 2 M thiourea solution.", "18.3.2 Protein Digestion with Trypsin 1. Quantitate proteins using the Qubit 2.0 fluorometric assay kit according to the manufacturer’s instructions.", "2. Carry out reduction of disulfide bonds in proteins by incubating samples with DTT or TCEP solution at a final concentration of 10 mM for 1 h at 30 °C. 3. Alkylate thiol groups in proteins by incubating samples with IAA solution at a final concentration of 40 mM for 30 min at room temperature in the dark. 4. Add trypsin at a 1:50 enzyme/protein ratio and incubate 12 –18 h at 37 °C ( see Note 5. Stop the reaction by adding 10% TFA to give a final concentration of 0.1% ( see Note 12 ).", "18.3.3 iTRAQ Peptide Labeling [ 11, 12]", "min and centrifuge at 2000 × g for 1 min.", "2. Add the same amount of ACN and repeat the centrifu gation step. 3. Equilibrate columns with 150 μL 0.1% TFA and centrifuge at 2000 × g as above. 4. Repeat this step three times.", "5. Add 75 –150 μL sample and centrifuge at 2000 × g as above. 6. Wash the columns using 0.1%TFA and centrifuge at 2000 × g as above. 7. Repeat the wash/centrifugation cycle three times. 8. Elute the peptides in two successive steps into the same collection tube by add- ing 0.1% TFA/50% ACN and 0.1% TFA/70% ACN followed by centrifugation at 2000 × g as above.", "9. Dry the peptides by vacuum centrifugation.", "10. Suspend peptides in 30 μL 20 mM TEAB (pH 8.5) ( see Note 13 ) and quantify using the Qubit 2.0 fluorometric assay to normalize peptide amounts in each condition (20 –100 11. Briefly centrifuge the iTRAQ reagent solution vial at room temperature to collect the content in the bottom of the tube and add 70 μL ethanol to each vial. 12. Vortex the vials and centrifuge briefly as above. 13. Transfer the contents of each vial to the specific sample tube, vortex, and centrifuge again ( see Note 14).", "14. Incubate samples at room temperature for 1 h. 15. Stop the reaction by adding formic acid at a final concentration of 1% and vor- tex and centrifuge as above ( see Note 15).", "16. Combine the contents of all samples labeled with different iTRAQ tags into one tube, vortex, and centrifuge.", "17. Dry the contents in a vacuum centrifuge but stop before complete dryness is reached (see Note 16 ).", "18.3.4 iTRAQ -Labeled Peptide Fractionation", "1. SCX fractionation: suspend the semidry pellets in 100 μL of 5 mM KH 2PO4, 25% ACN solution to give an approximate 1 μg peptides/ μL concentration and vortex. 2. Incubate the SCX spin column with 500 μL of the same solution for 15 min at room temperature.", "3. Centri fuge at 2000 × g until all solution has passed through the column and repeat this step.", "4. Add the sample to the spin column, centrifuge at 2000 × g, and collect the col - umn flow through.", "5. Carry out four sequential elution steps using 150 μL of the 5 mM KH 2PO 4/25% ACN solution, containing 75, 150, 250, and 500 mMKCl, followed by centrifu - gation each time at 2000 × g, and collect the eluates in separate tubes. 6. Desalt the samples using the peptide cleaning step above (3.4.1 –3.4.9). 7. Suspend the samples in 0.1% formic acid and quantify as above. 8. For HILIC fractionation [ 13, 14], suspend the samples in 100 μL of HILIC -A solution at approximately 1 μg/μL, vortex, centrifuge briefly, and collect the supernatant. 9. Load samples at a flow rate of 0.2 mL/min into the TSKgel Amide -80 column on the LC-20AT HPLC system.", "10. Fractionate peptides by applying 100% HILIC -A (0% HILAC -B) for 10 min, 12% HILIC -B for 2 min, 20% HILIC -B for 30 min, 30% HILIC -B for 30 min, 100% HILIC - B for 5 min, and return into 100% HILIC -A for 5 min.", "18.3.5 Labeled Peptide Analysis by Nano LC-MS/MS 1. Load 1 μg labeled peptides onto the trap and capillary columns on the nanoLC system coupled online to LTQ Orbitrap Velos mass spectrometer. min at a flow rate of 200 nL/min.", "3. After each run, wash the column with 90% phase B and re -equilibrate with phase A. 4. Acquire spectra in positive mode applying a da ta-dependent automatic survey MS scan and MS/MS ( see Note 17 ).", "5. Set the resolution of the Orbitrap mass analyzer at 60,000 at m/z 400, automatic gain control target at 1 × 10 6, and maximum ion injection at 500 ms. 6. Acquire MS/MS spectra at a resolution of 7500 at 400 m/z, a signal threshold of 30,000, normalized collision energy of 40, and dynamic exclusion enabled for 30 s with a repeat count of 1.", "7. Place an Eppendorf tube covered with 5% ammonia water solution under the nano ESI needle ( see Note 18 ).", "18.3.6 Data Analysis", "1. Inspect raw data using the Xcalibur software. 2. Perform database searches against target and decoy (reverse) databases from UniProt, NCBI, and neXtProt using the following search parameters: MS accuracy = 10 ppm, MS/MS accuracy = 0.1 Da, trypsin digestion with two missed cleavages allowed, fixed carbami domethyl modification of cysteine, and variable modification of oxidized methionine.", "3. For identification of iTRAQ -labeled peptides, also include the iTRAQ 4-plex monoisotopic mass = 144.102 and variable modification for N -terminus, lysine, and tyrosine.", "4. Accept false discovery rates of less than 1% and peptide rank = 1.", "18.4 Notes", "1. Reagents should be of analytical grade, solvents HPLC or LC -MS grade and solutions should be prepared with ultrapure water (18 M Ω-cm at 25 °C). LC -MS solutions should be made with LC -MS grade water.", "2. It is advisable to use protease inhibitors in this step to prevent degradation of proteins caused by proteases in the sample. In addition, for phosphoproteomics, it is necessary to use phosphatase inhibitors to prevent dephosphorylation during preparation and handling of samples.", "3. It is recommended to use a fresh DTT stock solution.", "4. TCEP has the advantage of being a more powerful reducing agent than DTT, by providing an irreversible reaction. In addition, it is more hydro philic, active in alkaline and acidic conditions, and more resistant to air oxidation. Also, it does not reduce metals and is significantly more stable than DTT in the absence of a metal chelator. 5. It is necessary to prepare the IAA solution immediately before use and keep it protected from light because it is unstable and light sensitive. 6. The C18 macro -spin column has a binding capacity of 30 –300 μg of sample, accepting a sample volume of 70–150 μL. Review the manufacturer’s specifica - tions before use.", "7. The SCX macro -spin column has an ion capacity of 0.18 –0.25 mmol (Cl)/mL, has a binding capacity of 30 –300 μg of protein sample, and accepts a sample volume of 70 – 150 μL. Review the manufacturer’s specifications before use. 8. It is possible to use a HPLC instrument with an equivalent configuration. 9. HILIC is recommended to remove excess iTRAQ reagent from iTRAQ -labeled peptides to increase compatibility with mass spectrometry analysis. This elimi - nates an additional step of sample cleaning.", "10. We recommend addition of 200 μL of 0.1% RapiGest per 100 mg of tissue. 11. Samples in 7 M urea, 2 M thiourea must be diluted to final concentrations lower than 1 M urea using 100 mM TEAB and heating must be avoided. Check the pH to ensure that it is close to 8.", "12. For RapiGest samples, acidify the samples with TFA to a final concentration of 1% to stop the reaction and incubate 40 minutes at room temperature. Centrifuge for 30 min at 20,000 × g to remove the insoluble material.", "13. Before peptide labeling, ensure that the pH is close to 8.5. 14. It is advisable to use commercial peptides (e.g., Glu -1-fibrinopeptide B) at a known concentration at the time of labeling to serve as an internal control and to facilitate data normalization.", "15. It is advisable to analyze a peptide sample aliquot by mass spectrometry before making the final mix of all iTRAQ labels in order to confirm the presence of labeled peptides with the appropriate m/z peaks for each reporter ion. If the labeling process was not successful, repeat the labeling procedure.", "16. The peptide pellets are easier to resuspend if they are not completely dry. 17. The data-dependent acquisition method consisted of the selection and fragmen - tation of the tenth most intense precursor ions by high -energy collision disso - ciation. The MS 2 spectra range must include the m/z of the reporter ions.", "18. The presence of 5% ammonia during analysis avoids the supercharge effect of the iTRAQ 4-plex tag [15].", "Acknowledgments National Council of Technological and Scientific Development (CNPq) (Grant number: 477325/2013 -0) and Rio de Janeiro State Foundation for Research Support (FAPERJ) (Grant number: E-26/202.801/2015).", "References 1. Patel V, Chisholm D, Parikh R, Charlson FJ, Degenhardt L, Dua T et al (2016) Addressing the burden of mental, neurological, and substance use disorders: key messages from disease con - trol priorities, 3rd 2. Cosgrove VE, Suppes T (2013) Informing DSM -5: biological boundaries between bipolar I disorder, schizoaffective disorder, and schizophrenia. BMC Med 11:127 3. Filiou MD, Turck CW (2011) General overview: biomarkers in neuroscience research. Int Rev Neurobiol 101:1 –17. Rauniyar N, Yates JR 3rd (2014) Isobaric labeling -based relative quanti - fication in shotgun proteomics. J Proteome Res 13:5293 –5309 4. Martins -de-Souza D (2015) Brainproteomics. Proteomics ClinAppl 9:795. doi: 10.1002/ 5. Guest PC, Guest FL, Martins -de Souza D (2015) Making sense of blood -based proteomics and metabolomics in psychiatric research. Int J Neuropsychopharmacol. pii: pyv138. doi: 10.1093/ ijnp/pyv138 . [Epub ahead of print] 6. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S et al (2004) Multiplexed protein quantitation in Saccharomyces cerevisiae using amine -reactive isobaric tagging reagents. Mol Cell 7. Nogueira FC, Domont GB (2014) Survey of shotgun proteomics. Methods MolBiol 1156:3 –23 8. Rauniya r N, Yates JR 3rd (2014) Isobaric labeling -based relative quantification in shotgun proteomics. J Proteome Res 13:5293 –5309 9. Choe L, D’Ascenzo M, Relkin NR, Pappin D, Ross P, Williamson B et al (2007) 8 -plex quan - titation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer’s disease. Proteomics 7:3651 –3660 10. Aquino PF, Lima DB, Fischer JSG, Melani RD, Nogueira FC, Chalub SR et al (2014) Exploring the proteomic landscape of a gastric cancer biopsy with the shotgun imaging ana - lyzer. J Proteome Res 11. Nogueira FC, Palmisano G, Schwämmle V, Campos FA, Larsen MR, Domont GB et al (2012) Performance of isobaric and isotopic labeling in quantitative plant proteomics. J Proteome Res 11:3046 – 12. Nogueira FC, Palmisano G, Schwämmle V, Soares EL, Soares AA, Roepstorff P et al (2013) Isotope labeling -based quantitative proteomics of developing seeds of castor oil seed (Ricinus communis L.). J 13. Palmisano G, Lendal SE, Engholm -Keller K, Leth -Larsen R, Parker BL, Larsen MR (2010) Selective enrichment of sialic acid -containing glycopeptides using titanium dioxide chroma - tography with analysis by HILIC and mass spectrometry. Nat Protoc 5:1974 –1982 14. Melo -Braga MN, Verano -Braga T, León IR, Antonacci D, Nogueira FC, Thelen JJ et al (2012) Modulation of protein phosphorylation, N -glycosylation and Lys -acetylation in grape (Vitisvinifera) mesocarp and exocarp owing to Lobesiabotrana infection. Mol Cell Proteomics 11:945 –956 15. Thingholm TE, Palmisano G, Kjeldsen F, Larsen MR (2010) Undesirable charge -enhancement of isobaric tagged phosphopeptides leads to reduced identification efficiency. J Proteome Res 9:4045 –4052", "APÊNDICE B- ANÁLISES PROTEÔMICA DO SINAPTOSSOMA DO CÓRTEX ORBITOFRONTAL DE PACIENTES COM ESQUIZOFRENIA USANDO LABEL - FREE E iTRAQ . Artigo publicado na edição especial da revista Journ al of Proteome Research . J Proteome Res. 2017 Dec 1;16(12):4481 -4494. doi:", "SYNAPTOSOMAL PROTEOME OF THE ORBITOFRONTAL CORTEX FROM SCHIZOPHRENIA PATIENTS USING QUANTITATIVE LABEL -FREE AND ITRAQ -BASED SHOTGUN PROTEOMICS", "Erika Velásquez1, Fabio CS Nogueira1,2, Ingrid Velásquez3, Andrea Schmitt4, Peter Falkai4, Gilberto B Domont1* and Daniel Martins -de-Souza5,6* 1Proteomics Unit, Department of Biochemistry, Institute of Chemistry, Federal University of Rio de Janeiro.", "2Laboratory of Proteomics, LADETEC, Institute of Chemistry, Federal University of Rio de Janeiro.", "3University of Carabobo, Venezuela.", "4Department of Psychiatry and Psychotherapy, Ludwig Maximilian University of Munich (LMU), Munich, Germany.", "5Laboratory of Neuroproteomics, Department of Biochemistry, Institute of Biology, University of Campinas (UNICAMP).", "6UNICAMP’s Neurobiology Center, Campinas, Brazil.", "Corresponding authors: dmsouza@unicamp.br; gilberto@iq.ufrj.br", "ABSTRACT: Schizophrenia is a chronic and incurable neuropsychiatric disorder which affects about one percent of the world population. The proteomic characterization of the synaptosome fraction of the orbitofrontal cortex is useful for providing valuable information about the molecular mechanisms of synaptic functions in these patients . Quantitative analyses of synaptic proteins were made with 8 paranoid schizophrenia patients and a pool of 8 healthy controls free of mental diseases. Lab el-free and iTRAQ labeling identified a total of 2018 protein groups. Statistical analyses revealed 12 and 55 significantly dysregulated proteins by iTRAQ and label -free, respectively. Quantitative proteome analyses showed an imbalance in the calcium signa ling pathway and proteins such as Reticulon -1 and Cytochrome c, related to endoplasmic reticulum stress and programmed cell death. Also, it was found that there is a significant increase of limbic system -associated membrane protein and α -calcium/calmodulin -dependent protein kinase II, associated to the regulation of human behavior. Our data contribute to a better understanding about apoptosis as a possible pathophysiological mechanism of this disease, as well as neural systems supporting social behavior in schizophrenia. This study also is a joint effort of the Chr 15 C -HPP team and the Human Brain Proteome Project of B/D-HPP. All MS proteomics data are deposited in the ProteomeXchange Repository under PXD006798.", "Keywords: Schizophrenia, synaptosome, orbitof rontal cortex, quantitative proteomics", "1. INTRODUCTION", "Considered chronic and incurable neuropsychiatric disorder schizophrenia affects about one percent of the world population. Typical clinical manifestations of this disease are the positive symptom s as hallucinations, delusions , disordered thoughts and spee ch, negative symptoms like anhedonia, apathy, blunting of affect, social withdrawal with substantial functional deficiency in interpersonal relationships, work or personal care along and cognitive deficit with difficulty in attention and working memory 1 2. Around 30% of patients with schizophrenia will not respond satisfactorily to the use of antipsychotics3 and current pharmacological therapy is largely ineffective for the treatment of cognitive impairments and negative symptoms4. Schizophrenia inheritance is passed along by several genetic variations each with small effects . The genome -wide association studies ( GWA) made by the Schizophrenia Working Group of Psychiatric Genomics Con sortium5 revealed in a total of 128 significant independent single nucleotide polym orphisms distributed in 108 independent loci are related to schizophrenia , highlighting genes involved in glutamatergic neurotransmission, synaptic plasticity, dopamine receptor D2, voltage -gated calcium channel subunits, and also the major histocompatibil ity complex, a consistent candidate found in other GWA studies6. However , the und erlying causes and pathophysiological mechanisms of this disease are still not fully elucidated.", "The evidence of synaptic dysfunction present in the etiology of schizophrenia was indirectly demonstrated after the discovery of the antipsychotic properties a nd mechanism of action of dopamine D2 -like receptor antagonists, which ameliorated psychotic symptoms through their action upon neurotransmitter systems7. In the last decade, proteomics studies have tried to elucidate the pathophysiology of schizophrenia using different areas of post-mortem brain tissue from schizophrenia patients and comparing the results to mentally healthy controls8. Already, proteomic characterization of different brain areas has revealed the following biochemical alterations: energy me tabolism9; oligodendrocyte function10; signaling pathways associated with axon formation and synaptic plasticity11; calcium homeostasis and the immune system12; expression of synaptic proteins like syntaxin -binding protein, brain abundant memb rane-attached signal protein 1, and limbic system -associated membrane protein13; and in the clathrin -mediated endocy tosis and N -methyl -D-aspartate proteins, which are part of the endocytic and long - term potentiation pathways, respectively14.", "Despite the development of animal15 and in vitro16 biological models for understanding the interactions between neurotransmitter systems and correlat ing their relationship with schizophrenia symptoms, these models are limited in the evaluation of pathophysiological processes of negative symptoms and suicidal ideation17. However, t he study of post -mortem brain tissue can still provide valuable information about the pathophysiology of schizophrenia18. The objective of this study was to perform a proteomic characterization of the synaptosome fraction of the orbitofrontal cortex, which was still unexplored. This brain region receives connections from the medial prefrontal cortex, amygdala, hypoth alamus, insula/operculum, and dopaminergic midbrain, as well as areas of the basal ganglia, like the ventral and dorsal striatum19 20. Its function re gulates appropriate emotional responses in association with learning, prediction, and decision - making for emotional - and reward -related behaviors19. Additionally, protein functions are related to subcellular localization, because organelles offer different interaction p artners and chemical environments; these changes in protein localization regulate the activity of the biological pathways involved21. In this context, synaptosomes are useful for studying the molecular mechanisms of synaptic function and the identification. The quantification of synaptic proteins us ing label -free and iTRAQ labeling will be helpful to unravel new cellular mechanisms for this disease, providing a better understanding of schizophrenia pathogenesis and allowing the identification of possible candidates as new therapeutic targets.", "Finally , this research improved the characterization of disease -associated proteins that will contribute to the construction of a comprehensive map of the entire human proteome following the goal of the Chromosome -centric and Biology/ Diseases Human Proteome Proj ects.", "2. EXPERIMENTAL PROCEDURES", "2.1. Brain samples", "Brain tissue samples (Orbitofrontal, Prefrontal cortex, PFC) were collected postmortem from 8 chronic schizophrenia patients diagnosed antemortem by an experienced psychiatrist according to the Diagnostic and Statistical Manual of Mental Disorders (DSM -IV) criteria as residual schizophrenia, with paranoid episodes (295.6) and 8 controls (Table S -1). Patient samples were collected at the State Mental Hospital in Wiesloch, and control samples from the Institute of Neuropathology, Heidelberg University, in Hei delberg, both in Germany. Controls were free from any brain or somatic diseases and had not taken antidepressants or antipsychotics during their lifetime. All brains analyzed here were submitted for neuropathological characterization to rule out any other associated brain disorders. Braak staging was required to be less than II for all brains. Schizophrenia patients have a record of antipsychotic treatment, so chlorpromazine equivalents (CPE) could be calculated. For typical neuroleptics and clozapine, we u sed Jahn and Mussgay’s algorithm 22. All patients and controls were wh ite Germans with no history of alcohol or drug abuse, according to subjects and familial information. All assessments, postmortem evaluations, and procedures were approved by the ethics committee of the Faculty of Medicine, Heidelberg University, Heidelber g, Germany.", "2.2. Subcellular enrichment.", "PFC brain tissue (50mg) was homogenized in 10 volumes of buffer A (0.32M sucrose, 4mM HEPES pH 7.4, protease cocktail inhibitor tablet (Roche) and phosphatase inhibitor cocktail I and II (Sigma). All procedures w ere performed at 4 0C. The homogenate was centrifuged at 1,000 x g for 10 min, the supernatant was transferred to a new tube (S1) and the pellet (P1) was resuspended in 10 volumes of buffer A and centrifuged at 1,000 x g for 10 min (S2, P2). S1 and S2 (S) were combined and centrifuged at 17,000 x g for 55 min (S3, P3). P3 was resuspended in 0.32M sucrose and laid on top of a discontinuous sucrose density gradient (1ml 0.32/1ml 0.8/1ml 1.2) and ultracentrifuged at 25,000 rpm for 2h. The synaptosomal fraction was (SYN) extracted from 1.2/0.8 interphase, diluted 1:1 (v/v) in water and ultracentrifuged at 40,000 rpm for 60 min (S4, P4). P4 was diluted in 10 μl distilled water and stored at -20 0C. Efficiency of cellular compartment enrichment was verified by Wes tern blot (Figure 1) . Once enriched, proteins from each of the compartments were extracted as described in the study of Saia -Cereda and collaborators 23.", "2.3. Western blot", "Protein lysates had their protein concentrations determined using a Bradford assay (BioRad; Munich, Germany). Protein extracts (20 μg) from each sample were electrophoresed in 12% SDS -PAGE (BioRad; Hercules, CA, USA). Proteins were then transferred electro phoretically to Immobilon -FL polyvinyldiphenyl fluoride (PVDF) membranes (Millipore; Bedford, MA, USA) at 100 V for 1 h, using a cooling system. PVDF membranes containing the transferred proteins were treated with 5% Carnation instant non -fat dry milk powd er in Tris buffered saline (pH 7.4) containing 0.1% Tween −20 (TBS -T) for 4 h, rinsed in TBS -T three times for a total of 20 min and incubated with collapsin 2 for cytosolic proteins, ATP5A1 for mitochondrial proteins, PSD95 for synaptosomal proteins, and HDAC1 for nuclear proteins, at a dilution of 1:1000 in TBS - T overnight at 4 0C (all antibodies were from Abcam; Cambridge, UK). Following the overnight incubation, the membranes were washed twice with TBS -T for 15 min per wash. Next, the membranes were inc ubated with anti -c-MYC -peroxidase antibody 1:10000 (GE Healthcare; Uppsala, Sweden) for 40 min at room temperature, washed with water and TBS -T, and incubated with Enhanced Chemiluminescence (ECL) solution (GE Healthcare) for 1 min. The membranes were scan ned using a Gel DocTM XR+ System (Silk Scientific Incorporated; Orem, UT, USA) and the optical densities of the immunoreactive bands were measured using Quantity One software (Bio -Rad). Protein loading was determined by staining PVDF membranes with Ponceau S to ensure equal loading in each gel lane.", "2.4. Enzymatic digestion.", "Ten µg of SYN proteins were reduced with 5 mM tris(2 -carboxyethyl)phosphine (1 hour at 30 0C), alkylated with 10 mM iodoacetamide (30 min at room temperature), and diluted 1:10 with 50 mM triethylammonium bicarbonate (TEAB) pH 8, followed by digestion with trypsin (1:50) for 18 hours at 35 0C. Peptides were desalted in C18 micro columns (Harvard apparatus), dried in a vacuum centrifuge, resuspended in 30 µl of 20 mM TEAB pH 8,0 and quantified by Qubit® protein assay (Invitrogen) for iTRAQ labeling, following the manufacturer’s recommendations. In label -free analyses the peptides were resuspended in 0.1% formic acid, quantified by Qubit® protein assay, and analyzed by mass spectrometr y.", "2.5. iTRAQ Labeling", "Following manufacturer's instructions, 5 µg of peptides were labeled with iTRAQ® Reagents – 4-plex. The organization of iTRAQ 4 -plex was made up as follows: three channels (114, 115 and 116) were labeled with one different schizop hrenia preparation and one channel (117) containing a pool of control samples (n=8). The pool of controls was the common element used for normalization and comparison between the iTRAQ sets .Labeled peptides were dried to 20 µl and diluted to a final volum e of 100 µl with KH 2PO 4 5 mM / ACN 25% pH 3 for SCX chromatography (Harvard apparatus ) by one-step peptide elution with 500 mM KCl24. Samples were cleaned in a C18 column, dried, and resuspended in 0.1% formic acid for quantification (Qubit®) and LC -MS/MS analyses.", "2.6. LC -MS/MS analyses", "Two μg of peptides were analyzed in technical triplicate after three hours of gradient (5% to 40% B / 167 minutes; 40% to 95% B / 5 min; 95% B / 8 minutes). nanoLC solvent A consisted of (95% H 2O / 5% acetonitrile (ACN) / 0.1% formic acid) and solvent B of (95% ACN / 5% H 2O / 0.1% formic acid). Trap -column length was 3 cm with an internal diameter of 200 µm (5 µm spheres -Reprosil Pur C18, Dr. Maish) and analytical column of 15 cm and internal diameter of 75 µm (3 µm spheres - Reprosil Pur C18, Dr. Maish). In iTRAQ analyses, nanoESI was carried out under steam atmosphere provided by 5% ammonium hydroxide using a nLC Proxeon EASY -II system (Thermo Scientific) on-line with LTQ Orbitrap Velos (Thermo Scientific) mass spectrometer; label -free quantification was performe d in an Easy -nLC 1000 (Thermo Scientific) coupled to a QExactive Plus (Thermo Scientific).", "LTQ Orbitrap Velos settings for data -dependent acquisition mode (DDA) were: dynamic exclusion list of 90 s, spray voltage at 2.5 kV, and no auxiliary gas flow. Full MS scan was acquired at a resolution of 60,000 and at m/z 400 in the Orbitrap analyzer, and the ten most intense ions were selected for fragmentation by higher -energy collision dissociation (HCD) with normalized collision energy of 40. MS2 spectra were an alyzed in the Orbitrap (resolution of 7,500at m/z 400). QExactive Plus in FullScan -DDA MS2 mode used a dynamic exclusion list of 45 s and spray voltage at 2.30 kV . Full scan was acquired at a resolution of 70,000 at m/z 200, with a m/z range of 350 -2000, A GC of 1x106, and injection time of 50 ms. Selection of the twenty most intense ions for HCD fragmentation used a normalized collision energy of 30, precursor isolation window of m/z 1.2 and 0.5 off -set, a resolution of 17,500 at m/z 200, AGC at 5x105, and injection time of 100 ms.", "2.7. Data analysis", "Data were analyzed by the Proteome Discoverer 2.1 software using a human database downloaded from neXtprot (May 2017). The parameters used were: full -tryptic search space, up to two missed cleavages allowed for trypsin, precursor mass tolerance of 10 ppm, and fragment mass tolerance of 0.1 Da. Carbamidomethylation of cysteine was included as fixed modification, and methionine oxidation and protein N -terminal acetylation as dynamic mod ifications in Label -free quantification. iTRAQ modifications (K, Y, and N -terminal) were additionally considered as dynamic modifications for the iTRAQ labeled samples.", "Spectra analyses used a target -decoy strategy considering maximum delta CN of 0.05, al l available peptide -spectrum matches, and a target false discovery rate (FDR) 0.01 (strict). Parameters in the peptide filter were set up for high confidence with a minimum peptide length of 6 aminoacids. For protein filter was considered the minimum numbe r of peptide sequence as 1, counting only rank 1 peptides. Peptide shared between multiple proteins was counted for the top scoring protein. The confidence thresholds in FDR protein validator were 0.01 for target FDR (strict). The strategy for protein grou ping was strict parsimony. In the peptide and protein quantification module, for iTRAQ and label - free analysis, unique peptides were considered. The calculation of fold -change was made using the patients as numerator and pool of controls as denominator. Fo r iTRAQ quantification, reporter abundance was automatic, applying the correction for the impurity reporter and a filter to do not report quantitative values for a single -peak in the precursor isotope pattern. Extraction ion chromatography strategy was use d for label -free quantification.", "2.8. Statistical analyses", "Statistical evaluation of the data was performed by the Inferno RDN program (Polpitiya et al., 2008), unique peptides being normalized using Central Tendency and the absolute deviation of adjusted median (MAD). The peptides were extrapolated to their corresponding protein through RRollup using the Grubbs test, with a minimum of three peptides and p -value <0.05. To determine the statistical significance of dysregulated proteins the z -score and the p -value associated with a 95% confidence level were calculated using robust estimators such as the median and median absolute deviation (MAD).", "2.9. Bioinformatics Functional Analysis Comparative analyses were carried out with the program Venny 2.125. For the cellular component, biological processes, and molecular function of quantified proteins, we used the program DAV ID 6.826 , Human Protein Reference Database27 and Reactome Pathways28. Proteins whose variation in abundance was statistically significant, STRING 1029 (considering high -confidence interactions) and KEGG program30, were used for protein -protein interaction analyses and evaluations of functional enrichment in the network .", "2.10. PRM analysis", "We have used 2 µg of peptides from patients and control samples spiked with the heavy version of the peptide VAGALQAQVK (K:13C(6)15N(2)) (JPT Peptide Technologies). Peptide separation were carried out using an EASY -nLC 1000 (Thermo Scientific), trap column (2 cm x 100 µm ID, 5 µm spheres -Reprosil Pur C18, Dr. Maish) and analytical column (30 cm x 75 µm ID, 3 µm spheres - Reprosil Pur C18, Dr. Maish). Peptide elution was performed by applying a flow of 300 nL/min and gradient of 5 to 40% of solvent B (95% acetonitrile, 0.1% formic acid) over 100 min followed by 10 min of 40 -95% solvent B and 10 min of washing at 95% solvent B. Solvent A is composed by 5% of acetonitrile and 0.1% of formic acid. PRM mode was performed in a QExactive Plus ( Thermo Scientific ) using an inclusion list for the target ions with 2 -Th window, resolution of 35,000 (at m/z 200), AGC of 5x105, injection time of 150 ms, spray voltage at 2.30 kV, and MS/MS scans were acquired with a starting mass of m/z 100 and normalized collision energy of 27. We analyzed the PRM data using the Skyline software", "3. RESULTS AND DISCUSSION", "3.1. General proteome analysis", "Our strategy consisted of a synaptosome enrichment of postmortem PFC brain tissue from p atients with schizophrenia and from controls. Label -free and iTRAQ -based quantitative proteomics were employed as complementary approaches to characterize the synaptosome proteome (Figure 2). In the total synaptosome proteome, 2018 proteins were identified , combining results from the iTRAQ and label -free techniques (Figure 3A and 3B, Table S -2 and Table S -3). Quantitative analysis by iTRAQ identified 1176 proteins comprising 513 groups, 127 of them with robust quantification (Figure 3A). The selection criteria for up - and down -regulated proteins included, besides p -value, the same quantitative behavior in at least half of the patients studied (n≥3) (Table 1 and Table S - 4). Statistical analysis of iTRAQ data revealed 12 significantly dysregulated proteins. On the other hand, label -free quantification identified 4904 proteins in 1917 groups (Figure 3A); and of the 341 quantified proteins, 55 showed statistically significant variations in their abundance (Table 1 and Table S -4). They were found 3 deregulated pro teins in common between iTRAQ and Label -free data (Table S -4).", "GO analyses of the synaptosome proteome, using DAVID for all identified proteins showed the cellular component distribution of proteins expected for a synaptosome fraction (Figure 3D, Table S -5). Important biological processes in this total proteome were related to signal transduction and cell -cell adhesion, whereas the most important molecular functions of proteins were ATP and protein binding, and cell - cell adhesion. In more detailed analyses , Reactome pathway highlighted axon guidance and membrane trafficking as principal biological processes (Table S -5).", "3.2. Label free qualitative analysis", "The label -free comparative analysis of patients and control groups (Figure 3C) showed that 161 prote ins were identified only in the control, but only 10 of those were identified with two or more unique peptides (Table S -6). Proteins detected only in the control condition were involved in the biological processes of neural cell adhesion, protein binding, molecular chaperones, and the activation of the GABA A receptor (Table S-7). Deficiencies in GABA function in the prefrontal cortex result in neurotransmissive and cognitive impairments in schizophrenia patients31. It was shown that Disrupted -in- schizophrenia 1 gene (DISC1) participates in the dynamic regulation and trafficking of GABAAR, and the knockdown of DISC1 significantly reduced changes of GABAAR - mediated synaptic inducing in surface expression32.", "On the other hand, 741 proteins were identified in the patient group; but only 6 proteins of these were present in all patients and identified with tw o or more unique peptides (Table S -6). The biological functions of the proteins identified only in patients are associated with membrane traffic processes and chemical synaptic transmission (Table S -7). Moreover, among these proteins the Programmed cell de ath 6 -interacting protein, HSP70 and the adhesion protein Cadherin -13 stand out.", "Cadherin -13 mediates cell –cell adhesion and is involved in intracellular signaling pathways such as synaptogenesis, early embryonic patterning to circuit formation, and synap tic plasticity in the mature brain33. Cadherin -13 is associated with neuropsychiatric disease, suggesting that it may contribute to the genetic risk of schizophrenia34. Recently, a relationship between the Cadherin -13 and the GABA system was demonstrated. Cadherin -13 is located at GABA synapses and Cdh13−/− mice show an increase in inhibitory activity without changes in excitatory input, resulting in an excitatory – inhibitory imbal ance35, but the relationship and the impact of the interaction of these proteins in the pathophysiology of schizophrenia has not been determined.", "3.3. Quantitative analysis of iTRAQ and Label free data", "In relation to proteins with robust quantification, the functional analyses of these with DAVID and Reactome Pathways software, revealed that most of these proteins contribute mainly to cell adhesion processes, membrane trafficking, and vesicle - mediated transport (Table S -8). However, the proteins that presented statistically significant variation and met the criteria to be considered as dysregulated (Table 1) are mostly associated with synaptic activity and signaling pathways associated with calcium (Figure 4A, Table S -9). PRM analysis con firmed the quantification of SERCA, MARCKS, CAM1, CYCS, RTN1 -C, LSAMP and PDCD6IP proteins in four patients (Table S -10), obtaining similar results regarding quantitative iTRAQ and Label -free techniques. Figure 5 shows XIC for the top 6 fragments of the in ternal standard (Figure", "5A) and the peptide EAFSLFDKDGDGTITTK from calmodulin -1 (Figure 5B). This", "protein presents a lower abundance in patients with schizophrenia compared with the control group, which confirm our finds of the label -free and iTRAQ labelin g data.", "The protein -protein interaction analysis of dysregulated proteins (Figure 4B) showed that the main point of interaction converges on CaM , an important intracellular calcium sensor that converts the Ca2+ signal into a variety of biochemical changes, whereby regulating important proteins for synaptic plasticity36. CaM is downregulated in this study and it was shown that the knockdown of CaM decreased the probability of synaptic vesicle release37. Moreover, a significant decrease was reported through immunostaining in the Brodmann area 9, layer III of schizophrenia patients , indicating a loss of CaM in pyramidal cells, which suggests that calcium/CaM -dependent pathways may be affected in the pyramidal cells of the prefrontal cortex 38.", "In the analysis of network associations, it was observed that CaM interacts with relevant proteins in the processes of synaptic plasticity such as MARCKS and αCaMKII (Figure 4B). CaM binds to MARCKS, removing it from membranes 39. Curiously, in our study, MARCKS is found to be up -regulated in the SYN fraction simultaneously with a down -regulation of C aM. MARCKS acts to modulate actin -dependent processes by regulating the membrane -associated phospholipid PIP 2 availability40, to participate in neuronal migration, proliferation, and neurite outgrowth, and is known for its importance for memory and maintenance in synaptic plasticity 40. It was shown that the upregulation of MARCKS is able to produce significant impairments in spatial learning 41. In addition, MARCKS is increased in the membrane fraction of postmortem hippocampal tissue from patients with suicidal behavior, with and without major depressive disorder 42. In dorsolateral prefrontal cortices from schizophrenia and bipolar disorder pa tients, MARCKS mRNA expression was increased. Rats with chronic administration of haloperidol or clozapine did not show significant changes in the relative expression of MARCKS mRNA 43, or protein expression in the frontal cortex44. On the other hand, CaMKII is important for interaction with the NMDA receptor and long-term potentiation. Reduction of CaMKII activity is related to synaptic plasticity impairment, whereas its overexpression increases synaptic strength 45. However, recently, studies have rep orted that the overexpression of specific isoforms of αCaMKII in mutant mice induced a significant increase in anxiety and detrimental changes in social behavior, suggesting that changes in αCaMKII expression levels strongly affect emotional state 46.", "Parallel to the network associa tion analysis, KEGG pathway was used to highlight the activation of G-protein coupled receptors and PLCβ activation in the calcium signaling route (Figure 6). PLCβ activation is involved in a variety of cellular functions associated with the hydrolysis of phosphatidylinositol 4,5 -bisphosphate to produce secondary messengers such as inositol 1,4,5 -trisphosphate (IP 3)47. IP3 mediates an increase in cytosolic Ca2+ releasing intracellular stores through IP 3 receptor channel activation48. In response to calcium release from the ER, the up -regulation of SERCA and plasma membrane Ca2+ ATPase (PMCA) was observed in this signaling pathway (Figure 6). Their main functions are to deplete the excess of cytosolic calcium into ER lumen and outside the cell respectively, restoring the Ca2+ 49 to basal levels.", "An excess of intracellular calcium is as sociated with ER stress and activation of cell death pathways 50. In that sense, the up -regulation of Reticulon -1 (RTN1 -C) protein (Table 1) was found in our data. RTN1 -C is localized on the ER membrane, and its overexpression also results in elevated cytosolic Ca2+ levels due to ER store depletion, resulting in ER stress -induced cell death with ultrastructural changes in the mitochondria 51. In fact, the increase of RTN1 -C protein levels resulted in ER stress -induced cell death, mediated by an increase of cytosolic Ca2+, and significantly sensitized cells to different ER-stress inducers. Also , the Programmed cell death 6 -intera cting protein (PDCD6IP) was identified only in schizophrenia patients (Table S -6). When calcium imbalance from homeostasis occurs and ER stress is generated, PDCD6IP takes part in apoptosis as a crucial mediator of Caspase -9 activation 52. The overexpression of PDCD6I P in vivo is sufficient to induce cell death 53.", "There is a link between ER stress -mediated apoptosis and the mitochondria transition pore 5. The Ca2+ flux activates mitochondrial permeability transition pore stimulating the apo ptosis with the release of cytochrome c and other pro -apoptotic factors 54. Indeed , the second main point of the network association analysis (Figure 4) included proteins involved with apoptosis such as SLC25A6 and VDAC2, which participated in the formation of the permeab ility transition pore complex, controlling mitochondrial permeability55. During the activation of apoptosis, SLC25A6 overexpressio n increases caspases 9 and 356 and VDAC2 facilitates Bax stabilization in the mitochondrial outer membrane 57. Another important and classical indicator of apoptosis, CYCS, is part of this interaction network. When mitochondrial membrane permeability is altered, CYCS released into the cytosol triggers apoptotic processes. The overexpression of CYCS enhances Caspase activation58 forming the apoptosome through interaction with the Apoptotic pro tease activating factor -1 and subsequent activation of the caspase -9 death pathway59. Furthermore, the Serine/threonine -protein phosphatase PGAM5, a novel partner of Apoptosis -inducing factor , was also increased in schizophrenia patients and its overexpression induced caspase activation and cell death 60. Also, anti-apoptotic proteins were identified, such as BAG3, induced by stressful stimuli, which acted synergistically with Bcl -2 on the inhibition of apoptosis processes me diated by Bax and Fas61 62, Hsp70 protein, identified only in patients (Table S -6), enhanced cell survival under ER stress conditions, preventing the formation of an active apoptosome 63 ; and 14-3-3η w hich conferred neuroprotection in NMDA -induced cellular stress and cell death 64 There is a link between ER stress -mediated apoptosis and the mitochondria transition pore 5. The Ca2+ flux activates mitochondrial permeability transition pores, stimulating apoptosis with the release of cytochrome c and other pro -apoptotic factors 54. Indeed , the second main point of the network association analysis (Figure 4) included proteins involved with apoptosis s uch as SLC25A6 and VDAC2, which participated in the formation of the permeability transition pore complex, controlling mitochondrial permeability55. During the activation of apoptosis, SLC25A6 overexpression increases caspases 9 and 356 and VDAC2 facilitates Bax stabilization in the mitochondrial ou ter membrane 57. Another important and classical indicator of apoptosis, CYCS, is pa rt of this interaction network. When mitochondrial membrane permeability is altered, CYCS released into the cytosol triggers apoptotic processes. The overexpression of CYCS enhances Caspase activation58 forming the apoptosome through interaction with the Apoptotic protease activating factor -1 and subsequent activation of the caspase -9 death pathway 59. Furthermore, the Serine/threonine -protein phosphatase PGAM5, a novel partner of Apoptosis -inducing factor , was also increased in schizophrenia patients and its overexpression induced caspase activation and cell death 60. Also, anti-apoptotic pr oteins were identified, such as BAG3, induced by stressful stimuli, which acted synergistically with Bcl -2 on the inhibition of apoptosis processes mediated by Bax and Fas61 62. Hsp70 protein, identified only in patients, enhanced cell survival under ER stress conditions, preventing the formation of an active apoptosome 63 ; and 14-3-3η which conferred neuroprotection in NMDA -induced cellular stress and cell death 64.", "Apoptosis has been proposed as a process in the pathophysiology of schizophrenia. There is evidence including reduced gray matter volume, synaptic markers, and neuropil, that suggests a form of programmed cell death in the progressive gray matter volume loss during the course of illness in the frontal, parietal and temporal areas 65. A longitudinal study that determined the long -term effects of antipsychotic treatment in brain volumes proposed the possibility that antipsycho tic treatment is not efficient in counteracting the pathophysiologic processes of schizophrenia, rather aggravating the progressive brain tissue volume reductions 66. In fact, an increase in caspase -3 activity was reported as a delayed effect of typical and atypical antip sychotic treatment; but there was no evidence of DNA fragmentation, indicating that antipsychotic treatment did not induce apoptosis by itself but could still contribute to the progressive cortical gray matter loss in the early stages of schizophrenia65. On the other hand, in fibroblast cultures from first -episode schizophrenia patients, there is an increased susceptibility to apoptosis, displaying a correlation between regional brain volume and changes in levels of brain glutamate and N-acetylaspartate in the anterior cingulate and the left thalamus 67. Besides this, the serum levels of apoptotic markers were significantly higher in deficit schizophrenia syndrome patients than in non-deficit schizophrenia patients and healthy controls68 suggesting the importance of apoptotic processes in the negative symptoms of schizophrenia .", "The third most important point of protein -protein interaction network revealed the dysregulation of oligodendrocyte proteins connected to myelin sheath formation (Figure 4B). We found three main proteins: myelin basic protein (MBP), a calmodulin binding protein whose main function is related to the adhesion of multi -lamellar compact myelin into the plasma membrane; the proteolipid protein (PLP), a principal component of compa ct myelin; and the myelin oligodendrocyte glycoprotein (MOG), a specific constituent of CNS myelin, mostly present on the outer loop of the myelin sheath10 69. MBP, PLP, and MOG are expressed during the beginning of myelin sheath formation around axons70. However, PLP increase and sequestration of MOG have been associated to myelin degeneration and the axonopathy observed in PLP1 -transgenic animals and Pelizaeus -Merzbacher patients71. The overexpression of PLP in transgenic animals leads to ER stress is associated with inefficient transpor t of PLP from the ER to the myelin sheath, causing a blockage of transport for other myelin proteins such as MOG71. ER stress induces apoptosis with a loss of myelin and the death of oligodendrocytes in gray matter of the central nervous system.71 Moreover, expression of Contactin -1, a cell adhesion molecule, is also increased in our study. Contactin -1 is implica ted in axon growth and guidance, neural differentiation, synapse formation, myelination formation, organization, and as a critical signal for axon –glia communication in CNS myelin72 . In vitro experiments of unmyelinated axons have associated the up -regulation of Contactin - mediated signals with trigger events that orchestrate the expression of proteins such as PLP, MBP, and MGO for myelin formation 73. Also, it was demonstrated that calmodulin regulation of MPB modifies cytoskeleton -mediated events in myelinogenesis74 The dysregulation of oligodendrocyte proteins has already been described in previous proteomic studies10 and a qualitative electron microscopy study of the prefrontal cortex from patients with schizophrenia or bipolar disorder confirmed ultrastructural changes in oligodendrocytes corresponding to apoptosis75. Findings associated with myelin must be accepted cautiously and require validation, as these proteins (or their fragments) could be contaminants to the synaptosomal fraction, which is supposed to be separated from the myelin fraction.", "In the last group o f dysregulated proteins, it is necessary to highlight variations in the abundance of proteins related to cell adhesion processes and cytoskeletal organization (Table 1). One of these proteins is LSAMP, increased in all patients analyzed by iTRAQ strategy. LSAMP is a glycosylated protein with three immunoglobulin (Ig) domains integrated into membranes via a glycosyl -phosphatidyl -inositol (GPI) anchor76. It is predominantly expressed on the surface of proximal dend rites and soma, and acts in neural cell adhesion and neuritis formation and outgrowth 77. The LSAMP gene is linked to human behavior and it has been shown that a transcript level increment in the amygdaloid area, periaqueductal gray, raphe, hippocampus, and frontal cortex is connected with acute fear reaction, fear conditionin g, and higher trait anxiety 78. Allelic variants loc ated in the intronic region of the LSAMP gene are correlated with the pathoetiology of suicidal behavior79 and there is a significant allelic and haplotype association between the LSAMP gene and schizophrenia 80. Also, in a proteomic study of membrane microdomains of postmortem brain tissue in the dorsolateral prefrontal cortex from schizophrenia patients, LSAMP expression appeared significantly increased exclusively in the brains of patients with schizophrenia and not in the brains of patient s with bipolar disorder (Behan et. al, 2008)13 , indicating that this protein may play an important role in the path ophysiology of schizophrenia. Currently, LSAMP has been suggested to have a possible role in the mechanisms of psychiatric disorders, specifically in the regulation of emotional behavior77. Another protein, alpha -internexin is also up- regulated in this fraction . Primarily expressed in the CNS axons of neurons undergoing differ entiation and maturation, this suggests that it has important role in the regulation of the outgrowth and shape of neurites, thus maintaining the network of intermediate filaments in mature neurons 81. Previously, alpha -internexin was found to be increased in the synaptic membrane fraction of the left dorsolateral prefrontal cortex of patients with schizophrenia82. The overexpression of this protein causes a deficit in motor coordination in transgenic mice with varying degrees of neuronal dysfunction and degeneration proportional to the lev els of mis -accumulated neuronal intermediate filaments83 ; however the exact relationship between this protein and the impairments in motor coordination in schizophrenia must be investigated.", "3.4. M issing proteins candidates", "Finally, through this study, it was possible to suggest the existence of two missing proteins (Figure S -1). Protein unc -79 homologous isoform Iso 3 located on chromosome 14, initially with evidence only at transcript level, was identified with 2 unique peptides. The second protein, putative cytochrome b -c1 complex subunit Rieske -like protei n 1 isoform Iso 1, belonging to chromosome 22, with evidence classified as uncertain, was identified with 1 unique peptide (Table S -11).", "4. CONCLUSION", "The orbitofrontal cortex, a subdivision of the prefrontal cortex, is directly involved in the regulatio n of emotions. Neuropsychology and neurophysiology studies, as well as structural and functional neuroimaging, indicate that this area of the brain plays an important role in the development of diseases such as mood, anxiety, and personality disorders; dru g addiction; and schizophrenia; 84 which makes proteomic characterization important for the comprehension of this diseases.", "The calcium signaling pathway was one of the main dysregulated routes in this brain area in schizophrenia patients. Imbalance in the calcium signaling pathway has bee n implicated in the development of psychiatric diseases, reported to play a major role in regulating several neuronal processes like transmitter release, neuronal excitability, and synaptic plasticity 85. Cognitive impairment is a common symptom that prevails after treatment with currently available antipsychotics; and, in association, this study shows a higher level of MARCKS protein in patients. The abnormal expression of MARCKS may contribute to impairments in the synaptic plasticity in schizophrenia patients. Since long time, apoptosis has been proposed as one possi ble mechanism that contributes to the pathophysiology of schizophrenia. A great deal of evidence indicates progressive clinical deterioration and neurostructural changes in schizophrenia patients, and recent studies have linked apoptosis with the negative symptoms of schizophrenia 86 68. This research found for the first time in post -mortem brain tissues in an important brain area involved in the regulation of emotions as the orbitofrontal cortex, evidences of deregulated apoptotic proteins related to ER stress and programmed cell death tr iggering such as reticulon -1 and cytochrome C. In here we propose as a potential mechanism, based on the deregulation of these proteins, the apoptosis mediated by ER stress in the orbitofrontal area Finally, schizophrenia patients are characterized by soci al interaction difficulties that do not improve after standard treatments87. Two important proteins, previously related with the regulation of human behavior in other studies were found significantly increased in this study: LSAMP whose increment was prev iously correlated with abnormal response to fear, panic, and suicidal behavior 78 79 80 and αCaMKII linked to an increase in anxiety and detrimental effects on social behavior in mouse model46 .The increment of these proteins in the orbitofrontal cortex could be related to the aberrant social behavior in these patients. We propose these proteins as potentials markers of social impairment.", "Authors recognize that the protein -level FDR is an estimate based on several imperfect assumptions, and present the FDR with appropriate precision and acknowledge that not all proteins surviving the threshold are “confidently identified”. All MS proteomics data are deposited in the ProteomeXchange Repository under", "ACNOWLEDGEMENTS Authors thank Bradley J. Smith for proof -reading the article and LADETEC (Chemistry I nstitute, UFRJ) for the Q -Exactive Plus (Thermo Scientific) analysis. DMS is supported by S ão Paulo Research Foundation (FAPESP), grants 2013/08711 -3 and 2014/10068 -4 and the Brazilian National Council for Scientific and Technological Development (CNPq) grant 460289/2014 -4. EV thanks CNPq for her PhD scholarship; FCSN for grant E -26/202.801/2015 from the Rio de Janeiro State Foundation for Science Support (FAPERJ); and GBD for CNPq grant 306316/2015 -3. Authors acknowledge", "REFERENCES", "(1) Gaur, N.; Gautam, S.; Gaur, M.; Sharma, P.; Dadheech, G.; Mishra, S. THE BIOCHEMICAL WOMB OF SCHIZOPHRENIA : A REVIEW. 2008 , 23 (4), 307 –327.", "(2) Kambarova, D. K.; Golubev, A. G. Biochemical and Genetic Aspects of Pathogenesis of Schizophrenia. 2011 , 47 (5).", "(3) Lally, J.; MacCabe, J. H. Antipsychotic medication in schizophrenia: A review. Br. Med. Bull. (4) Steeds, H.; Carhart -Harris, R. L.; Stone, J. M. Drug models of schizophrenia. Ther. Adv. (5) Ripke, S.; Neale, B. M.; Corvin, A.; Walters, J. T. R.; Farh, K. -H.; Holmans, P. A.; Lee, P.; Bulik - Sullivan, B.; Collier, D. A.; Huang, H.; et al. Biological insights from 108 schizophrenia -associated genetic (6) Giegling, I.; Hosak, L.; Mössner, R.; Serretti, A.; Bellivier, F.; Claes, S.; Collier, D. A.; Corrales, A.; DeLisi, L. E.; Gallo, C.; et al. Genetics of schizophrenia: A consensus paper of the WFSBP Task Force on Genetics. World J. B iol. Psychiatry 2017 , 0 (0), 1 –14.", "(7) Iritani, S. What happens in the brain of schizophrenia patients?: an investigation from the viewpoint of neuropathology. Nagoya J. Med. Sci. 2013 , 75 (1–2), 11 –28.", "(8) Nascimento, J. M.; Martins -de-Souza, D. The pro teome of schizophrenia. npj Schizophr. 2015 , 1 (9) Saia-Cereda, V. M.; Cassoli, J. S.; Martins -de-Souza, D.; Nascimento, J. M. Psychiatric disorders biochemical pathways unraveled by human brain proteomics. Eur. Arch. Psychiatry Clin. Neurosci . 2017 , (10) Cassoli, J. S.; Guest, P. C.; Malchow, B.; Schmitt, A.; Falkai, P.; Martins -de-Souza, D. Disturbed macro -connectivity in schizophrenia linked to oligodendrocyte dysfunction: from structural findings to molecules. npj Schizophr. 2015 , 1 (1), 15034.", "(11) English, J. A.; Pennington, K.; Dunn, M. J.; Cotter, D. R. The neuroproteomics of schizophrenia. (12) Martins -De-Souza, D.; Gattaz, W. F.; Schmitt, A.; Rewerts, C.; Maccarrone, G.; Dias -Neto, E.; Turck, C. W. Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. Eur. Arch. Psychiatry C lin. Neurosci. 2009 , 259 (3), 151 –163. (13) Behan, Á.; Byrne, C.; Dunn, M. J.; Cagney, G.; Cotter, D. R. Proteomic analysis of membrane microdomain -associated proteins in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder reveals alt erations in LAMP, STXBP1 and BASP1 protein expression. Mol. Psychiatry 2009 , 14 (6), 601 – (14) Föcking, M.; Lopez, L. M.; English, J. A.; Dicker, P.; Wolff, A.; Brindley, E.; Wynne, K.; Cagney, G.; Cotter, D. R. Proteomic and genomic evidence implicat es the postsynaptic density in schizophrenia. (15) Gottschalk, M. G.; Sarnyai, Z.; Guest, P. C.; Harris, L. W.; Bahn, S. Translational neuropsychiatry of genetic and neurodevelopmental animal models of schizophrenia. Rev. Psiquiatr. Clin. 2013 , 40 (1), 41 – (16) Cassoli, J. S.; Iwata, K.; Steiner, J.; Guest, P. C.; Turck, C. W.; Nascimento, J. M.; Martins -de- Souza, D. Effect of MK -801 and Clozapine on the Proteome of Cultured Human Oligodendrocytes. Front. Cell. Ne urosci. 2016 , 10 (March), 1 –14.", "(17) Filiou, M. D.; Turck, C. W.; Martins -De-Souza, D. Quantitative proteomics for investigating psychiatric disorders. Proteomics - Clin. Appl. 2011 , 5 (1–2), 38 –49.", "(18) Harrison, P. J. Using our brains: The findings, fl aws, and future of postmortem studies of psychiatric disorders. Biol. Psychiatry 2011 , 69 (2), 102 –103.", "(19) Hospital, J. R.; Kringelbach, M. L. and FMRIB, Oxford Centre for Functional Magnetic Resonance Imaging of the Brain THE HUMAN ORBITOFRONTAL CORTEX : LINKING REWARD TO HEDONIC EXPERIENCE. 2005 , 6 (September), 691 –702.", "(20) Rempel -Clower, N. L. Role of orbitofrontal cortex connections in emotion. Ann. N. Y. Acad. Sci. (21) Itzhak, D. N.; Tyanova, S.; Cox, J.; Borner, G. H. H. Globa l, quantitative and dynamic mapping of protein subcellular localization. Elife 2016 , 5 (JUN2016), 1 –36.", "(22) Jahn T, M. L. Die statistische Kontrolle moeglicher Medikamenteneinfluesse in experimentalpsychologischen Schizophreniestudien: Ein Vorschlag zur Berechnung von Chlorpromazina aequivalenten. Z Klin Psychol Psychother 1989 , 18:10 .", "(23) Saia-Cereda, V. M.; Cassoli, J. S.; Schmitt, A.; Falkai, P.; Martins -de-Souza, D. Differential proteome and phosphoproteome may impact cell signaling in the corpus callosum of schizophrenia patients. (24) Núñez, E. V.; Guest, P. C.; Martins -de-souza, D. Proteomic Methods in Neuropsychiatric (25) Oliveros, J. C. NoVENNY. An interactive tool for comparing lists with Venn Diagrams Title http://bioinfogp.cnb.csic.es/tools/venny/index.html.", "(26) Huang, D. W.; Sherman, B. T.; Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2008 , 4 (1), 44 –57. (27) Peri, S.; Navarro, J. D.; Kristiansen, T. Z.; Amanchy, R.; Surendranath , V.; Muthusamy, B.; Gandhi, T. K. B.; Chandrika, K. N.; Deshpande, N.; Suresh, S.; et al. Human protein reference database as a discovery resource for proteomics. Nucleic Acids Res. 2004 , 32 (Database issue), D497 –D501. (28) Fabregat, A.; Sidiropoulos, K .; Garapati, P.; Gillespie, M.; Hausmann, K.; Haw, R.; Jassal, B.; Jupe, S.; Korninger, F.; McKay, S.; et al. The reactome pathway knowledgebase. Nucleic Acids Res. 2016 , (29) Szklarczyk, D.; Franceschini, A.; Wyder, S.; Forslund, K.; Heller, D.; Huerta -Cepas, J.; Simonovic, M.; Roth, A.; Santos, A.; Tsafou, K. P.; et al. STRING v10: Protein -protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015 , 43 (D1), D447 –D452. (30) Ogata, H.; Goto, S.; Sato, K.; F ujibuchi, W.; Bono, H.; Kanehisa, M. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 1999 , 27 (1), 29 –34.", "(31) Yoon, J. H.; Maddock, R. J.; Rokem, A.; Silver, M. a; Michael, J.; Ragland, J. D.; Carter, C. S. Gamma -Aminobutyric Acid Conce ntration is Reduced in Visual Cortex in Schizophrenia and Correlates with Orientation -Specific Surround Suppression. J Neurosci. 2010 , 30 (10), 3777 –3781. (32) Wei, J.; Graziane, N. M.; Gu, Z.; Yan, Z. DISC1 Regulates GABAA Receptor Trafficking and Inhibitory Synaptic Transmission in Cortical Neurons. J. Biol. Chem. 2015 , 290 (46), jbc.M115.656173. (33) Redies, C.; Hertel, N.; Hübner, C. A. Cadherins and neurops ychiatric disorders. Brain Res. 2012 , (34) Otsuka, I.; Watanabe, Y.; Hishimoto, A.; Boku, S.; Mouri, K.; Shiroiwa, K.; Okazaki, S.; Nunokawa, A.; Shirakawa, O.; Someya, T.; et al. Association analysis of the Cadherin13 gene with schizophren ia in the Japanese population. Neuropsychiatr. Dis. Treat. 2015 , 11, 1381 –1393. (35) Rivero, O.; Selten, M. M.; Sich, S.; Popp, S.; Bacmeister, L.; Amendola, E.; Negwer, M.; Schubert, D.; Proft, F.; Kiser, D.; et al. Cadherin -13, a risk gene for ADHD and comorbid disorders, impacts GABAergic function in hippocampus and cognition. Transl. Psychiatry 2015 , 5 (10), e655. (36) Xia, Z.; Storm, D. R. The role of calmodulin as a signal integrator for synaptic plasticity. Nat. Rev. (37) Pang, Z. P.; Cao, P.; Xu, W.; Sudhof, T. C. Calmodulin Controls Synaptic Strength via Presynaptic Activation of Calmodulin Kinase II. J. Neurosci. 2010 , 30 (11), 4132 –4142. (38) Broadbelt, K.; Jones, L. B. Evidence of altered calmodulin immunoreact ivity in areas 9 and 32 of schizophrenic prefrontal cortex. J. Psychiatr. Res. 2008 , 42 (8), 612 –621.", "(39) Kim, J.; Shishido, T.; Jiang, X.; Aderem, A.; McLaughlin, S. Phosphorylation, high ionic strength, and calmodulin reverse the binding of MARCKS to p hospholipid vesicles. J. Biol. Chem. 1994 , 269 (45), (40) Brudvig, J. J.; Weimer, J. M. X MARCKS the spot: myristoylated alanine -rich C kinase substrate in neuronal function and disease. Front. Cell. Neurosci. 2015 , 9 (October), 1 –10. (41) McNamara, R. K.; Hussain, R. J.; Simon, E. J.; Stumpo, D. J.; Blackshear, P. J.; Abel, T.; Lenox, R. H. Effect of myristoylated alanine -rich C kinase substrate (MARCKS) overexpression on hippocampus - dependent learning and hippocampal synaptic plasticity MA RCKS transgenic mice. Hippocampus 2005 , (42) Pandey, G. N.; Dwivedi, Y.; Ren, X.; Rizavi, H. S.; Roberts, R. C.; Conley, R. R.; Tamminga, C. Altered expression and phosphorylation of myristoylated alanine -rich C kinase substrate (MARCKS) in postmortem brain of suicide victims with or without depression. J. Psychiatr. Res. 2003 , 37 (5), 421 –432. (43) Konopaske, G. T.; Subburaju, S.; Coyle, J. T.; Benes, F. M. Altered prefrontal cortical MARCKS and PPP1R9A mRNA expression in schizophrenia a nd bipolar disorder. Schizophr. Res. 2015 , 164 (1–3), (44) Anita L. Pinner1,*, Vahram Haroutunian2, and J. H. M. -W. Alterations of the myristoylated, alanine -rich C kinase substrate (MARCKS) in prefrontal cortex in schizophrenia. Schizophr Res 2014, 154 (45) Griffith, L. C. Regulation of Calcium/Calmodulin -Dependent Protein Kinase II Activation by Intramolecular and Intermolecular Interactions. J. Neurosci. 2004 , 24 (39), 8394 –8398. (46) Hasegawa, S.; Furuichi, T.; Yoshida, T.; En doh, K.; Kato, K.; Sado, M.; Maeda, R.; Kitamoto, A.; Miyao, T.; Suzuki, R.; et al. Transgenic up -regulation of alpha -CaMKII in forebrain leads to increased anxiety -like behaviors and aggression. Mol. Brain 2009 , 2 (1), 6.", "(47) Szebenyi, S. A.; Ogura, T.; Sathyanesan, A.; AlMatrouk, A. K.; Chang, J.; Lin, W. Increases in intracellular calcium via activation of potentially multiple phospholipase C isozymes in mouse olfactory neurons. Front. Cell. Neurosci. 2014 , 8 (October), 336.", "(48) Decuypere, J. P.; Mon aco, G.; Bultynck, G.; Missiaen, L.; De Smedt, H.; Parys, J. B. The IP3 receptor -mitochondria connection in apoptosis and autophagy. Biochim. Biophys. Acta - Mol. Cell Res. (49) Glazner, G. W.; Fernyhough, P. Neuronal survival i n the balance : are endoplasmic reticulum membrane proteins the fulcrum ? 2002 , 32, 421 –433.", "(50) Ghibelli, L.; Cerella, C.; Diederich, M. The dual role of calcium as messenger and stressor in cell damage, death, and survival. Int. J. Cell Biol. 2010 , 2010 .", "(51) Di Sano, F.; Fazi, B.; Tufi, R.; Nardacci, R.; Piacentini, M. Reticulon -1C acts as a molecular switch between endoplasmic reticulum stress and genotoxic cell death pathway in human neuroblastoma cells. J. (52) Strappazzo n, F.; Torch, S.; Chatellard -Causse, C.; Petiot, A.; Thibert, C.; Blot, B.; Verna, J. M.; Sadoul, R. Alix is involved in caspase 9 activation during calcium -induced apoptosis. Biochem. Biophys. (53) Mahul -Mellier, A. -L. Alix, Making a Link between Apoptosis -Linked Gene -2, the Endosomal Sorting Complexes Required for Transport, and Neuronal Death In Vivo. J. Neurosci. 2006 , 26 (2), 542 – (54) Marchi, S.; Patergnani, S.; Pinton, P. The endoplasmic reticulum – mitochondr ia connection : One touch , multiple functions ☆ Author â€TM s personal copy. Biochim. Biophys. Acta 2014 , 1837 , 461 –469. (55) Tsujimoto, Y.; Nakagawa, T.; Shimizu, S. Mitochondrial membrane permeability transition and cell death. Biochim. Biophys. Acta - Bioenerg. 2006 , 1757 (9–10), 1297 –1300. (56) Zamora, M.; Granell, M.; Mampel, T.; Viñas, O. Adenine nucleotide translocase 3 (ANT3) overexpression induces apoptosis in cultured cells. FEBS Lett. 2004 , 563 (1–3), 155 –160. (57) Ma, S. B.; Nguyen, T. N.; T an, I.; Ninnis, R.; Iyer, S.; Stroud, D. A.; Menard, M.; Kluck, R. M.; Ryan, M. T.; Dewson, G. Bax targets mitochondria by distinct mechanisms before or during apoptotic cell death: a requirement for VDAC2 or Bak for efficient Bax apoptotic function. Cell Death Differ. 2014 , 21 (58) Chandra, D.; Liu, J. W.; Tang, D. G. Early mitochondrial activation and cytochrome c up - regulation during apoptosis. J. Biol. Chem. 2002 , 277 (52), 50842 –50854.", "(59) Xiong, S.; Mu, T.; Wang, G.; Jiang, X. Mitochondria -mediated apoptosis in mammals. Protei n (60) Lenhausen, A. M.; Wilkinson, A. S.; Lewis, E. M.; Dailey, K. M.; Scott, A. J.; Khan, S.; Wilkinson, J. C. Apoptosis Inducing Factor Binding Protein PGAM5 Triggers Mitophagic Cell Death That Is Inhibited by the Ubiquitin Ligase Activity of X -Linked Inhibitor of Apoptosis. Biochemistry 2016 , 55 (61) Lee, J. -H.; Takahashi, T.; Yasuhara, N.; Inazawa, J.; Kamada, S.; Tsujimoto, Y. Bis, a Bcl -2- binding protein that synergizes with Bcl -2 in preventing cell deat h. Oncogene 1999 , 18 (46), 6183 –6190. (62) Rosati, A.; Graziano, V.; De Laurenzi, V.; Pascale, M.; Turco, M. C. BAG3: a multifaceted protein that regulates major cell pathways. Cell Death Dis. 2011 , 2 (4), e141.", "(63) Gupta, S.; Deepti, A.; Deegan, S.; Li sbona, F.; Hetz, C.; Samali, A. HSP72 protects cells from ER stress -induced apoptosis via enhancement of IRE1?? -xbp1 signaling through a physical interaction. PLoS (64) Chen, J.; Lee, C. T.; Errico, S. L.; Becker, K. G.; Freed, W. J. In creases in expression of 14 -3-3 eta and 14 -3-3 zeta transcripts during neuroprotection induced by Δ9-tetrahydrocannabinol in AF5 cells. J. (65) Glantz, L. A.; Gilmore, J. H.; Lieberman, J. A.; Jarskog, L. F. Apoptot ic mechanisms and the synaptic pathology of schizophrenia. Schizophr. Res. 2006 , 81 (1), 47 –63.", "(66) Ho, B. -C.; Andreasen, N. C.; Ziebell, S.; Pierson, R.; Magnotta, V. Long -term Antipsychotic Treatment and Brain Volumes. Arch. Gen. Psychiatry 2011 , 68 (2), 128.", "(67) Batalla, A.; Bargalló, N.; Gassó, P.; Molina, O.; Pareto, D.; Mas, S.; Roca, J. M.; Bern ardo, M.; Lafuente, A.; Parellada, E. Apoptotic markers in cultured fibroblasts correlate with brain metabolites and regional brain volume in antipsychotic -naive first -episode schizophrenia and healthy controls. Transl. (68) Albayrak, Y.; Beyazyuz, M.; Kufeciler, T.; Bulut, L.; Unsal, C.; Baykal, S.; Soydas Akyol, E.; Kuloglu, M.; Hashimoto, K. Increased serum levels of apoptosis in deficit syndrome schizophrenia patients: a preliminary study. Neuropsychiatr. Dis. Treat. 2016 , 1261.", "(69) Holz, A.; Schwab, M. E. Developmental expression of the myelin gene MOBP in the rat nervous (70) Baumann, N.; Pham -Dinh, D. Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol. Rev. 2001 , 81 (2), 871 –927.", "(71) Bauer, J.; Bradl, M.; Klein, M.; Leisser, M.; Deckwerth, T. L.; Wekerle, H.; Lassmann, H. Endoplasmic reticulum stress in PLP -overexpressing transgenic rats: gray matter oligodendrocytes are more vulnerabl e than white matter oligodendrocytes. J. Neuropathol. Exp. Neurol. 2002 , 61 (1), 12 –22. (72) Bizzoca, A.; Corsi, P.; Polizzi, A.; Pinto, M. F.; Xenaki, D.; Furley, A. J. W.; Gennarini, G. F3/Contactin acts as a modulator of neurogenesis during cerebral co rtex development. Dev. Biol. 2012 , 365 (73) Colakoglu, G.; Bergstrom -Tyrberg, U.; Berglund, E. O.; Ranscht, B. Contactin -1 regulates myelination and nodal/paranodal domain organization in the central nervous system. Proc. Natl. Acad. Sci. (74) Hill, C. M. D.; Harauz, G. Charge effects modulate actin assembly by classic myelin basic protein isoforms. Biochem. Biophys. Res. Commun. 2005 , 329, 362 –369.", "(75) Uranova, N.; Orlovskaya, D.; Vikhreva, O.; Zimina, I.; Kolome ets, N.; Vostrikov, V.; Rachmanova, V. Electron microscopy of oligodendroglia in severe mental illness. Brain Res. Bull. 2001 , (76) Pimenta, A. F.; Zhukareva, V.; Barbe, M. F.; Reinoso, B. S.; Grimley, C.; Henzel, W.; Fischer, I.; Levitt, P. The limbic system -associated membrane protein is an Ig superfamily member that mediates selective neuronal growth and axon targeting. Neuron 1995 , 15 (2), 287 –297. (77) Innos, J.; Koido, K.; Philips, M. -A.; Vasar, E. Limbic system associated membrane protein as a potential target for neuropsychiatric disorders. Front. Pharmacol. 2013 , 4 (March), 1 –3. (78) Philips, M. A.; Lillev??li, K.; Heinla, I. ; Luuk, H.; Hundahl, C. A.; Kongi, K.; Vanaveski, T.; Tekko, T.; Innos, J.; Vasar, E. Lsamp is implicated in the regulation of emotional and social behavior by use of alternative promoters in the brain. Brain Struct. Funct. 2015 , 220 (3), 1381 –1393. (79) Must, A.; Tasa, G.; Lang, A.; Vasar, E.; Kõks, S.; Maron, E.; Väli, M. Association of limbic system -associated membrane protein (LSAMP) to male completed suicide. BMC Med. Genet. 2008 , 9 (1), (80) Koido, K.; Janno, S.; Traks, T.; Parksepp, M.; L jubajev, Ü.; Veiksaar, P.; Must, A.; Shlik, J.; Vasar, V.; Vasar, E. Associations between polymorphisms of LSAMP gene and schizophrenia. Psychiatry (81) Lee, W. C.; Kan, D.; Chen, Y. Y.; Han, S. K.; Lu, K. S.; Chien, C. L. Sup pression of extensive neurofilament phosphorylation rescues α-internexin/peripherin -overexpressing PC12 cells from neuronal cell death. PLoS One 2012 , 7 (8).", "(82) Smalla, K. -H.; Mikhaylova, M.; Sahin, J.; Bernstein, H. -G.; Bogerts, B.; Schmitt, a; van de r Schors, R.; Smit, a B.; Li, K. W.; Gundelfinger, E. D.; et al. A comparison of the synaptic proteome in human chronic schizophrenia and rat ketamine psychosis suggest that prohibitin is involved in the synaptic pathology of schizophrenia. Mol. Psychiatr y 2008 , 13 (9), 878 –896.", "(83) Ching, G. Y.; Chien, C. L.; Flores, R.; Liem, R. K. Overexpression of alpha -internexin causes abnormal neurofilamentous accumulations and motor coordination deficits in transgenic mice. J. Neurosci. (84) Jackowski, A. P.; Araújo Filho, G. M. de; Almeida, A. G. De; Araújo, C. M. De; Reis, M.; Nery, F.; Batista, I. R.; Silva, I.; Lacerda, A. L. T. The involvement of the orbitofrontal cortex in psychiatric disorders: an update of neuroimaging findings. Rev. Bras. Psiquiatr. 2012 , 34 (2), 207 –212. (85) Berridge, M. J. Calcium signalling and psychiatric disease: Bipolar disorder and schizophrenia. (86) Jarskog, L. F.; Glantz, L. A.; Gilmore, J. H.; Lieberman, J. A . Apoptotic mechanisms in the pathophysiology of schizophrenia. Prog. Neuro -Psychopharmacology Biol. Psychiatry 2005 , 29 (5), 846 – (87) Dodell -Feder, D.; Tully, L. M.; Hooker, C. I. Social impairment in schizophrenia: new approaches for treating a per sistent problem. Curr. Opin. Psychiatry 2015 , 28 (3), 236 –242.", "TABLE AND FIGURES Table 1: Dysregulated proteins and their biological process.", "Figure 1: A. Polyacrylamide Gel Electrophoresis (SDS -PAGE 12%.) B. Western blot evaluation of cellular compartment enrichment efficiency using collapsin 2 (CRMP2) for cytosolic (Cyto), histone deacetylase 1(HDAC1) for nuclear (Nuc), postsynaptic density protein 95 (PSD 95) for synaptosomal (Syn) and ATP synthase subunit alpha (ATP5A1) for mitochondrial proteins (Mito).", "Figure 2: Experimental pipeline for iTRAQ labeling and label -free quantifications. Figure 3: A . Proteins identified and quantified by iTRAQ and label -free analysis. B. Total coverage of proteins identified by iTRAQ and label -free. C. Qualitative analysis of label -free data. D. GO cellular component analyses of all proteins identified by iTRAQ and label -free.", "Figure 4: A. Reactome pathway analysis of protei ns with statistically significant variation. B. Protein -protein interaction network analysis of dysregulated proteins. The first hub is calmodulin -1 (CaM) that interacts with proteins responsible for synaptic plasticity such as αCa2 + proteins / calmodulin -dependent protein kinase II ( αCaMKII) and MARCK related protein (MARCKS). The second main interaction point discloses proteins involved in apoptosis as ADP/ATP translocase 3 (SLC25A6), voltage -dependent anion -selective channel protein 2 (VDAC2) and cytoch rome c (CYCS). The third hub is around myelin basic protein (MBP), which interacts with proteolipid protein (PLP) and the myelin oligodendrocyte glycoprotein (MOG), associated with cell -cell adhesion and formation of myelin sheath.", "Figure 5: PRM analysis u sing the software Skyline. Chromatogram of the internal standard (Figure 5A) and the peptide EAFSLFDKDGDGTITTK from calmodulin -1 (Figure 5B) from patient (Pat_1. Pat_2, Pat_3, and Pat_8) and control (Ctrl) samples. Figure 6: Adapted from KEGG pathway. The biological function of the main dysregulated proteins converges around the regulation of calcium signaling pathways and the apoptotic process. CALM1 modulates proteins related to synaptic plasticity as αCaMKII and the MARCKS. On the other hand, the activation of receptors GPCR generates second messengers as IP3 by Phospholipase C beta with the release of Ca2+ into the cytoplasm. The increment of RTN1 -C also increases the cytoplasmic Ca2+ levels inducing ER stre ss and cell death. It is also observed, the dysregulation of pro -apoptotic proteins as PGAM5 , SLC25A6, VDAC and CYCS and anti -apoptotic proteins as HSP70 and BAG3. Red: Down -regulated proteins. CALM1: Calmodulin -1. Yellow: Up- regulated proteins. PMCA : The plasma membrane Ca2+ ATPase, HSP70 : The 70 kilodalton heat shock proteins, Gq: heterotrimeric G protein subunit, PLC β: Phospholipase C beta , CYCS : cytochrome c, BAG3: Bcl2 -associated athanogene 3, PGAM5 : Serine/threonine -protein phosphatase PGAM5, mitochon drial, SLC25A6: ADP/ATP translocase 3 , VDAC : Voltage -dependent anion -selective channel protein. SERCA : Sarcoplasmic/endoplasmic reticulum calcium ATPase, RTN1 -C: Reticulon -1, MARCKS : Myristoylated alanine -rich C -kinase substrate, αCaMKII : Ca2+/Calmodulin - dependent Protein Kinase II α. Green: Quantified proteins with no significant variation in their abundance. CaV2: calcium voltage -gated channel, PKC : Protein kinase C. Blue: Proteins and second messengers that were not identified but are part of the metabol ic pathway. GPCR: G-protein -coupled receptors , IP3: inositol 1,4,5 -trisphosphate, IP3R : Inositol trisphosphate receptor, AIF: Apoptosis -inducing factor. ER: Endoplasmic reticulum, MIT: Mitochondria", "SUPPORTING INFORMATION Supporting Table S -1: Clinical data of patients and control. This file contains all the information related to the clinical history of the patients, such as type of schizophrenia, duration of illness, time and type of antipsychotic treatment etc. Supporting Table S -2: Protein s identified by iTRAQ labeling. The supporting information contains the table of proteins identified by iTRAQ strategy, as well as the groups of peptides per protein and their respective quantification. Supporting Table S -3: Proteins identified by label -free. This file contains all the information related to the proteins identified by Label -free strategy, as well as the groups of peptides per protein and their respective quantification.", "Supporting Table S -4: Up - and down regulated proteins by iTRAQ labeling and label -free. In this file is finding the information about the dysregulated proteins quantified by iTRAQ and Label -free in all patients analyzed.", "Supporting Table S -5: GO and Reacto me analysis of the synaptosome proteome. The supporting file contains gene ontology analyses, biological processes, cellular function and Reactome pathway analyses of the total proteome of synaptosome fraction. Supporting Table S -6: Proteins specifically i dentified by label -free in patient or control groups. The supporting table has the label free qualitative analysis of proteins identified in all patients or control groups with two or more unique peptides . Supporting Table S -7: GO and Reactome analysis o f proteins specifically identified by label -free in patient or control groups. Gene ontology analyses, biological processes, cellular function and Reactome pathway analyses of label free qualitative analysis of proteins identified in patients or control groups Supporting Table S -8: GO and Reactome analysis of quantified proteins. Gene ontology analyses, biological processes, cellular function and Reactome pathway analyses of proteins with robust quantification Supporting Table S -9: Reactome analys is of up - and down regulated proteins. This file contains the information about the Reactome pathway analyses of dysregulated proteins quantified by iTRAQ and Label -free strategy.", "Supporting Table S -10: PRM data. Parallel reaction monitoring analysis conf irming the quantification of proteins as SERCA, MARCKS, CAM1, CYCS, RTN1 -C, LSAMP and PDCD6IP protein in four patients and control pool.", "Supporting Table S -11: Missing protein candidates. The table contains the information of missing protein candidates as description, annotated sequences of peptides etc provided by Proteome discoverer software 2.1.", "Supporting Figure S -1: Spectra of missing proteins candidates. A. Spectrum of Putative cytochrome b -c1 complex subunit Rieske -like protein 1 isoform Iso 1. B, C. Spectra of Protein unc -79 homolog isoform Iso 3.", "Table 1. Dysregulated proteins and their biological process. ID Description Regula tion GO: Biological process nxp:NX P62158 -1 Calmodulin isoform Iso 1 Down Cell communication; Signal transduction nxp:NX O14880 -1 Microsomal glutathione S -transferase 3 isoform Iso", "1 Up Metabolism; Energy", "pathways nxp:NX P02686 -6 Myelin basic protein isoform Iso 6 Up Immune response; Neurogenesis nxp:NX P05023 -1 Sodium/ potassium -transporting ATPase subunit alpha -1 isoform Iso 1 Up Transport nxp:NX P12036 -1 Neurofilament heavy polypeptide isoform Iso 1 Up Cell growth and/or maintenance nxp:NX P12236 -1 ADP/ATP translocase 3 isoform Iso 1 Up Transport nxp:NX P37840 -1 Alpha -synuclein isoform Iso 1 Up Protein metabolism nxp:NX P51674 -1 Neuronal membrane glycoprotein M6 -a isoform Iso", "1 Up Neurogenesis", "nxp:NX P60201 -1 Myelin proteolipid protein isoform Iso 1 Up Cell growth and/or maintenance nxp:NX Q13449 -1 Limbic system -associated membrane protein isoform Iso 1 Up Cell communication; Signal transduction nxp:NX Q16352 -1 Alpha -internexin isoform Iso 1 Up Cell growth and/or maintenance nxp:NX Q16653 -1 Myelin -oligodendrocyte glycoprotein isoform Iso 1 Up Immune response nxp:NX O14827 -1 Ras-specific guanine nucleotide -releasing factor 2 isoform Iso 1 Up Cell communication; Signal transduction nxp:NX O14994 -1 Synapsin -3 isoform Iso 1 Up Transport nxp:NX O43426 -2 Synaptojanin -1 isoform Iso 2 Up Metabolism nxp:NX O43581 -3 Synaptotagmin -7 isoform Iso 3 Up Regulation of exocytosis nxp:NX O75396 -1 Vesicle -trafficking protein SEC22b isoform Iso 1 Up Cell communication; Signal transduction nxp:NX O75899 -1 Gamma -aminobutyric acid type B receptor subunit 2 isoform Iso 1 Up Cell communication; Signal transduction nxp:NX O75964 -1 ATP synthase subunit g, mitochondrial isoform Iso", "1 Up Metabolism; Energy", "pathways nxp:NX O94760 -1 N(G),N(G) -dimethylarginine dimethylaminohydrolase 1 isoform Iso 1 Up Metabolism; Energy pathways nxp:NX O94967 -4 WD repeat -containing protein 47 isoform Iso 4 Up Cell communication; Signal transduction nxp:NX O95817 -1 BAG family molecular chaperone regulator 3 isoform Iso 1 Up Apoptosis nxp:NX O95837 -1 Guanine nucleotide -binding protein subunit alpha - 14 isoform Iso 1 Up Cell communication; Signal transduction nxp:NX P00568 -1 Adenylate kinase isoenzyme 1 isoform Iso 1 Up Metabolism; Energy pathways nxp:NX P00918 -1 Carbonic anhydrase 2 isoform Iso 1 Up Metabolism; Energy pathways nxp:NX P06733 -1 Alpha -enolase isoform alpha -enolase Up Metabolism; Energy pathways nxp:NX P07437 -1 Tubulin beta chain isoform Iso 1 Up Cell growth and/or maintenance nxp:NX P11137 -1 Microtubule -associated protein 2 isoform Iso 1 Up Cell growth and/or maintenance nxp:NX P12532 -2 Creatine kinase U -type, mitochondrial isoform Iso 2 Up Energy pathways nxp:NX P13637 -3 Sodium/ potassium -transporting ATPase subunit alpha -3 isoform Iso 3 Up Transport nxp:NX P13637 -3 Sodium/potassium -transporting ATPase subunit alpha -3 isoform Iso 3 Up Transport nxp:NX P13861 -1 cAMP -dependent protein kinase type II -alpha regulatory subunit isoform Iso 1 Up Cell communication; Signal transduction nxp:NX P14618 -2 Pyruvate kinase PKM isoform M1 Up Energy pathways; Metabolism nxp:NX P15104 -1 Glutamine synthetase isoform Iso 1 Up Metabolism; Energy pathways nxp:NX P16615 -1 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 isoform Iso 1 Up Transport nxp:NX P18669 -1 Phosphoglycerate mutase 1 isoform Iso 1 Up Metabolism; Energy pathways nxp:NX P19086 -1 Guanine nucleotide -binding protein G(z) subunit alpha isoform Iso 1 Up Cell communication; Signal transduction nxp:NX ATP synthase F(0) complex subunit B1, Up Metabolism; Energy P24539 -1 mitochondrial isoform Iso 1 pathways nxp:NX P29966 -1 Myristoylated alanine -rich C -kinase substrate isoform Iso 1 Up Cell growth and/or maintenance nxp:NX P31930 -1 Cytochrome b -c1 complex subunit 1, mitochondrial isoform Iso 1 Up Energy pathways; Metabolism nxp:NX P37840 -1 Alpha -synuclein isoform Iso 1 Up Protein metabolism nxp:NX P45880 -1 Voltage -dependent anion -selective channel protein 2 isoform Iso 1 Up Transport nxp:NX P68366 -1 Tubulin alpha -4A chain isoform Iso 1 Up Cell growth and/or maintenance nxp:NX P78352 -2 Disks large homolog 4 isoform Iso 2 Up Cell communication nxp:NX P99999 -1 Cytochrome c isoform Iso 1 Up Metabolism; Energy pathways nxp:NX Q01814 -2 Plasma membrane calcium -transporting ATPase 2 isoform WA Up Transport nxp:NX Q04917 -1 14-3-3 protein eta isoform Iso 1 Up Cell communication; Signal transduction nxp:NX Q07960 -1 Rho GTPase -activating protein 1 isoform Iso 1 Up Cell communication; Signal transduction nxp:NX Q08495 -1 Dematin isoform Iso 1 Up Cell growth and/or maintenance nxp:NX Q13449 -1 Limbic system -associated membrane protein isoform Iso 1 Up Cell communication; Signal transduction nxp:NX Q13509 -1 Tubulin beta -3 chain isoform Iso 1 Up Cell growth and/or maintenance nxp:NX Q13885 -1 Tubulin beta -2A chain isoform Iso 1 Up Cell growth and/or maintenance nxp:NX Q15286 -1 Ras-related protein Rab -35 isoform Iso 1 Up Cell communication; Signal transduction nxp:NX Q16352 -1 Alpha -internexin isoform Iso 1 Up Protein metabolism nxp:NX Q16720 -1 Plasma membrane calcium -transporting ATPase 3 isoform XB Up Transport nxp:NX Q16799 -1 Reticulon -1 isoform RTN1 -A Up Cell communication; Signal transduction nxp:NX Q16851 -1 UTP --glucose -1-phosphate uridylyltransferase isoform Iso 1 Up Metabolism; Energy pathways nxp:NX Q2M2I8 -1 AP2-associated protein kinase 1 isoform Iso 1 Up Transport nxp:NX Q3ZCQ8 -2 Mitochondrial import inner membrane translocase subunit TIM50 isoform Iso 2 Up Cell communication; Signal transduction nxp:NX Q86UX6 -1 Serine/threonine -protein kinase 32C isoform Iso 1 Up Cell communication; Signal transduction nxp:NX Q96HS1 -1 Serine/threonine -protein phosphatase PGAM5, mitochondrial isoform Iso 1 Up Metabolism; Energy pathways nxp:NX Q9H115 -1 Beta-soluble NSF attachment protein isoform Iso 1 Up Transport nxp:NX Q9NQ66 -1 1-phosphatidylinositol 4,5 -bisphosphate phosphodiesterase beta -1 isoform A Up Signal transduction nxp:NX Q9UHC6 -1 Contactin -associated protein -like 2 isoform Iso 1 Up Cell communication; Signal transduction nxp:NX Q9UPV7 -1 PHD finger protein 24 isoform Iso 1 Up Biological_process unknown nxp:NX Q9UQM7 -1 Calcium/calmodulin -dependent protein kinase type II subunit alpha isoform A Up Cell communication; Signal transduction nxp:NX Q9Y2T3 -3 Guanine deaminase isoform Iso 3 Up Metabolism; Energy pathways", "FIGURE 1", "Figure 2", "FIGURE 2", "FIGURE 3", "FIGURE 4", "FIGURE 5", "FIGURE 6", "APÊNDICE C- ANÁLISES PROTEÔMICA DA FRAÇÃO MITOCONDRIAL, NÚCLEO E CITOPLASMA DO CÓRTEX ORBITOFRONTAL DE PACIENTES COM ESQUIZOFRENIA . Artigo submetido na edição especial da revista Journal of Proteome Research", "QUANTITATIVE SUBCELLULAR PROTEOMICS OF THE ORBITOFRONTAL CORTEX OF SCHIZOPHRENIA PATIENTS", "Erika Velásquez1, Daniel Martins -de-Souza2,3, Ingrid Velásquez4, Gabriel Reis Alves Carneiro5, Andrea Schmitt6, Peter Falkai6, Gilberto B Domont1* and Fabio CS Nogueira1,5*", "1Proteomics Unit, Department of Biochemistry, Institute of Chemistry, Federal University of Rio de Janeiro.", "2Laboratory of Neuroproteomics, Department of Biochemistry, Institute of Biology, University of Campinas (UNICAMP).", "3UNICAMP ’s Neurobiology Center, Campinas, Brazil. 4University of Carabobo, Venezuela. 5Laboratory of Proteomics, LADETEC, Institute of Chemistry, Federal University of Rio de Janeiro.", "6Department of Psychiatry and Psychotherapy, Ludwig Maximilian University of Munich (LMU), Munich, Germany.", "*Corresponding authors Gilberto B Domont , gilberto@iq.ufrj.br Fabio CS Nogueira, fabiocsn@iq.ufrj.br", "ABSTRACT Schizophreni a is a chronic disease characterized by the impairment of mental functions with a marked social dysfunction. A proteomic approach using iTRAQ labeling and selected reaction monitoring, applied to the characterization of mitochondria (MIT), crude nuclear fraction (NUC) and cytoplasm (CYT), can allow the observation of dynamic changes in cell compartments providing valuable insights concerning schizophren ia physiopathology. Mass spectrometry analyses of the orbitofrontal cortex from 12 schizophrenia patients and 8 healthy controls identified 655 protein groups in MIT fraction, 1500 in NUC and 1591 in CYT. We found 166 groups of proteins dysregulated among all enriched cellular fractions. Through the quantitative proteomic analysis, we detect as the main biological pathways those related to calcium and glutamate imbalance, cell signaling disruption of CREB activation, axon guidance and proteins involved in t he activation of NF -kB signaling along with the increase of complement proteins C3. Based on our data analysis, we suggest the activation of NF -kB as a possible pathway that links the deregulation of glutamate, calcium, apoptosis and the activation of the immune system in schizophrenia patients. All MS data are available in the ProteomeXchange Repository under the identifier PXD014284 and PXD014350 Keywords: Schizophrenia, cellular fractions, proteomics, quantification.", "1. INTRODUCTION", "Schizophrenia is a chronic disease characterized by the impairment of mental functions with a marked social dysfunction. Over the years several hypotheses have emerged about its etiology and physiopathology but it is widely accepted that factors such as genetic susceptibilit y and environmental influences can cause the onset of the disease1. Diagnosis and classification depend mainly upon a collection of clinical features through the observation of positive symptoms including delusions, hallucinations, speech or disorganized behavior, as well as negative symptoms as affective bottling, anhed onia, alogia, avolition, social withdrawal and impaired cognitive capacity2. Negative and cognitive symptoms currently remain without totally effective therapeutic options, persisting in the chronic phase3.", "One of the main brain areas related to cognitive and behavioral disturbances is the frontal cortex. The dysfunction of this brain region is associated with mental disorders like psychosis, de pression, and anxiety4. Particularly the orbitofrontal cortex (OFC), a subdivision of prefrontal cortex, is involved in the emotional and e xecutive processing, reward -guided behavior and decision -making duet to its connection with neuroanatomical structures as the hippocampus, ventral striatum, amygdala, hypothalamus, anterior cingulate and other medial temporal areas5. Clinical findings have linked social functioning impairment with anatomic structural abnormalities in the OFC in first - episode schizophrenia patients6. In the same way, it was showed the relationship between structural brain abnormalities in the OFC and the severity of nega tive symptoms7,8 suggesting the key role of OFC in the abnormal e motional responses and social disability. According to the Schizophrenia Working Group of the Psychiatric Consortium of Genomic ( 2014)9, single nucleotide polymorphisms related to schizophrenia gene risk are associated with several genes involving dopamine receptor, glutamate neurotrans mission, and immunity. Otherwise, transcriptomic data show that pathways linked with mitochondrial function and energy production, tight junction signaling, protein translation, neurodevelopment, and immune system seem to be very important in the pathophys iology of schizophrenia10, 11, 12.", "Several studies have been carried out the prote omic characterization of post - mortem brain tissue of different areas from patients with schizophrenia, showing that the dysregulation of synaptic function as the NMDA receptors hypofunction, calcium homeostasis, imbalance of mitochondrial energy metabolis m and oxidative stress, dysregulation in proteins of cytoskeleton and immune system are the main pathways reported so far13. However, only a few of these proteomic studies have deepened into the subcellular level14,15,16. The traditional proteomic approach lacks the important spatial information of the data; protein function is related to its environment, and the pathophysiological process can involve changes in protein subcellular localization17. We analyse OFC post -mortem brain tissue from patients classified as residual schizophrenia according to the DMS -IV manual. In this classification, the patients do not manifest prominent positive psychotic symptoms but prevail characteristic disturbance of negative symptoms18. Through the comparison of patient´s samples against a pool of control subjects without any history of psychiatric illness we generated an organellar proteome map from different subcellular fractions such as mitochondria (MIT), crude nuclear fraction (NUC) and cytoplasm (CYT) with the aim to monitor the subproteome changes using iTRAQ labelling for relative quantification and Selected Reaction Monitoring ( SRM) for targeted quantification. Subcellular proteome maps allowed to observe dynamic changes in cell compartments providing valuable insights concerning schizophrenia physiopathology in the chronic phase of the disease.", "2. EXPERIMENTAL PROCEDURES", "2.1. Brain samples", "The OFC postmortem tissues were collected from 12 schizophrenia patients at the State Mental Hospital in Wiesloch, Germany. Patients were diagnosed as residual schizophrenia (295.6) according to the Diagnostic and Statistical Manual of Mental Disorders (DSM -IV) criteria18. The OFC control samples were collected from eight individuals at the Institute of Neuropathology, Heidelberg University, in Heidelberg, Germany (Table S-1). It was selected control subjects without any medical records of mental clinical diseases, antidepressants or antipsychotics treatment during their lifetime and no history of alcohol or drug abuse. Other neuropathologies were ruled out by histopathological analysis, considering only brains with Braak staging less than II. All assessments, postmortem evaluations and procedures were approved by the ethics committee of the Faculty of Medicine, Heidelberg University, Heidelberg, Germany.", "2.2. Sub cellular enrichment", "For nuclear enrichment, fifty milligrams of OFC tissue were homogenized in 10 volumes of Buffer A pH 7.4 (0.32M sucrose, 4mM HEPES and protease cocktail inhibitor tablets (Roche)) and phosphatase inhibitor cocktail I and II (Sigma). The homogenate was centrifuged at 1.000g for 10 min, 4oC obtaining the P1: crude nuclei. In the case of the mitochondria and cytoplasm enrichment, t hirty milligrams of intact OFC brain tissue was incubated for 15 min on ice with 180µl of 250 -STM buffer (250 m M Sucrose, 50 mM Tris-HCl pH 7,4, 5 mM MgCl 2, Mini protease inhibitor and phosphatase inhibitor (Roche)). The tissue homogenization was made two times with a pestle for 1 -2 minutes incubating for 10 min. The sample was centrifugated at 800g for 15 min 4°C, obtaining the supernatant Cyt 1 (cytoplasm + mitochondria). The pellet was resuspended in 640µl 250-STM buffer, centrifuging at 800g, 15 min, 4°C until the supernatant was clear. All supernatants were combined and centrifugated at 6.000g, 15 min, 4°C. The last supernatant was collected as CYT fract ion and saved to -80°C until its use and the pellet (PM) was used for mitochondria enrichment.", "PM was resuspended in 250 µl of 250 -STM buffer and centrifuged at 6.000g, 15 min, 4°C. The pellet was resuspended in 250µl Hepes buffer (10 mM Hepes, (pH 7,9 / Mini protease inhibitor and phosphatase inhibitor (Roche) and incubated at 4°C for 30 min ( Eppendorf ThermoMixer® , cold room / mixing). The enriched mitochondria were loaded on a sucrose gradient containing 1,75ml of 50% sucrose, 1,75 ml of 36% sucrose and 0,75 ml of 20% sucrose centrifuging at 25.000rpm, 4°C, 60 min. The MIT fraction was transferred to a new tube, filling in with Hepes buffer until 2 ml and centrifuged at 17.200g, 20 min, 4°C. This procedure was repeated four times. Finally, the pellet was saved to -80°C until use.", "2.3. Protein extraction and western blot analysis", "Protein extraction was made according to Saia -Cereda and collaborators protocol (2016)15, determining the protein concentration by the Bradford assay ( BioRad; Munich, Germany ). For SDS -PAGE electrophoresis and the Western blot analysis we proceeded as previously described16. The western blot image has been published in our previous study16 where the subcellular enrichment efficiency was evaluated using antibodies against collapsin 2 for cytosolic protei ns, ATP synthase subunit alpha (ATP5A1) for mitochondrial proteins, postsynaptic density protein 95 (PSD95) for synaptosomal proteins, and histone deacetylase 1 (HDAC1) for nuclear proteins16.", "2.4. Protein digestion", "Enzymatic digestion for iTRAQ labeling experiment used 10 µg of protein from MIT (n=6), 25 µg of NUC (n=12), 50 µg of CYT (n=11) and control pool (20 µg MIT, 100 µg NUC, and 200 µg CYT, all with n= 8). The samples were reduced with 5 mM TCEP for 1 hour at 30 oC, alkylated with 10 mM iodoacetamide for 30 minutes at room temperature followed by dilution (1:10) with 50 mM triethylammonium bicarbonate (TEAB) pH 8 and digestion with trypsin (1:50) for 18 hours at 35 o C. The samples were cleaning in C 18 MacroSpin Columns ( Harvard Apparatus ) The peptides were dried in Speed Vac and resuspended in 30 µl of TEAB 20 mM for Qubit® assay quantification. For SRM experiments were digested 8 µg of proteins from all subcellular fractions (MIT n=12, NUC n=8, and CYT n=12) and 8 µg of control pool (n=8 for MIT, NUC, and CYT) following the procedure above.", "2.5. Isobaric tag labeling with iTRAQ and strong cation exchange (SCX) The peptides from each subcellular fraction were labeled according to Núñez and collaborators protocol (2017). The organization of 4-plex iTRAQ in all subcellular fractions was made up as follows: three channels (114, 115 and 116) were labeled with patients’ samples and one channel (117) containing the pool of 8 control samples. Labeled peptides were dried to a volume of 20 µl. For SCX chromatography (MacroSpin Columns - Harvard Apparatus ) the samples were completed to a final volume of 100 µl with a solution of KH 2PO 4 5 mM / ACN 25% pH 3. Peptides were eluted by one step with 500 mM KCl for MIT and NUC fractions and 75, 150, 250 a nd 500 mM KCl for CYT fraction. Samples were desalted in C 18 MacroSpin columns (Harvard apparatus ), dried and suspended in 0.1% formic acid for quantification ( Qubit ® protein assay Kit – Thermo Scientific).", "2.6. Mass spectrometry analyses", "Peptides (2 μg) were analyzed in technical triplicate by nLC Proxeon EASY -II system ( Thermo Scientific ). The chromatographic condition was as follow: flow -rate of 250 nL/min, three hours of gradient beginning with 5% to 40% B for 167 minutes, 40% to 95% B for 5 min, 95% B for 8 minutes, using as solvent A a solution of 95% H 2O / 5% ACN / 0.1% formic acid and solvent B 95% ACN / 5% H 2O / 0.1% formic acid. The analytical column length was 15 cm and an internal diameter of 75 µm (3 µm spheres - Reprosil Pur C18, Dr. Maish) and the trap -column length was 3 cm with an internal diameter of 200 µm (5 µm spheres -Reprosil Pur C18, Dr. Maish). Data acquisition was carried out under a stream atmosphere provided by 5% ammonium hydroxide19. The chromatographic system wa s coupled on -line to an LTQ Orbitrap Velos (Thermo Scientific ) mass spectrometer. A dynamic exclusion list of 90 s, spray voltage at 2.5 kV and no auxiliary gas flow were the settings used for data -dependent acquisition mode. For Full MS scan was used a sc an range of m/z 375 -2000 and a resolution of 60,000 (at m/z 400) in the Orbitrap analyzer. We selected the ten most intense ions for fragmentation, excluding unassigned and 1+ charge state , acquiring the MS2 spectra in the Orbitrap (resolution of 7,500 at m/z 400) with higher -energy collision dissociation (HCD) using normalized collision energy of 40.", "2.7. Mass spectra analysis", "Raw data was analyzed using Proteome Discoverer 2.1 software against the human database from neXProt (12/02/2019) using a target -decoy strategy (maximum delta CN of 0.05) and a false discovery rate (FDR) of 0.01. The search space was full - tryptic considering two missed cleavag es for trypsin . The precursor mass tolerance and fragment mass tolerance were 10 ppm and 0.1 Da respectively. As fixed modification was included the carbamidomethylation of cysteine. Methionine oxidation, protein N -terminal acetylation and iTRAQ modifications (K, Y, and N -terminal) were considered as dynamic modifications. The peptide filter was set up for high confidence counting only peptides rank 1 with a minimum lengt h of 6 amino acids using as peptide validation settings an automatic control level peptide error with a strict target FDR of 0.01 . The confidence threshold in FDR protein validator was 0.01, grouping the proteins by maximum parsimony.", "iTRAQ quantificatio n was made with unique peptide using patients’ value as nominator and pool of controls as the denominator for fold -change calculation. Additional filters as a correction for the impurity reporter and a filter to do not report quantitative values for a sing le-peak in the precursor isotope pattern were applied.", "2.8. Statistical evaluation of the data", "Data analyses were performed in the InfernoRDN program20 using unique peptides. For data normalization was applied to the Central Tendency and the absolute deviation of the adjusted median. Grubbs test, with a minimum of three peptides and p - value <0.05, was used as a parameter to group the peptides in their corresponding protein. Robust estimators such as the median and median absolute deviation were used to calculate the z -score and the p -value associated with a 95% confidence level, determining the statistically significant variations in the relative abundance of proteins. Also, InfernoRDN was used for the principal component analysis (PCA) of the different subcellular fractions.", "2.9. Biological and functional analysis", "Subcellular localization protein assignment was made using UniProt21. Comparative analyses of data were performed in Venny 2.1 program22. The biological function was analyzed by Reactome Pathways23 together with the STRING 10.5 software24 (considering hi gh-confidence interactions) and KEGG program25.", "2.10. SRM Analysis", "The SRM analysis was performed in an EASYII -nano -LC (ThermoScientific) in a C18 column PicoChip 75µm x 105mm (New Objective) and C18 trap column Acclaim PepMap 75µm x 2 cm (ThermoScientific). As Solvent A was used a solution of 95% H2O / 5% ACN / 0.1% formic acid and solvent B 95% ACN / 5% H 2O / 0.1% formic acid in a flow -rate 320 nL/min during 60 min.", "The data were acquired in a positive mode using the SRM (Selected Reaction Monitoring) mode in the T SQ Quantiva ( Thermo Scientific ) mass spectrometer. The first and third quadrupoles were set up with a resolution of 0.7 (FWHM) using a cycle time of 2 s. The precursor ions fragmentation was carried out with Argon gas with a CID gas pressure of 1.5 mTorr u sing normalized collision energy for each peptide in a range of 10-30. Regarding the ion source parameters, the spray voltage and the ion transfer tube temperature used was 2,6kV and 280ºC, respectively, and the sweep gas was set up as 0 (Arb). The data an alysis of SRM results was performed with Skyline v. 4.2 software using a public NIST library of peptide ion fragmentation spectra from Peptide Atlas (Ion Trap: Human. SpectraST format with short peptides (<7AA) excluded. File Name: NIST_human_IT_2012 -05-30_7AA.splib.zip). For data normalization, we use as global standard the heavy peptide sequence AVLDLFEETSNIGSK. For quantification analysis, we consider at least three transitions per peptides, two peptides per protein family considering at least a dotp of 0.7. For proteins with more than one monitored peptide, the sum of normalized areas of all peptides was used for the statistical analyses. The Statistix 8.0 software was used for the calculation of the significant variations in protein abundance applying a completely randomized ANOVA test followed by Tukey HSD all -pairwise comparisons considering a p -value < 0.05.", "3. RESULTS AND DISCUSSION", "3.1. Proteins identified by mass spectrometry", "In the mass spectrometry analyses we identified 655 protein groups from MIT fraction, 1500 proteins groups in NUC and 1591 protein groups in CYT ( Table S -2), getting the identification of 2159 protein groups among all fractions (Figure 1). Venny diagram reveals that the proteins identified in all fractions ( 17.8%) are mainly related to metabolism and axon guiance. Nine percent of proteins were identified only in MIT and they are involved in electron transport, citric acid cycle, and ATP synthesis. The percentage of proteins found only in NUC and CYT represents 26,3 % and 36 % respectively. In NUC the biological function of these proteins is related to mRNA splicing, on the other hand, in CYT fraction proteins are involved in polyamines metabolism and NF-κB activation (Figure 1B; Table S-3). In figure 1C, the PCA show s three well -defined different subpopulations corresponding to the patient data distribution for each fraction.", "After data normalization, we applied the Grubbs test with a minimum of three peptides and p -value <0.05 per protein, in order to obtain the highest quality data for protein quantification. iTRAQ labeling robustly quantified a total of 1279 proteins, in which 329 for MIT fraction, 888 for NUC and 948 for CYT (Figure 1D ; Table S-4).", "3.2. Dysregulated protein s and their functional analysis For the selection of dysregulated proteins, in addition to the use of rigorous statistical criteria, we also consider the same quantitative behavior for up - and down - regulated proteins in at least 50% of patients. These crit eria drastically reduce the number of proteins considered as dysregulated to a total of 166 in all fractions (Figure 1D ; Table S-5). We performed the SRM analyses to monitor the endogenous peptides of key proteins previously quantified by iTRAQ such as γCaMKII, GS and MAPK2 as another method to confirm the quantification of these proteins. Additionally, the label -free SRM quantification was able to monitor peptides of important proteins such as C3 and NF -kB family, who participate in key biological pathwa ys previously quantified by the iTRAQ strategy (Table S -6).", "3.2.1. Mitochondrial fraction", "Mitochondrial dysfunction and structural changes have been widely reported in schizophrenia patients26,27,28. According to a recent review29 in post-mortem brain tissue, mitochondrial abnormalities in these patients vary according to the brain area, cell type and also to treatment response. Thirteen proteins were found dysregulated in MIT fraction (Table S -5). We detected two proteins down -regulated such as CLTC and PPIase A (Table S -5), related to endocytosis and protein folding respectively. Additionally, we found eleve n up-regulated proteins, mainly involved in the biological processes such as the citric acid cycle and respiratory electron transport, mitochondrial membrane organization and cristae formation (Table 1; Table S-7;).", "In our study, we found up -regulated pro teins involved in mitochondrial membrane organization such as voltage -dependent anion -selective channel protein 1 (VDAC1) previously reported as dysregulated in schizophrenia patients27. VDAC1 overexpression mediated the mitochondrial apoptosis and its oligomerization seems to be important for the releas e of the pro -apoptotic proteins from the mitochondrial intermembrane space to the cytosol30 .We also found increased the Protein FAM162A, who interacts with VDAC1 inducing the permeabilization of the mitochondrial transition pore, triggering the apop tosis with the release of cytochrome c and the activation of caspases31,32,33. Another indication of the imbalance in apoptosis is the increase in proteins such as Complex III and NipSnap1. Under ox idative stress condition Complex III can trigger the the intrinsic pathway of apoptosis34 and NipSnap1 involved in Ca2+ imbalance35, can trigger the mitophagy s ignals36. These results agree with those previously reported in a study made by our group, where we analyze the synaptosome fraction of schizophrenic patients from the same brain area 16, we observed the deregulation of calcium metabolism pathway concomitantly with the activation of an apoptotic process (Figure 2).", "When an apoptotic signal is activated the balance between pro - and anti -apoptotic stimulus determines the cell death. One of the most noticeable alterations in the apoptotic processes is the structural changes of mitochondria and it has been suggested that mitochondrial cristae remodeling can impact Cyt c release and mitochondrial storage37. In response to the apoptotic signals, we found increased in schizophrenia patients the ATPase inhibitor (IF1) and mitochondrial cristae proteins such as Mic19 and Mic25. IF1 overexpression has the capacity to limit the cell death avoiding the ATP depletion from the mitochondrial matrix induced by the reverse pumping of F1Fo -ATP synthase during reduced membrane potential conditions38. IF1 also c ontrols the mitochondrial cristae structure39 and together with Mic19 and its paralog Mic25 contribute to the maintenance the of the mitochondrial crista architecture and me mbrane organization 40,41,42", "3.3. Crude Nuclear fraction", "In NUC fraction we found 87 proteins with significant variation in their relative abundance (Table S -5). Three less abundant proteins as APP, S100A1, PRKCB are related to Ca2+ signal transduction and apoptosis. On the other hand, 83 proteins increased the abundance in this s ubcellular fraction, and many of these are involved in apoptosis and chemical synapses transmission (Table1; Table S -7).", "3.3.1 - Proteins located in the cell nucleus", "3.3.1.1. Apoptosis and chemical synapses transmission", "The biological function related to one of the main dysregulated protein groups is involved in the activation of apoptosis and the localization of FOXO transcription factors (Table S -7). Among these proteins, we can highlight the 14 -3-3 protein family, involved in the regulation of various cellular events such as the apoptosis, interacting with apoptotic proteins as BAX, BAD, and caspases43,44, autophagy45 and MAPK activity signaling pathway46,47. Another function associated with the 14 -3-3 protein family is the regulation of the FOXO transcription factor through phosphorylation48, inducing the cytoplasmic translocation of FOXO inhibiting its binding to DNA48,49. As a consequence, the cytoplasmic FOXO is not available t o regulate the transcription of various genes like those belonging to the NF -kB signaling pathway50. The deficit in FOXO function leads to an increase in the in vivo activity of NF -kB51,52.", "In parallel, we were able to detect the increase of several nuclear proteins related to NF -kB activation such as 1) RhoB53 which can also elevate the caspase 3 in the corticohippocampal neurons54, 2) HMGB1, involved in the excitoneurotoxicity mediated by NF -kB55 is released from neurons to astrocytes activating the nuclear factor -kB56,57; it is important to mention that HMGB1 activates NF -kB pathway via ERK -depend ent mechanism58, in this sense, we have detected by SRM the protein ERK -2 which is increased in NUC fraction (Table S -6), an indirect evidence of ERK activation59. Also, we found down -regulated the nuclear Protein kinase C beta involved in NF -kB regulation 60,61 (Figure 3A). A microarray profiled from the superior temporal gyrus of patients with schizophrenia suggest that NF -kB signaling is down -regulated in this brain area62, but a recent study of Volk and colle agues63 extensively map the expression of genes related to NF-kB signaling through the canonical and non -canonical pathways in the prefrontal cortex of schizoph renia patients, concluding that both pathways are increased and they are not affected by the antipsychotic treatment.", "On the other hand, we found deregulated proteins that stand out for participating in the chemical synapses transmission, represented prin cipally with the increase of proteins as Calcium/calmodulin -dependent protein kinase type II gamma ( γCaMKII). γCaMKII is a shuttle protein that binds Ca2+/CaM. After the cytosolic increase of Ca2+, γCaMKII translocates CaM from the cytoplasm to the nucleus64. This protein was reported previously up -regulated (together with CaM) in a nuclear fraction from corpus callosum and anterior temporal lobe of schizophrenia patients15, also it was shown that γCaMKII has an abnormal regulation in the prefrontal cortex by the miR -219 in the dizocilpine murine model65. γCaMKII unique peptides were mapped and quantified using the SRM technique in the NUC and CYT fractions (where previously it could not be identified) demonstrating that γCaMKII apparently is mainly located in NUC since it was found increased in that fraction and no significant ch ange in CYT. However, how can be increased the nuclear γCaMKII in our results if the nuclear CaM have the tendency to remains decreased? (Table S -5). Previously, studies demonstrated that γCaMKII needs to be phosphorylated in Thr287 for effective CaM nucle ar delivery66,67 and for this process, it was shown that βCaMKII kinase function is responsible for pThr28766. In accordance with these observations, we found βCaMKII down -regulated in CYT fraction. Ma and colleagues (2014) elegantly demonstrated that without βCaMKII phosphorylation at T287, the nuclear translocation of the γCaMKII in not affected but nuclear delivery of CaM and CREB activation is impaired66 (Figure 4). Imbalance in CREB activation is detrimental to synaptic plasticity68.", "The crude nuclear fraction obtained during the sample processing, in addition to enriching nuclear proteins, brings common contaminants such as mitochondria (especially those located in the perinuclear region), sheets of the plasma membrane and also, possibly, minor contaminants such as lysosomes, peroxisomes, Golgi membranes, and various membrane vesicles69. The methodology implemented restricts the interpretation of the biological function of proteins that can share different subcellular locations besides the nucleus, in this data set, we detect as the main contaminants of NUC fraction, proteins whose more frequ ent subcellular location has been reported in mitochondrion and cellular membrane, nevertheless, some of these proteins are interesting to mention due to their biological importance.", "3.3.2. Mitochondrial proteins present in the crude nuclear fraction", "We quantified proteins in the crude nuclear fraction whose subcellular location has been reported only in the mitochondrion and for which in the MIT fraction we have not identified or observed any significant variation in the relative abundance compared to the control group. What could, then, explain that these proteins do not significantly change their abundance in the MIT fraction and, at the same time, are dysregulated in this crude nuclear fraction? One possible answer is that these proteins have a nuclear function not yet described or, the most plausible explanation is that these proteins could reflect the activity of the perinuclear mitochondria, due to the technical limitations mentioned above for this type of enrichment for nuclear proteins. Since a lon g time ago, the heterogeneity of mitochondria in a single cell has been reported70. In the same cell the mitochondria can be morphologically heterogeneous in terms of ultrastructure, cristae density, and shape, having different respiratory status and functional prope rties as divergences in Ca2+ and reactive oxygen species (ROS) levels, protein composition, mitochondrial membrane potential, respond differently to apoptotic and mitophagy signals and also, they can have a different fission and fusion dynamic70,71,72,73,74.", "Among these mitochondrial proteins are dysregulated those belonging electron transport chain. We found several subunits of the NADH dehydrogenase (Complex I) as up-regulated in our data set. Complex I sub units were previously reported down -regulated in post -mortem brain tissues from different brain areas in schizophrenia patients13,75,76 and it was demonstrated that antipsychotic treatment and early onset of illness have a strong correlation with Complex I decline75. On the other hand , the mRNA expression of certain Complex I subunits was significantly higher in blood samples of schizophrenia group, having a positive correlation with the first -episode schizophrenia subgroup77. It is still not fully elucidated the biological meaning about the discrepancy in the abundance of th e different complex I subunits, nevertheless, impairments in mitochondrial metabolism have been associated with cognitive and behavioral abnormalities during the clinical course of schizophrenia77.", "Another set of key proteins that we detect in this fraction were those related to the glutamate metabolism s uch as glutamine synthetase (GS) increased in NUC fraction and glutamate dehydrogenase (GLDH) found as decreased in CYT fraction (Figure 5).", "Almost all of them are located in the astrocytes, where the glutamate is taken up from the synaptic cleft and conv erted to glutamine by GS, or in α-ketoglutarate by GLDH 78. On the other hand, once th e glutamine is produced in the astrocytes it is transported to the neurons where it is converted back into glutamate by the glutaminase GA79, we observe a tendency of the increase of this protein in our p atients (Table S -5).", "Over the years, the deregulation of glutamate has been formulated as one of the main hypotheses in the pathophysiology of schizophrenia in patients. High levels of glutamate plus glutamine have been reported in unmedicated patients whe n they are compared with healthy subjects80. GS transcripts have been reported as up -regulated in schizophrenia thalamus suggesting the enhanced glutamatergic neurotransmission81. Moreover, GS was found decreased in the prefrontal cortex and increased in the anterior cingulate and cerebellar cortex whereas no significant differences were observed in the posterior cingulate cortex82. Despite this, a study points out that there are no significant differences between the GS activit y in the prefrontal cortex of schizophrenia patients and controls83. In this case, we monitor GS by SRM confirming that it is increased in our patients (Table -S6) suggesting that glutamine production can be dysregulated in these patients. On the other hand, the level of platelet GLDH before antipsychotic treatment has been reported as significantly lower 84 and higher in post -mortem brain tissues from the pre-frontal cortex of chronic schizophrenia patients83. Nevertheless, in a study performed by Lander and colleges85 the gene expression profile of Glud -1 was found down -regulated in the CA1 region of schizophrenia patients, proving that Glud -1 deficient mouse had an elevated excitatory/ inhibitory balance in CA1 region with similar behavioral abnormalities to the schizophrenia symptoms.", "3.3.2. Membrane proteins present in the crude nuclear fraction", "The first cluster of proteins dysregulated that we would like to highlight are those related to glutamate pathways , such as excitatory amino acid transporter 2 (EAAT2) whose main function is the regulation of total glutamate uptake (Figure 5). EAAT2 is localized in the plasma membrane of astrocytes, but also in other cells as oligodendrocytes, microglia; and recently EAAT2 was also identified in neurons86. EAAT2 is the main transporter, r esponsible for about 90% of the glutamate clearance in the synaptic cleft87.", "It is reported the different amounts of transcript and protein level of EAATs in diverse brain areas of schizophrenia patients. In the dorsolateral prefrontal cortex of schizophrenia patients was not detected any variation in the amount of EAAT2 transcript or protein level88. However, in an other study from the prefrontal cortex of medication - free schizophrenia patients, the mRNA levels of EAAT2 was increased compared to controls89; in fact, data reveals that in the thalamus, the in excitatory neurons had a compensatory increment of the EAAT2 mRNA expression, suggesting an impairment in the clearance of glutamate capacity by astrocytes and decoupled glutamate metabolism in the tripartite synapse90.", "The second group of proteins that we would like to mention is involved in the complement system pathway . First, we quantified as up -regulated the CD59 glycoprotein, an important cell membrane whose main function is the inhibition of C9 complement molecule to prevent the pore membrane attack complex (MAC)91. In Alzheimer disease was observed that CD59 activation is not efficient to suppress the complement pathway92. Recently, it was described the activation of the complement pathway through the NF -kB signaling. Astrocytes are one of the main sources of NF -kB, which promote the production of complement C3, C3R neuronal receptors stimulation, calci um imbalance and morphological change in dendrites93. Based on this information and in the evidence of NF -kB dysregulation in our data, we decided to implement a targeted approach to quantify the complement C3 and members of the NF -kB family using SRM (Table S -6). We observed that C3 is increased in schizophrenia patients compared to the contro l only in the NUC fraction, which probably indicates, due to the technical limitations related to the enrichment of this fraction mentioned above, the location of C3 in the plasma membrane and the activation of complement pathway (Figures 3B and 3C) . The N F-kB family members such as NF -kB1 and NF -kB2 were also increased in NUC fraction (Table S-6), suggesting an important role of this pathway as a possible mechanism for C3 activation. Complement proteins are required for the central nervous system to carry out the elimination of inappropriate synapses94. The ex pression of C3 fragments on the cell surface also allows the recognition of this signal by microglia CR3 receptors promoting the engulfment of synaptic elements95.This process could participate in the active elimination of long -term depression synapses when apoptotic mechanism as caspase -3 cascade is activated in dendrites without causing cell death96,94.", "Over the years the complement system has been indicated as an important element in the schizophrenia pathogenesis. Recently, one of the most extensive genetic studies links the human major histocompatibility complex as one of the most significant loci related to schizophrenia9. In 2016, Sekar and colleagues97 have reported elevated expression of the C4A transcript in schizophrenia patients, reinforcing the theory that C4 leads the C3 activation and the synapsis elimina tion.", "3.4. Cytoplasmatic fraction", "In the CYT fraction, we quantified 87 dysregulated proteins (Table S -5). This fraction stands out because most of the proteins, that fulfilled our selection criteria, are not only down -regulated but counter -regulated in relation to the other fractions, that is, the same protein is mostly up -regulated in NUC or/and in MIT fraction. The biological functions associated with these proteins are the axon guidance process which also includes the dysregulation of the proteasome proteins and ribosomal proteins (Table 1; Table S -7).", "One of the main proteins involved in axon guidance, neuronal outgrowth, and synaptic plasticity is the neuromodulin (GAP -43), decreased in the schizophrenia cohort. GAP -43 down -regulation inhibits the initiation of axonal regrowth after axotomy98. In schizophrenia, subjects were observed a significant reduction of GAP -43 in the dentate gyrus99. Moreover, the astrocytic GAP43 knockdown induces the over -expression of EAAT2 what causes the excessive extracellular glutamate uptake activating the astrocyte - induced neurotoxicity and microglial activation100.", "Ribosomal proteins is another important cluster that also participates in the axonal growth with the local mRNA translati on101 . We found decreased principally the ribosomal proteins (RP), from the 60S and 40S ribosomal subunits (RS), responsible for catalyzing , during the protein synthesis process, the peptide bond formation and for binding, decoding and pairing the mRNAs codons and aminoacylated tRNAs respectively102. New protein synthesis is essential for axon guidance, structural remodeling and functional change behind the long -term potentiation and depression, to establish new synaptic connections and/or strength the pre -existing synaptic communication; the molecular bas is for memory formation and maintenance103. An integrated study of proteomics and transcriptomic analysis using human olfactory neurosphere -derived from schizophrenia patient, detect a significant reduction in 17 ribosomal proteins with a lower global protein synthesis rates compared with control, also it was noticed a dysregulation in the upstream signaling pathways that control the protein synthesis such as the eIF2 and mTOR signaling104.", "Neverthe less, in this study, our dataset reveals something else about the ribosomal protein cluster. When we look the quantification in the other fractions, specifically in NUC fraction, two of that RP are up -regulated in NUC. For years, it has been investigated the role of extraribosomal function of RS in different physiological and pathological processes, especially during ribosomal stress, development, immune response, and tumorigenesis105. The main function of the dysregulated RP with extraribosomal function are described in Table 2.", "Among all quantified RP w e can highlight S19 and L23. S19 inhibits the Macrophage migration inhibitory factor (MIF) and prevents its transcription and protein expression106,107. MIF -knockout is characterized by the increase in caspase 3 activity and down -regulation of MIF, under hypoxia condition, increment the neuronal loss through the NF -kB signaling108. On the other hand, L23 inhibits the transactivation of MIZ1, a protein responsible for the activation of genes that control cell arrest cycle in carcinoma cell lines109,110. Furthermore, in our NUC proteins set, we found to increase the Far upstream element -binding protein 1, a regulator that induces the overexpression of MYC111,112, a key protein with opposite biological functions, depending on the cellular context, as cell proliferation, and apoptosis113. Specifically, in neurons, MYC overexpression promotes the activation of the cell cycle leading to neuronal cell death114,115 and p articipates in the apoptotic response mediated by NF -kB signaling in response to neuronal excitotoxicity116. Among all its functions, MYC also regulates the expression of the target gene of L23110 and it can inhibit MIZ1 as well as L23117. In myelod ysplastic syndrome, the RPL23/Miz -1/c-Myc circuit provides a regulatory feedback to lead apoptotic resistance118; nevertheless, it was reported that in fibroblast models, MIZ1 inactivation is essential for MYC apoptotic function not for ce ll cycle progression and transformation119. However, in the context of nervous system cells (NSC), it has b een described as different functions for MIZ1 such as the regulation of genes responsible for vesicular transport and autophagy120. Until the mo ment, the function of L23 -MIZ1 in the cells of the nervous system has not been described, but it is possible that L23 could exert a regulation of the MIZ1 function on the transcription of this type of genes in the NSC. Although, despite the lack of evidenc e in this sense, it is curious that in our data, we observed the decreased of proteins such as TBC1 domain family member 24 which have related functions to those observed by Wolf and collaborators120, but the biological functions of L23 -MIZ1 -Myc remain to be elucidated in schizophrenia physiopathology.", "Finally, proteins belonging to the ubiquitin -proteasome system (UPS) were found dysregulated. UPS is the main system for protein degradation but acts in receptors recycling, vesicle trafficking, vacuolar degradation121 and axon development122. The decrease of UPS system in the superior temporal gyrus and dentate granule neurons of individuals with schizophrenia results in impairment of AMPAR homeostasis, an abnormal structure in dendritic spine and accumulation of aberrant proteins in the endoplasmic reticulum (ER)123,124. An inefficient UPS can make the neurons more vulnerable to reactive oxygen species contributing to the mitochondrial impairments reported in schizophrenia124.", "4. CONCLUSION", "OFC is a brain area that plays a key role i n sensory integration and feedback processing. Changes in OFC volume gray matter is associated with the severity of negative as well as cognitive deficits in schizophrenia. In a previous study of this same brain area, we perform the proteomic characterizat ion of the synaptosome fraction, finding as one of the main dysregulated routes the calcium signaling pathway together with proteins involved in ER stress and activation of the apoptosis process16. Following our previous results16, one of our first conclu sions is that activation of apoptosis is important in the physiopathology of schizophrenia, at least in the OFC. This is reflected in the increase of pro -apoptotic proteins in MIT as VDAC1, Protein FAM162A, and Complex III. Second, the decreased in the abu ndance of cytoplasmatic βCaMKII may impact the nuclear function of γCaMKII 66 with a negative impact in a Ca2+/CaM shuttle and CREB activation impairments associated with cognitive disability in schizophrenia patients.", "The dysregulation of glutamate metabolism apparently happens in the regulation of its synthesis and clearance from the synaptic cleft , simult aneously with impairment of the cytoplasmatic membrane traffic, which impact in EAATs regulation. Evidence indicates that glutamate dysregulation can lead to synaptic damage and neuron death, with a marker behavioral and cognitive dysfunction125. Also, glutamate can activate NF-kB pathway126. One of the most important findings of this study is the overexpression of proteins intimately related to NF -kB signaling pathway. In NUC fraction, we found the activation of 14 -3-3 protein family, RhoB, HMGB1; in the same way, we also found in NUC and CYT fraction, proteins involved in the regulation of NF -kB signaling as Protein kinase beta and L23 respectively, as well as proteins that can induce neuronal loss through NF-kB pathway, for instance, S19 by means of MIF down -regulation.", "Finally, the abnormality in the cytoarchitecture of schizophrenia patients’ brains has been widely reported and this evidence indicates that the loss of volume in the OFC is not a consequence of the antipsychotic drug treatment127. As we mentioned earlier, in astrocytes the NF -kB signaling pathway activation can promote the astrocytic production of C3, stimulating the C3R neuronal receptors which entail a calcium imbalance and changes in neural morphology93. Our data reveal the increase of the complement system C3 in the OFC. The expression of C3 can promote and excessive synaptic pruning by microglia engulfmen t constituting one of the possible main mechanisms of gray matter loss in schizophrenia patients. Based on our data analysis, we suggest the activation of NF-kB as a possible pathway that links the deregulation of glutamate, calcium, apoptosis and the acti vation of the immune system in schizophrenia patients.", "Note: Authors recognize that the protein -level FDR is an estimate based on several imperfect assumptions, and present the FDR with appropriate precision and acknowledge that not all proteins surviving the threshold are “confidently identified”.", "ACNOWLEDGEMENT S DMS is supported by S ão Paulo Research Foundation (FAPESP), grants 2013/08711 -3 and 2014/10068 -4 and the Brazilian National Council for Scientific and Technological Development (CNPq) grant 460289/2014 -4. EV thanks CNPq for her PhD scholarship; FCSN for grant E -26/202.650/2018 from the Rio de Janeiro State Foundation for Science Support (FAPERJ); and GBD for CNPq grant 306316/2015 -3. REFERENCES", "(1) Patel, K. R.; Cherian, J.; Gohil, K.; Atkinson, D. Schizoph renia: Overview and Treatment Options. (2) Stępnicki, P.; Kondej, M.; Kaczor, A. A. Current Concepts and Treatments of Schizophrenia. (3) Möller, H. -J. The Relevance of Negative Symptoms in Schizophrenia and How to Treat Them with Psychopharmaceuticals? Psychiatr. Danub. 2016 , 28 (4), 435 –440.", "(4) Gao, W. -J.; Wang, H. -X.; A., M.; L i, Y.-C. The Unique Properties of the Prefrontal Cortex and Mental Illness. When Things Go Wrong - Dis. Disord. Hum. Brain 2012 . https://doi.org/10.5772/35868. (5) Jackowski, A. P.; Araújo Filho, G. M. de; Almeida, A. G. De; Araújo, C. M. De; Reis, M.; Ne ry, F.; Batista, I. R.; Silva, I.; Lacerda, A. L. T. The Involvement of the Orbitofrontal Cortex in Psychiatric Disorders: An Update of Neuroimaging Findings. Rev. Bras. Psiquiatr. 2012 , 34 (2), 207 –212. (6) Taka yanagi, Y.; Takahashi, T.; Orikabe, L.; Masuda, N.; Mozue, Y.; Nakamura, K.; Kawasaki, Y.; Itokawa, M.; Sato, Y.; Yamasue, H.; et al. Volume Reduction and Altered Sulco -Gyral Pattern of the Orbitofrontal Cortex in First -Episode Schizophrenia. Schizophr. Re s. 2010 , 121 (1–3), 55 –65. (7) Kanahara, N.; Sekine, Y.; Haraguchi, T.; Uchida, Y.; Hashimoto, K.; Shimizu, E.; Iyo, M. Orbitofrontal Cortex Abnormality and Deficit Schizophrenia. Schizophr. Res. 2013 , 143 (2–3), 246 –252. (8) Ohtani, T.; Bo uix, S.; Hosokawa, T.; Saito, Y.; Eckbo, R.; Ballinger, T.; Rausch, A.; Melonakos, E.; Kubicki, M. Abnormalities in White Matter Connections between Orbitofrontal Cortex and Anterior Cingulate Cortex and Their Associations with Negative Symptoms in Schizop hrenia: A DTI Study. (9) Ripke, S.; Neale, B. M.; Corvin, A.; Walters, J. T. R.; Farh, K. -H.; Holmans, P. A.; Lee, P.; Bulik - Sullivan, B.; Collier, D. A.; Huang, H.; e t al. Biological Insights from 108 Schizophrenia -Associated (10) Enwright, J. F.; Huo, Z.; Arion, D.; Corradi, J. P.; Tseng, G.; Lewis, D. A. Transcriptome Alterations of Prefrontal Cortical Parvalbumin Neurons in Schizophrenia. Mol. Psychiatry 2018 , 23 (7), (11) Arion, D.; Huo, Z.; Enwright, J. F.; Corradi, J. P.; Tseng, G.; Lewis, D. A. Transcriptome Alterations in Prefrontal Pyramidal Cells Distinguish Schizophrenia From Bipolar and Major Depressive (12) Sanders, A. R.; Drigalenko, E. I.; Duan, J.; Moy, W.; Freda, J.; Göring, H. H. H.; Gejman, P. V.; Levinson, D. F.; Shi, J.; Buccola, N. G.; et al. Transcriptome Sequencing Study Implicates Immune -Related Genes Diff erentially Expressed in Schizophrenia: New Data and a Meta -Analysis. Transl. Psychiatry 2017 , (13) Nascimento, J. M.; Martins -de-Souza, D. The Proteome of Schizophrenia. npj Schizophr. 2015 , 1 (14) Shan, D.; Mount, D.; Moore, S.; Haroutunian, V.; Meador -Woodruff, J. H.; McCullumsmith, R. E. Abnormal Partitioning of Hexokinase 1 Suggests Disruption of a Glutamate Transport Protein Complex (15) Saia-Cereda, V. M.; Santana, A. G.; Schmitt, A.; Falkai, P.; Martins -de-Souza, D. The Nuclear Proteome of White and Gray Matter from Schizophrenia Postmortem Brains. Mol. Neuropsychiatry 2017 , (16) Velásquez, E.; Nogueira, F. C. S.; Velásquez, I.; Schmitt, A.; Falkai, P.; Domont, G. B.; Martins - De-Souza, D. Synaptosomal Proteome of the Orbitofrontal Cortex from Schizop hrenia Patients Using Quantitative Label -Free and ITRAQ -Based Shotgun Proteomics. J. Proteome Res. 2017 , 16 (12), 4481 – (17) Itzhak, D. N.; Tyanova, S.; Cox, J.; Borner, G. H. H. Global, Quantitative and Dynamic Mapping of Protein Subcellular Localization. Elife 2016 , 5 (JUN2016), 1 –36. https://doi.org/10.7554/eLife.16950. (18) Eroglu S., Toprak S., Urgan O, MD, Ozge E. Onur, MD, Arzu Denizbasi, MD, Haldun Akoglu, MD, Cigdem Ozpolat, MD, Ebru Akoglu, M. DSM -IV Diagnostic and Statistical Manual of Mental (19) Larsen, M. R.; Thingholm, T. E.; Jensen, O. N.; Roepstorff, P.; Jørgensen, T. J. D. Highly Selective Enrichment of Phosphorylated Pep tides from Peptide Mixtures Using Titanium Dioxide Microcolumns *. (20) Polpitiya, A. D.; Qian, W. J.; Jaitly, N.; Petyuk, V. A.; Adkins, J. N.; Camp, D. G.; Anderson, G. A.; Smith, R. D. DAnTE: A Statistical Tool for Quantitative Analysis of -Omics Data. Bioinformatics 2008 , (21) Bateman, A.; Martin, M. J.; O’Donovan, C.; Magrane, M.; Alpi, E.; Antunes, R.; Bely, B.; Bingley, M.; Bonilla, C.; Britto, R.; et al. UniProt: The Universal Protein Knowledgebase. Nucleic Acids Res. 2017 , (22) Oliveros, J. C. NoVENNY. An interactive tool for comparing lists with Venn Diagrams Title http://bioinfogp.cnb.csic.es/tools/venny/index.html.", "(23) Fabregat, A.; Sidiropoulos, K.; Garapati, P.; Gillespie, M.; Hausmann, K.; Haw, R.; Jassal, B.; Jupe, S.; Korninger, F.; McKay, S.; et al. The Reactome Pathway Knowledgebase. Nucleic Acids Res. 2016 , (24) Szklarczyk, D.; Franceschini, A.; Wyder, S.; Forslund, K.; Heller, D.; Huerta -Cepas, J.; Simonovic, M.; Roth, A.; Santos, A.; Tsafou, K. P.; et al. STRING V10: Protein -Protein Interaction Networks, Integrated over the Tree of Life. Nucleic Acids Res. 2015 , 43 (D1), D447 –D452. (25) Ogata, H.; Goto, S.; Sat o, K.; Fujibuchi, W.; Bono, H.; Kanehisa, M. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 1999 , 27 (1), 29 –34. https://doi.org/10.1093/nar/27.1.29. (26) Iwamoto, K.; Bundo, M.; Kato, T. Altered Expression of Mitochondria -Related Genes in Postmortem Brains of Patients with Bipolar Disorder or Schizophrenia, as Revealed by Large -Scale DNA Microarray Analysis. Hum. Mol. Genet. 2005 , 14 (2), 241 –253. https://doi.org/10.1093/hmg/ddi022. (27) English, J. A.; Pennington, K.; Dunn, M. J.; Cot ter, D. R. The Neuroproteomics of Schizophrenia. (28) Robicsek, O.; Ene, H. M.; Karry, R.; Ytzhaki, O.; Asor, E.; McPhie, D.; Cohen, B. M.; Ben - Yehuda, R.; Weiner, I.; Ben-Shachar, D. Isolated Mitochondria Transfer Improves Neuronal Differentiation of Schizophrenia -Derived Induced Pluripotent Stem Cells and Rescues Deficits in a Rat Model of the Disorder. Schizophr. Bull. 2018 , 44 (2), 432 –442. https://doi.org/10.1093/s chbul/sbx077. (29) Roberts, R. C. Postmortem Studies on Mitochondria in Schizophrenia. Schizophr. Res. 2017 , 187, (30) Weisthal, S.; Keinan, N.; Ben -Hail, D.; Arif, T.; Shoshan -Barmatz, V. Ca2+ -Mediate d Regulation of VDAC1 Expression Levels Is Associated with Cell Death Induction. Biochim. Biophys. Acta - Mol. Cell (31) Lee, M.; Kim, J.; Suk, K.; Park, J. Identification of the Hypoxia -Inducible Factor 1_ -Responsive HGTD -P Gene as a Mediator in the Mitochondrial Apoptotic Pathway. Society 2004 , 24 (9), 3918 –3927. (32) Cho, Y. E.; Ko, J. H.; Kim, Y. J.; Yim, J. H.; Kim, S. M.; Park, J. H. MHGTD -P Mediates Hypoxic Neuronal Cell Death via the Release of Apoptosis -Inducing Factor. Neurosci. Lett. 2007 , 416 (2), 144 –149. (33) Qu, Y.; Mao, M.; Zhao, F.; Zhang, L.; Mu, D. Proapoptotic Role of Human Growth and Transformation -Dependent Protein in the Developing Rat Brain after Hypoxia -Ischemia. Stroke 2009 , 40 (34) Dibrova, D. V.; Chere panov, D. A.; Galperin, M. Y.; Skulachev, V. P.; Mulkidjanian, A. Y. Evolution of Cytochrome Bc Complexes: From Membrane -Anchored Dehydrogenases of Ancient Bacteria to Triggers of Apoptosis in Vertebrates. Biochim. Biophys. Acta - Bioenerg. 2013 , 1827 (11–12), 1407 – (35) Schoeber, J. P. H.; Topala, C. N.; Lee, K. P.; Lambers, T. T.; Ricard, G.; Van Der Kemp, A. W. C. M.; Huynen, M. A.; Hoenderop, J. G. J.; Bindels, R. J. M. Identification of Nipsnap1 as a Novel Auxiliary Protein Inhibiting TRPV6 Activity. Pflugers Arch. Eu r. J. Physiol. 2008 , 457 (1), 91 –101. (36) Princely Abudu, Y.; Pankiv, S.; Mathai, B. J.; Håkon Lystad, A.; Bindesbøll, C.; Brenne, H. B.; Yoke Wui Ng, M.; Thiede, B.; Yamamoto, A.; Mutugi Nthiga, T.; et al. NIPS NAP1 and NIPSNAP2 Act as “Eat Me” Signals for Mitophagy. Dev. Cell 2019 , 49 (4), 509 -525.e12.", "(37) Frezza, C.; Cipolat, S.; Martins de Brito, O.; Micaroni, M.; Beznoussenko, G. V.; Rudka, T.; Bartoli, D.; Poli shuck, R. S.; Danial, N. N.; De Strooper, B.; et al. OPA1 Controls Apoptotic Cristae Remodeling Independently from Mitochondrial Fusion. Cell 2006 , 126 (1), 177 –189.", "(38) Campanella, M.; Parker, N.; Tan, C. H.; Hall, A. M.; Duchen, M. R. IF1: Setting the Pace of the F1Fo -ATP Synthase. Trends Biochem. Sci. 2009 , 34 (7), 343 –350.", "(39) Faccenda, D.; Nakamura, J.; Gorini, G.; Dhoot, G. K.; Piacentini, M.; Yoshida, M.; Campanella, M. Control of Mitochondrial Remodeling by the ATPase Inhibitory Factor 1 Unveils a Pro -Survival Relay (40) Darshi, M.; Mendiola, V. L.; Mackey, M. R.; Murphy, A. N.; Koller, A.; Perkins, G. A.; Ellisman, M. H.; Taylor, S. S. ChChd3, an Inner Mitochondrial Membrane Protein, Is Essential for Maintaining Cris ta Integrity and Mitochondrial Function. J. Biol. Chem. 2011 , 286 (4), 2918 –2932.", "(41) An, J.; Shi, J.; He, Q.; Lui, K.; Liu, Y.; Huang, Y.; Sheikh, M. S. CHCM1/CHCHD6, Novel Mitochondrial Protein Linked to Regulat ion of Mitofilin and Mitochondrial Cristae Morphology. J. Biol. (42) Friedman, J. R.; Mourier, A.; Yamada, J.; Michael McCaffery, J.; Nunnari, J. MICOS Coordinates with Respiratory Complexes and Lipids to Establish Mitochondrial Inner Membrane Architecture. Elife (43) Rosenquist, M. 14 -3-3 Proteins in Apoptosis. Brazilian J. Med. Biol. Res. 2003 , 36 (4), 403 –408. (44) Smidova, A.; Alblova, M.; Kalabova, D.; Psenakova, K.; Rosulek, M.; Herman, P.; Obsil, T.; Obsilova, V. 14 -3-3 Protein Masks the Nuclear Localization Sequence of Caspase -2. FEBS J. 2018 , 285 (45) Jia, H.; Liang, Z.; Zhang, X.; Wang, J.; Xu, W.; Qian, H. 14 -3-3 Proteins: An Important Regulator of Autophagy in Diseases. Am J Transl Res 2017 , 9 (11), 4738 –4746.", "(46) Xing, H.; Zhang, S.; Weinheimer, C.; Kovacs, A. ; Muslin, A. J. 14 -3-3 Proteins Block Apoptosis and Differentially Regulate MAPK Cascades. EMBO J. 2000 , 19 (3), 349 –358.", "(47) Dong, S.; Kang, S.; Gu, T. L.; Kardar, S.; Fu, H.; Lonial, S.; Khoury, H. J.; Khuri, F.; Chen, J. 14 - 3-3 Integrates Prosurvival Signals Mediated by the AKT and MAPK Pathways in ZNF198 -FGFR1 - Transformed Hematopoietic Cells. Blood 2007 , 110 (1), 360 –369. htt ps://doi.org/10.1182/blood -2006 -12- (48) Obsilova, V.; Vecer, J.; Herman, P.; Pabianova, A.; Sulc, M.; Teisinger, J.; Boura, E.; Obsil, T. 14-3-3 Protein Interacts with Nuclear Localization Sequence of Forkhead Transcription Factor FoxO4. (49) Silhan, J.; Vacha, P.; Strnadova, P.; Vecer, J.; Herman, P.; Sulc, M.; Teisinger, J.; Obsilova, V.; Obsil, T. 14 -3-3 Protein Masks the DNA Binding Interface of Forkhead Transcription Factor FOXO4. J. (50) Zanella, F.; dos Santos, N. R.; Link, W. Moving to the Core: Spatiotemporal Analysis of Forkhead Box O (FOXO) and Nuclear Factor -ΚB (NF -ΚB) Nuclear Tra nslocation. Traffic 2013 , 14 (3), 247 –258. (51) Lin, L.; Hron, J. D.; Peng, S. L. Regulation of NF -ΚB, Th Activation, and Autoinflammation by the Forkhead Transcription Factor Foxo3a. Immunity 2004 , 21 (2), 203 –213.", "(52) Zhou, W.; Cao, Q.; Peng, Y.; Zhang, Q. J.; Castrillon, D. H.; DePinho, R. A.; Liu, Z. P. FoxO4 Inhibits NF -ΚB and Protects Mice Against Colonic Injury and Inflammation. Gastroenterology 2009 , 137 (53) Rodriguez, P. L.; Sahay, S.; Olabisi, O. O.; Whitehead, I. P. ROCK I -Mediated Activation of NF - (54) Barberan, S.; , Kara McNair, Khalil Iqbal, Nicola C. Smith, G. C. P.; Trevor W. Stone, Stuart R. Cobb, and B. J. M. Altered Apoptotic Responses in Neurons Lacking RhoB GTPase. Eur J Neurosci. 2011 , (55) Sakamoto, K.; Okuwaki, T.; Ushikubo, H.; Mori, A.; Nakahara, T.; Ishii, K. Activation Inhibitors of Nuclear Factor Kappa B Protect Neurons against the NMDA -Induced Damage in the Rat Retina. J. (56) Hulya Karatas, Sefik Evren Erdener, Yasemin Gursoy -Ozdemir, Sevda Lule, Emine Eren -Koçak, Zümrüt Duygu Sen, T. D. Spreading Depression Triggers Headache by Activating Neuronal Panx1 (57) Shi, Y.; Zhang, L.; Teng, J.; Miao, W. HMGB1 Mediates Microglia Activation via the TLR4 / NF - κ B Pathway in Coriaria Lactone Induced Epilepsy. 2018 , 5125 –5131.", "(58) Palumbo, R.; Galvez, B. G.; Pusterla, T.; De Marchis, F.; Cossu, G.; Marcu, K. B.; Bianchi, M. E. Cells Migrating to Sites of Tissue Damage in Response to the Danger Signal HMGB1 Require NF -ΚB (59) Chen, B.; Liu, J.; Ho, T. -T.; Ding, X.; Mo, Y. -Y. ERK -Mediated NF -ΚB Activation through ASIC1 in Response to Acidosis. Oncogenesis 2016 , 5 (12), e279 –e279.", "(60) Saijo, K.; Mecklenbräuker, I.; Santana, A.; Leitger, M.; Schmedt, C.; Tarakhovsky, A. Protein Kinase C β Controls Nuclear Factor ΚB Activation in B Cells Through Selective Regulation of the I κB (61) Kim, S. W.; Schifano, M.; Oleksyn, D.; Jordan, C. T.; Ryan, D.; Insel, R.; Zhao, J.; Chen, L. Protein Kinase C -Associated Kinase Regulates NF -ΚB Activation through Inducing IKK Activation. Int. (62) Roussos, P.; Katsel, P.; Davis, K. L.; Giakoumaki, S. G.; Siever, L. J.; Bitsios, P.; Haroutunian, V. Convergent Findings for Abnormalities of the NF -ΚB Signaling Pathway in Schizophrenia. (63) Volk, D. W.; Moroco, A. E.; Roman, K. M.; Edelson, J. R.; Lewis, D. A. The Role of the Nuclear Factor -ΚB Transcriptional Complex in Cortical Immune Activation in Schizophrenia. Biol. Psychiatry (64) Li, B.; Tsien, R. W.; Ma, H. Distinct Roles of Multiple Isoforms of CaMKII in Signaling to the (65) Coyle, J. T. MicroRNAs Suggest a New Mechanism for Altered Brain Gene Expression in (66) Ma, H.; Groth, R. D.; Cohen, S. M.; Emery, J. F.; Li, B.; Hoedt, E.; Zhang, G.; Neubert, T. A.; Tsien, R. W. ΓcaMKII Shuttles Ca 2+ /CaM to the Nucleus to Trigger CREB Phosphorylation and Gene (67) Cohen, S. M.; Suutari, B.; He, X.; Wang, Y.; Sanchez, S.; Tirko, N. N.; Mandelberg, N. J.; Mullins, C.; Zhou, G.; Wang, S.; et al. Calmodulin Shuttling Mediates Cytonuclear Signaling to Trigger Experience - Dependent Transcription and Memory. Nat. Commun. 2018 , 9 (1), 1 –12. https://doi.org/10.1038/s41467 - (68) Saura, C. A.; Valero, J. The Role of CREB Signaling in Alzheimer’s Disease and Other Cognitive (69) Graham, J. M. Preparation of Crude Subcellular Fractions by Differential Centrifugation. (70) Collins, T. J. Mitochondria Are Morphologically Heterogeneous within Cells. J. Exp. Biol. 2003 , (71) Kuznetsov, A. V.; Troppmair, J.; Sucher, R.; Hermann, M.; Saks, V.; Margreiter, R. Mitochondrial Subpopulations and Heterogeneity Revealed by Confocal Imaging: Possible Physiological Role? Biochim. (72) Brown, M. R.; Sullivan, P. G.; Geddes, J. W. Synaptic Mitochondria Are More Susceptible to Ca2+ Overload than Nonsynaptic Mitochondria. J. Biol. Chem. 2006 , 281 (17), 11658 –11668. (73) Kuznetsov, A. V.; Margreiter, R. Hete rogeneity of Mitochondria and Mitochondrial Function within Cells as Another Level of Mitochondrial Complexity. Int. J. Mol. Sci. 2009 , 10 (4), 1911 –1929. (74) Woods, D. C. Review Article Mitochondrial Heterogeneity : Evaluating Mitochondrial Subpopulation Dynamics in Stem Cells. 2017 , 2017 . https://doi.org/10.1155/2017/7068567. (75) Rollins, B. L.; Morgan, L.; Hjelm, B. E.; Sequeira, A.; Schatzberg, A. F.; Barchas, J. D.; Lee, F. S.; Myers, R. M.; Watson, S. J.; Akil , H.; et al. Mitochondrial Complex I Deficiency in Schizophrenia and Bipolar Disorder and Medication Influence. Mol. Neuropsychiatry 2017 , 3 (3), 157 –169. (76) Holper, L.; Ben -Shachar, D.; Mann, J. Multivariate Meta -Anal yses of Mitochondrial Complex I and IV in Major Depressive Disorder, Bipolar Disorder, Schizophrenia, Alzheimer Disease, and Parkinson (77) Akarsu, S.; Toru n, D.; Bolu, A.; Erdem, M.; Kozan, S.; Ak, M.; Akar, H.; Uzun, Ö. Mitochondrial Complex I and III Gene MRNA Levels in Schizophrenia, and Their Relationship with Clinical Features. J. (78) Farinelli, S. E.; Nicklas, W. J. Glutamate Metabolism in Rat Cortical Astrocyte Cultures. J. (79) Hassel, B.; Bachelard, H. Trafficking of Amino Acids Between Neurons and Glia I n Vivo . Effects of Inhibition of Glial Metabolism by Fluoroacetate Journal of Cerebral Blood Flow & Metabolism - Trafficking of Arnino Acids Between ... Page 2 of 6. 2007 , No. 1997, 1230 –1238. (80) Poels, E. M. P.; Kegeles, L. S.; Kantrowitz, J. T.; Slifstein, M.; Javitt, D. C.; Lieberman, J. A.; Abi-Dargham, A.; Girgis, R. R. Imaging Glutamate in Schizophrenia: Review of Findings and Implications for Drug Discovery. Mol. Psyc hiatry 2014 , 19 (1), 20 –29. https://doi.org/10.1038/mp.2013.136. (81) Bruneau, E. G.; McCullumsmith, R. E.; Haroutunian, V.; Davis, K. L.; Meador -Woodruff, J. H. Increased Expression of Glutaminase and Glutamine Synthetase MRNA in the Thalamus in Schizoph renia. (82) Boksha, I. S.; Tereshkina, E. B.; Savushkina, O. K.; Prokhorova, T. A.; Vorobyeva, E. A.; Burbaeva, G. S. Comparative Studies of Glutamine Synthetase Levels in the Brains of Patients with Schizophrenia and Mentally Healthy People. Neurochem. J. 2018 , 12 (1), 95 –101.", "(83) Burbaeva, G. S.; Boksha, I. S.; Turishcheva, M. S.; Vorobyeva, E. A.; Savushkina, O. K.; Tereshkina, E. B. Glutamine Synthetase and Glutamate Dehydrogenase in the Prefrontal Cortex of Patients with Schizophrenia. Prog. Neuro -Psychopharmacology Biol. Psychiatry 2003 , 27 (4), 675 –680. (84) Prokhorova, Т. А.; Boksha, I. S.; Savushkina, O. K.; Tereshkina, E. B.; Vorobyeva, Е. А.; Pomytkin, A. N.; Kaleda, V. G.; Burbaeva, G. S. Glutamate Dehydrogenase Activity in Platelets of Patients with Endogenous Psychosis. Zhurnal Nevrol. i psikhiatrii im. S.S. Korsakova 2016, 116 (3), 44. (85) Lander, S. S.; Khan, U.; Lewandowski, N.; Chakraborty, D.; Provenzano, F. A.; Mingote, S.; Chornyy, S.; Frigerio, F.; Maechler, P.; Kaphzan, H.; et al. Glutamate Dehydrogenase -Deficient M ice Display Schizophrenia -Like Behavioral Abnormalities and CA1 -Specific Hippocampal Dysfunction. (86) Desilva, T. M.; Borenstein, N. S.; Volpe, J. J.; Kinney, H. C.; Rosenberg , P. A. Expression of EAAT2 in Neurons and Protoplasmic Astrocytes during Human Cortical Development. J. Comp. Neurol. (87) Parkin, G. M.; Udawela, M.; Gibbons, A.; Dean, B. Glutamate Transporters, EAAT1 and EAAT2, Are Potentially Important in the Pathophysiology and Treatment of Schizophrenia and Affective Disorders. (88) Deborah Bauer, Daya Gupta, Vahram Harotunian, J. H. M. -W. and; McCullumsmith, R. E. Abnormal Expression of Glutamate Transporter and Transporter Interacting Molecules in Prefrontal Cortex in Elderly Patients with Schizophrenia. Schizophr Res 2008 , 104(1 -3), 108 –120.", "(89) Matute, C.; Melone, M.; Vallejo -Illarramendi, A.; Conti, F. Increased Expression of the Astrocytic Glutamate Transporter GLT -1 in the Prefrontal Cortex of Schizophre nics. Glia 2005 , 49 (3), 451 –455. (90) McCullumsmith, R. E.; O’Donovan, S. M.; Drummond, J. B.; Benesh, F. S.; Simmons, M.; Roberts, R.; Lauriat, T.; Haroutunian, V.; Meador -Woodruff, J. H. Cell -Specific Abnormalities o f Glutamate Transporters in Schizophrenia: Sick Astrocytes and Compensating Relay Neurons? Mol. (91) Farkas, I.; Baranyi, L.; Ishikawa, Y.; Okada, N.; Bohata, C.; Budai, D.; Fukuda, A.; Imai, M.; Okada, H. CD59 Blocks Not Only the Insertion of C9 into MAC but Inhibits Ion Channel Formation by Homologous C5b -8 as Well as C5b -9. J. Physiol. 2002 , 539 (2), 5 37–545.", "(92) Yasojima, K.; McGeer, E. G.; McGeer, P. L. Complement Regulators C1 Inhibitor and CD59 Do Not Significantly Inhibit Complement Activation in Alzheimer Disease. Brain Res. 1999 , 833 (2), 297 – (93) Lian, H.; Yang, L.; Cole, A.; Sun, L.; Chiang, A. C.; Fowler, S. W.; Shim, D. J.; Rodriguez -rivera, J.; Taglialatela, G.; Jankowsky, J. L. NF κB-Activated Astroglial Release of Complement C3 Compromises Neuronal Morphology and Function Associated with Alzheimer’s Disease. Neuron 2016 , 85 (1), 101 –115. (94) Stephan, A. H.; Barres, B. A.; Stevens, B. The Complement System: An Unexpected Role in Synaptic Prunin g During Development and Disease. Annu. Rev. Neurosci. 2012 , 35 (1), 369 –389. (95) Presumey, J.; Bialas, A. R.; Carroll, M. C. Complement System in Neural Synapse Elimination in Development and Disease. Adv. Immunol. 2017 , 135, 53–79. https://doi.org/10.1016/bs.ai.2017.06.004. (96) Zheng Li, Jihoon Jo, Jie -Min Jia, Shih -Ching Lo, Daniel J. Whitcomb, S.; Jiao, Kwangwook Cho, and M. S. Caspase -3 Activation via Mitochondria Is Required for Long -Term Depression and AMPA (97) Sekar, A.; Bialas, A. R.; De Rivera, H.; Davis, A.; Hammond, T. R.; Kamitaki, N.; Tooley, K.; Presumey, J.; Baum, M.; Van Doren, V.; et al. Schizophrenia Risk from Complex Variation of Complement (98) Holahan, M. GAP -43 in Synaptic Plasticity: Molecular Perspectives. Res. Reports Biochem. 2015 , (99) Chambers, J. S.; Thomas, D.; Saland, L.; Neve , R. L.; Perrone -Bizzozero, N. I. Growth -Associated Protein 43 (GAP -43) and Synaptophysin Alterations in the Dentate Gyrus of Patients with Schizophrenia. Prog. Neuro -Psychopharmacology Biol. Psychiatry 2005 , 29 (2), 283 –290.", "(100) Hung, C. -C.; Lin, C. -H.; Chang, H.; Wang, C. -Y.; Lin, S. -H.; Hsu, P. -C.; Sun, Y. -Y.; Lin, T. -N.; Shie, F. -S.; Kao, L. -S.; et al. Astrocytic GAP43 Induced by the TLR4/NF -ΚB/STAT3 Axis Attenuates Astrogliosis -Mediated Microglial Activat ion and Neurotoxicity. J. Neurosci. 2016 , 36 (6), 2027 –2043. (101) Jung, H.; Yoon, B. C.; Holt, C. E. Axonal MRNA Localization and Local Protein Synthesis in Nervous System Assembly, Maintenance and Repair. Nat. Rev. Neurosci. 2012 , 13 (5), 308 –324. (102) Jennifer A Doudna, V. L. R. Structure and Function of the Eukaryotic Ribosome: The Next (103) Buffington, S. A.; Huang, W.; Costa -Mattioli, and M. Translational Control in Synaptic Plasticity and Cognitive Dysfunction. Annu Rev Neurosci 2014 , 37, 17–38. https://doi.org/10.1146/annurev -neuro - (104) English, J. A.; Fan, Y.; Föcking, M.; Lopez, L. M.; Hryniewiecka, M.; Wynne, K.; Dicker, P.; Matigian, N.; Cagney, G.; Mackay -Sim, A.; et al. Reduced Protein Synthesis in Schizophrenia Patient - Derived Olfactory Cells. Transl. Psychiatry 2015 , 5 (April), e6 63. https://doi.org/10.1038/tp.2015.119. (105) Xiang, Z.; Wen -Juan, L.; Jun -Ming, L.; Peng, L.; Hua, L. Ribosomal Proteins: Functions beyond the Ribosome. J. Mol. Cell Biol. 2015 , 7 (2), 92 –104.", "(106) Filip, A. M.; Klug, J.; Cayli, S.; Fröhlich, S.; Henk e, T.; Lacher, P.; Eickhoff, R.; Bulau, P.; Linder, M.; Carlsson -Skwirut, C.; et al. Ribosomal Protein S19 Interacts with Macrophage Migration Inhibitory Factor and Attenuates Its Pro -Inflammatory Function. J. Biol. Chem. 2009 , 284 (12), 7977 –7985. (107) Lv, J.; Huang, X. R.; Klug, J.; Fröhlich, S.; Lacher, P.; Xu, A.; Meinhardt, A.; Lan, H. Y. Ribosomal Protein S19 Is a Novel Therapeutic Agent in Inflammatory Kidney Disease. Clin. Sci. 2013 , (108) Zhang, S.; Zis, O.; Ly, P. T. T.; Wu, Y.; Zhang, S.; Zhang, M.; Cai, F.; Bucala, R.; Shyu, W. C.; Song, W. Down -Regulation of MIF by NF κB under Hypoxia Accelerated Neuronal Loss during Stroke. (109) Jin, A.; Itahana, K.; O’Keefe, K.; Zhang, Y. Inhibition of HDM2 and Activation of P53 by Ribosomal Protein L23. Mol. Cell. Biol. 2004 , 24 (17), 7669 –7680.", "(110) Wanzel, M.; Russ, A. C.; Kleine -Kohlbrecher, D.; Colombo, E.; Pelicci, P. G.; Eilers, M. A Ribosomal Protein L23 -Nucleophosmin Circuit Coordinates Miz1 Function with Cell Growth. Nat. Cell (111) Yang, L.; Zhu, J. ya; Zhang, J. guo; Bao, B. jun; Guan, C. qi; Yang, X. jing; Liu, Y. hua; Huang, Y. jiao; Ni, R. zhou; Ji, L. li. Far Upstream Element -Binding Protein 1 (FUBP1) Is a Potential c -Myc Regulator in Esophageal Squamous Cell Carc inoma (ESCC) and Its Expression Promotes ESCC (112) Duan, J.; Bao, X.; Ma, X.; Zhang, Y.; Ni, D.; Wang, H.; Zhang, F.; Du, Q.; Fan, Y.; Chen, J.; et al. Upregulat ion of Far Upstream Element -Binding Protein 1 (FUBP1) Promotes Tumor Proliferation and Tumorigenesis of Clear Cell Renal Cell Carcinoma. PLoS One 2017 , 12 (1), 1 –16.", "(113) Dang, C. V. C -Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism. Mol. Cell. (114) Lee, H. G.; Casadesus, G.; N unomura, A.; Zhu, X.; Castellani, R. J.; Richardson, S. L.; Perry, G.; Felsher, D. W.; Petersen, R. B.; Smith, M. A. The Neuronal Expression of MYC Causes a Neurodegenerative Phenotype in a Novel Transgenic Mouse. Am. J. Pathol. 2009 , 174 (3), 891 –897. (115) Lee, H. P.; Kudo, W.; Zhu, X.; Smith, M. A.; Lee, H. gon. Early Induction of C -Myc Is Associated with Neuronal Cell Death. Neurosci. Lett. 2011 , 505 (2), 124 –127.", "(116) Qin, Z. H.; Chen, R. W.; Wang, Y.; Nakai, M.; Chuang, D. M.; Chase, T. N. Nuclear Factor KappaB Nuclear Translocation Upregulates C -Myc and P53 Expression during NMDA Receptor -Mediated Apoptosis in Rat Striatum. J. Neurosci. 1999 , 19 (10), 4023 –4033.", "(117) Herold, S.; Wanzel, M.; Beuger, V.; Frohme, C.; Beul, D.; Hillukkala, T.; Syvaoja, J.; Saluz, H. P.; Haenel, F.; Eilers, M. Negative Regulation of the Mammalian UV Response by Myc through (118) Qi, Y.; Li, X.; Chang, C.; Xu, F.; He, Q.; Zhao, Y.; Wu, L. Ribosomal Protein L23 Negatively Regulates Cellular Apoptosis via the RPL23/Miz -1/c-Myc Circuit in Higher -Risk Myelodysplastic (119) Patel, J. H.; McMahon, S. B. Targeting of Miz -1 Is Essential for Myc -Mediated Apoptosis. J. Biol. (120) Eyss, V.; Wagner, N.; Wolf, E.; Gebhardt, A.; Kawauchi, D.; Walz, S.; Renninger, C.; Krohne, G.; Asan, E.; Roussel, M. F.; et al. Miz1 Is Required to Maintain Autophagic Flux ¨. 2013 , 1–12. (121) Kleiger, G.; Mayor, T. Perilous Journey: A Tour of the Ubiquitin -Proteasome System. Trends Cell (122) Hsu, M. T.; Guo, C. L.; Liou, A. Y.; Cha ng, T. Y.; Ng, M. C.; Florea, B. I.; Overkleeft, H. S.; Wu, Y. L.; Liao, J. C.; Cheng, P. L. Stage -Dependent Axon Transport of Proteasomes Contributes to Axon (123) Altar, C. A.; Jurata, L. W.; Charles, V.; Lemire, A.; Liu, P.; Bukhman, Y.; Young, T. A.; Bullard, J.; Yokoe, H.; Webster, M. J.; et al. Deficient Hippocampal Neuron Expression of Proteaso me, Ubiquitin, and Mitochondrial Genes in Multiple Schizophrenia Cohorts. Biol. Psychiatry 2005 , 58 (2), 85 –96. (124) Rubio, M. D.; Wood, K.; Haroutunian, V.; Meador -Woodruff, J. H. Dysfunction of the Ubiqui tin Proteasome and Ubiquitin -Like Systems in Schizophrenia. Neuropsychopharmacology 2013 , 38 (10), (125) Haroon, E.; Miller, A. H.; Sanacora, G. Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood D isorders. Neuropsychopharmacology 2017 , 42 (1), 193 –215. https://doi.org/10.1038/npp.2016.199. (126) Guerrini, L.; Blasi, F.; Denis -Donini, S. Synaptic Activation of NF -Kappa B by Glutamate in Cerebellar Granule Neurons in Vitro. Proc. Natl. Acad. Sci. 1995, 92, 9077 –9081.", "(127) Homayoun, H.; Moghaddam, B. Orbitofrontal Cortex Neurons as a Common Target for Classic and Glutamatergic Antipsychotic Drugs. Proc. Natl. Acad. Sci. 2008 , 105 (46), 18041 –18046. (128) Dai, M. -S.; Zeng, S. X.; Jin, Y.; Sun, X. -X.; David, L.; Lu, H. Ribosomal Protein L23 Activates P53 by Inhibiting MDM2 Function in Response to Ribosomal Perturbation but Not to Translation (129) Clasen, S. J.; Shao, W.; Gu, H.; Espenshade, P. J. Prolyl Dihydroxylation of Unassembled US12/Rps23 Regulates Fungal Hypoxic Adaptation. Elife 2017 , 6, 1 –29.", "TABLES Table 1: Proteins of the main dysregulated pathways in each subcellular fraction Table 2: Extra -ribosomal functions of ribosomal proteins.", "FIGURES Figure 1. A) Venn diagram of proteins identified among all cellular fractions. B) Biological functions of the proteins identified exclusively in each subcellular fraction. C) Principal component analysis of the patient proteome data from different fractions. D) The tot al number of proteins identified, quantified and dysregulated in each subcellular fraction.", "Figure 2. Representation of the main proteins involved in apoptosis from the MIT fraction. During the apoptotic process proteins as VDAC1 and Protein FAM162A intera ct, leading the increase of mitochondrial Ca2+ uptake, triggering the apoptosis with the release of cytochrome c release. In response to the apoptotic signals, IF1 and mitochondrial cristae proteins such as Mic19 and Mic25 are overexpressed to preserve the crista architecture. Voltage -dependent anion -selective channel protein 1 (VDAC1), ATPase inhibitor (IF1) Figure 3. A) NF-kB signaling pathway. The increase of RhoB , HMGB1 and ERK -2 together with the glutamate activate the NF-kB signaling pathway and the decrease of protein kinase beta is involved in its regulation. NF-kB signaling pathway activation can promote the astrocytic production of complement C3. B) Quantifi cation of complement C3 in NUC fraction C) Quantification of complement C3 in CYT fraction . NF-kB: Nuclear Factor kappa B, RhoB: Ras Homolog Family Member B, HMGB1: High Mobility Group Box 1, ERK -2: Mitogen -activated protein kinase 1. Figure 4. CREB imbal ance hypothesis by γCaMKII . Cytoplasmatic βCaMKII quantified as down -regulated in CYT fraction was reported as a key kinase that phosphorylates γCaMKII. It is represented how the low availability of βCaMKII could affect γCaMKII phosphorylation which would impact γCaMKII/ Ca2+/CaM interaction. The inappropriate interaction between γCaMKII with Ca2+/CaM can lead to an inefficient nuclear shuttle of Ca2+/CaM by γCaMKII . Inappropiated γCaMKII shuttles can impact CREB activation by other Ca2+/CaM dependent kinases such as CaMKK, CaMKIV, and αCaMKII. CREB: Ca2+/cAMP response element -binding protein , βCaMKII: Calcium/calmodulin -dependent protein kinase beta, γCaMKII: Calcium/calmodulin - dependent protein kinase gamma, Ca2+/CaM: Calcium/calmodulin Figure 5. Dysregulation in glutamate metabolism . In astrocytes, the glutamate is taken up from the synaptic cleft by the excitatory amino acid transporters and converted to glutamine by glutamine synthetase (GS). In the pre -synaptic ter minal, the glutamine is transported and it is converted back into glutamate by glutaminase (GA). The deviation of the metabolism towards the preferential production of glutamine is also favored whereby the decrease of GLDH in astrocytes and neurons. Gln: g lutamine, Glu: glutamate, EAAT2: excitatory amino acid transporters 2, GLDH: glutamate dehydrogenase, TCA: tricarboxylic acid cycle.", "SUPPORTING INFORMATION Supporting Table S -1: Clinical information of patients and controls. Supporting Table S -2: Group of proteins and peptides identified by iTRAQ in each enrichment of subcellular fraction.", "Supporting Table S -3: Reactome pathway analysis of the proteome from each enriched subcellular fraction .", "Supporting Table S -4: Group of proteins quantified after InfernoRND normalization. Supporting Table S -5: Dysregulated proteins quantified by iTRAQ in each enriched subcellular fraction.", "Supporting Table S -6: Selected reaction monitoring analysis of proteins as γCaMKII, MAPK2, GS, C3 and NF -kB family.", "Supporting Table S -7: Biological analysis of dysregulated proteins quantified by iTRAQ of each enriched subcellular fraction.", "FIGURE 1", "FIGURE 2", "FIGURE 3", "FIGURE 4", "FIGURE 5", "Table 1: Proteins of the main dysregulated pathways in each subcellular fraction", "Protein ID Description Subcellular fraction Regulation Biological function Subcellular localization (Uniprot) NX_P22695 -1 Cytochrome b -c1 complex Mitocondrial up Aerobic respiration Mitochondrion inner membrane NX_P50213 -1 Isocitrate dehydrogenase Mitocondrial up Carbohydrate metabolic process Mitochondrion NX_P21796 -1 Voltage -dependent anion -selective channel Mitocondrial up Anion transport Mitochondrion outer membrane NX_P09622 -1 Dihydrolipoyl dehydrogenase Mitocondrial up 2-oxoglutarate metabolic process Mitochondrion matrix, nucleus NX_P07305 -1 Histone H1.0 isoform Nuclear up Apoptotic DNA fragmentation Nucleus NX_P09429 -1 High mobility group protein Nuclear up Inflammatory response Nucleus NX_O60313 -2 Dynamin -like 120 kDa protein Nuclear up Apoptotic process Mitochondrion membrane NX_Q15149 -1 Plectin isoform Iso 1 Nuclear up Hemidesmosome assembly Cytoplasm NX_P20700 -1 Lamin -B1 Nuclear up Interleukin -12-mediated signaling pathway Nucleus inner membrane NX_P31946 -2 14-3-3 protein beta/alpha Nuclear up MAPK cascade Nucleus, cytosol, mitochondrion NX_P27348 -1 14-3-3 protein theta Nuclear up Negative regulation of transcription Nucleus, cytosol, mitochondrion NX_P63104 -1 14-3-3 protein zeta /delta Nuclear up Apoptotic signaling pathway Nucleus, cytosol, mitochondrion NX_Q99436 -1 Proteasome subunit beta type -7 Cytoplasmic Down Ubiquitin -dependent protein catabolic process Cytoplasm, Cell membrane NX_P17677 -1 Neuromodulin Cytoplasmic Down Axon choice point recognition Cytoplasm, nucleus NX_O43242 -1 26S proteasome non -ATPase regulatory Cytoplasmic Down Ubiquitin -dependent protein catabolic process Cytoplasm, nucleus NX_P62266 -1 40S ribosomal protein S23 Cytoplasmic Down Cytoplasmic translation Cytoplasm, nucleus NX_P62847 -4 40S ribosomal protein S24 Cytoplasmic Down Translational initiation Cytoplasm, nucleus NX_P35080 -1 Profilin -2 Cytoplasmic Down Actin cytoskeleton organization Cytoplasm NX_P04156 -1 Major prion protein Cytoplasmic Down Activation of protein kinase activity Cell membrane, Golgi apparatus NX_Q01518 -1 Adenylyl cyclase -associated protein Cytoplasmic Down Actin polymerization or depolymerization Cell membrane NX_Q9Y490 -1 Talin -1 Cytoplasmic Down IRE1 -mediated unfolded protein response Cytoplasm NX_P25786 -2 Proteasome subunit alpha type -1 Cytoplasmic Down Ubiquitin -dependent protein catabolic process Cytoplasm, nucleus NX_P39019 -1 40S ribosomal protein S19 Cytoplasmic Down Translational initiation Cytoplasm, nucleus", "Table 2: Extra -ribosomal functions of ribosomal subunits.", "Ribosomal protein CYT fraction NUC fraction Extra -ribosomal function Reference S19 ↓ ↑ Inhibition of Mif, ERK and NF - L23 n.q. ↑ p53 activation. Regulation of S23 ↓ n.q Sre1 activity modulation (yeast) 129 L28 = ↑ Extraribosomal functions unknown n.q.: not quantified =: non -significant quantitative changes"]}